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The process of the brain developing from a single fertilized egg to the most 
sophisticated known organ requires precise spatial and temporal control to 
produce the necessary correct brain size and architecture. A particular region 
of interest is the cerebral cortex, responsible for higher functions such as 
language, reasoning and conscious thought. Its expansion in size and 
complexity from smaller mammals, such as mice, to humans is thought to 
contribute to our higher functions. However, a caveat of this increased 
complexity is the increased challenge of generating such a complex 
structure, and the potential for subtle changes during neurodevelopment to 
manifest in neurodevelopmental disorders such as Autism Spectrum 
Disorders (ASD).  
 
ASD is a spectrum disorder diagnosed early in childhood based on a range 
of diagnostic criteria. It is frequently characterised by impaired social 
interaction, repetitive behaviour and delayed development. While ASD 
patients share some symptoms, the genetic underpinnings of ASD are highly 
heterogeneous, with mutations to many single genes or larger genetic 
regions implicated as ASD risk factors. 
 
The 593kbp 16p11.2 locus encompasses 29 protein coding genes and its 
copy number variation (CNV) by heterozygous microduplication or 
microdeletion is implicated in around 1% of ASD cases, with many patients 
born with macrocephaly (deletion) or microcephaly (duplication), potentially 
indicating a possible problem with generating the correct number of brain 
cells during development. This suggests the hypothesis that some of the 
16p11.2 region genes are involved in neural proliferation in early 
corticogenesis, and changes to the levels of these genes may affect 
proliferation, contributing to the 16p11.2 patient phenotype. This hypothesis 
is supported by a 16p11.2 deletion mouse model which exhibits ASD-like 
symptoms and altered proliferation in the cortex during embryonic 
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development. Given that the 16p11.2 CNV’s 1% autism incidence makes it 
the most frequent aetiology of ASD, this region is a promising area of study 
to understand how genetic dysregulation during critical prenatal cortical 
neurogenesis can contribute to the ASD phenotype.  
 
Despite its strong association with ASD, very little is known about the 
majority of the 16p11.2 genes, especially regarding brain development. In 
this thesis, focussing on the developing human neocortex, we aimed to 
identify which, if any, of these 29 genes were expressed in progenitor cells 
and describe their expression pattern during critical stages of cortical 
neurogenesis.  
 
We first used a bioinformatics approach to identify 16p11.2 genes expressed 
in progenitors to narrow down from the 29 genes in the region. We analysed 
a publicly available single-cell RNA sequencing (scRNA-seq) dataset from 
the proliferative zones, the ventricular zone and subventricular zone, of the 
16-18 gestational week (GW) human fetal cortex. We identified six genes as 
being highly expressed in the cortical progenitor cells, and two as being 
significantly higher expressed in progenitors compared to post mitotic cells: 
KIF22 and ALDOA. We described their protein expression pattern in vivo at 
key stages of human fetal cortex development.  
 
We showed KIF22 protein to be expressed in the germinative zones, and its 
expression to be restricted to proliferating cells, suggesting a role for this 
protein in proliferation. We showed KIF22 protein levels to vary with the cell 
cycle, increasing from G1 through S and G2 phases to peak in mitosis. This 
suggests that changing the KIF22 protein level, as in the microduplication or 
microdeletion patients, will affect cell cycle and proliferation manifesting in 




ALDOA protein was shown to be present throughout the cortex, although 
higher in the proliferating regions. We demonstrated that ALDOA is 
predominantly localised to cytoplasm, and its protein levels or sub-cellular 
localisation do not change in proliferating or non-proliferating cells. ALDOA 
has a critical role in energy metabolism, and we can hypothesise that due to 
its expression throughout the cortex any changes to the ALDOA protein by 
the 16p11.2 CNV will induce a wide range of effects on brain development  
 
In conclusion we have identified two genes highly expressed in progenitors 
and expressed at much lower levels in post-mitotic cells from the 16p11.2 
locus. These genes provide interesting targets for future studies to elucidate 
the mechanism by which they mediate proliferation and the effects of 
manipulating their protein levels. This is outwith the scope of this PhD thesis 
however a range of new techniques are emerging such as cerebral 
organoids, which can be easily manipulated. These will be a powerful tool to 





The nine-month process that starts with a single fertilised egg and ends with 
a newborn human is a truly remarkable one. We are particularly interested in 
the development of the human brain during this nine-month period; to 
understand the mechanisms that precisely control the formation of the brain. 
Over many years and using many different techniques, models and 
approaches, scientists from research groups around the world are 
unravelling the multitude of processes which control brain development. Our 
work is particularly focussed on the region of the brain called the cerebral 
cortex. This is the part of the brain responsible for thought, language and 
much of our information processing. The cerebral cortex in humans is 
particularly enlarged when compared to small mammals. It is often 
postulated that it is our enlarged cerebral cortex is what makes us unique as 
humans.  
 
Sometimes however, there are disruptions to the complex process of brain 
development. These disruptions can lead to neurodevelopmental disorders: 
perhaps one of the most well-known, and the subject of this thesis, is Autism 
Spectrum Disorder (ASD). Symptoms of ASD vary between patients (as does 
severity), however the disorder is typically characterised by impaired social 
behaviour, repetitive and obsessive behaviours, and delayed learning and 
development. Research to identify genetic mutations that may lead to ASD 
has identified hundreds of possible genetic changes. Genetic mutations 
associated with ASD are extremely diverse. For example, the most common 
genetic mutation associated with ASD, the 16p11.2 copy number variation 
(CNV), has only been found in 1% of ASD patients. 
 
Our research and this thesis focus on this most common genetic cause of 
ASD, the 16p11.2 CNV. The 16p11.2 region is located on the 16th 
chromosome of humans and contains 29 genes. The 16p11.2 CNV is a 
heterozygous mutation, meaning that of the pair of chromosomes, one of the 
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two chromosomes is affected by the mutation whilst the other is unaffected. 
This heterozygous copy number variation can occur as either a duplication or 
a deletion. In the duplication, the region is duplicated on one chromosome 
resulting in three copies of each gene. In the deletion, the region is deleted 
from one chromosome resulting in only one copy of each gene.  
 
Around 1% of ASD patients have the 16p11.2 CNV, making it the most 
frequent known genetic cause of autism. Research is focused on 
understanding how the changes to gene level, or dosage, during 
development, can cause ASD in patients. One clue of this disruption is 
evident at birth: many 16p11.2 CNV patients are born with changes to head 
size. In patients with the duplication, many are born with a smaller than 
average head - known as microcephaly. Conversely, many patients with the 
deletion are born with a larger than average head - macrocephaly. These 
changes to head size (indicative of changes to brain size) suggest that the 
16p11.2 CNV alters brain development in some way.  
 
The final cerebral cortex should possess both correct overall cell number and 
proportions of the different cell types. This requires a balance of cells dividing 
(proliferating) to produce correct final cell number, and cells to specialise 
(differentiation) to produce correct proportion of cell types. In 16p11.2 CNV 
patients, the changes to brain size suggest that something may have altered 
this balance. Therefore, it is possible these patients may have altered final 
cell number and proportions which could contribute to their ASD.  
 
 
We wanted to investigate how the 16p11.2 CNV could impact human brain 
development, and this balance of proliferation and differentiation. As the 
16p11.2 region contains 29 genes, they are likely to have many effects 
throughout the body at different stages of life. Therefore, the first step for our 
research was to identify individual genes from this region which were active 
during the proliferation stage of pre-natal cortical development, in a cell class 
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known as progenitor cells. The majority of neurons in the final cerebral cortex 
are descended from early progenitor cells, therefore it is likely that any 
alteration to progenitors during early cortical development will have many 
effects on the cerebral cortex. 
 
The first aim of our study was to identify genes from the 16p11.2 region 
which are switched on in proliferating progenitor cells and are then switched 
off as these cells differentiate into neurons and stop dividing. To identify 
these genes, we used a computational approach. We used a previously 
published dataset which provided us with information about whether a gene 
was switched on or off in different cell types in the developing brain. From 
this we were able to show that two of the 16p11.2 region genes were 
switched on and expressed at high levels in cells which were proliferating, 
and switched off in cells which had stopped dividing to become neurons. 
These two genes were KIF22 and ALDOA.  
 
The gene eventually encodes a protein, and it is this protein that exerts an 
effect within the cell. Therefore, we wanted to study the roles of KIF22 and 
ALDOA proteins in human cerebral cortex development. This thesis is a 
descriptive work: we aimed to describe the normal expression pattern of 
these two proteins in the human cerebral cortex during the late-first and 
early-second trimester. By understanding the normal roles that genes and 
proteins play within development, we can later consider how mutations to 
them may adversely affect development.  
 
We started by examining the KIF22 protein and where it is found in the 
cortex. We found it to be exclusively expressed in the proliferating progenitor 
cells, and to be absent from cells which had stopped dividing and 
differentiated into neurons. We also found that the amount of KIF22 protein 
present in these progenitor cells varies as cells go through the preparatory 
stages before they divide – it is highest when the cells undergo division. 
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This finding tells us that this KIF22 protein likely has an important role in 
controlling divisions of progenitor cells. Altering the amount of KIF22 protein 
as in the 16p11.2 CNV may cause changes to progenitor proliferation. For 
example, they could prematurely become neurons which could reduce the 
overall number of cells in the final cerebral cortex.  
 
We next looked at the second protein identified: ALDOA. Unlike KIF22, we 
found this protein to be present in both dividing progenitors and neurons that 
had ceased dividing. This suggests ALDOA protein to have many different 
roles in these different cell types and we think that altering it will affect many 
aspects of brain development.  
 
Our research has studied the 16p11.2 copy number variation, which is known 
to be mutated in 1% of autism patients. We questioned which of the genes 
from the 16p11.2 region are expressed in actively dividing progenitor cells of 
the developing human cerebral cortex, and found two. We would next like to 
study the effects of changing the level at which these genes are expressed in 
the developing brain. However, we cannot do this in the developing human 
brain so we will need to use other models. To answer these questions we 
have proposed from our findings in this study, future work could make use of 
“mini-brains” grown in the laboratory from stem cells, which would allow us to 
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1  Introduction 
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1.1 The history of the human cerebral cortex 
The earliest recorded reference to the brain from 1700BC was written in the 
Edwin Smith Surgical Papyrus describing the correlation between brain injury 
site with specific injury symptoms. During Roman times the physician Galen 
overturned the previous views of Aristotle that the heart was the epicentre of 
human intellect. Through careful dissections he deduced the brain to be the 
site of human cognition, memories and sensations (Gross, 2009). Galen’s 
deductions of the brain remained unchallenged for nearly 1500 years and 
were not substantially expanded until the 1600s when Thomas Willis 
pioneered research of the brain and nervous systems (Feindel, 1962). Willis 
was the first to argue that it was the cerebral cortex that provides higher 
cognitive functions in humans through many careful comparative 
neuroanatomy dissections. With these he highlighted the enlarged cortical 
size and convoluted gyri of humans compared to other species and proposed 
the advanced human intellect was due to these differences (Molnár, 2004). 
 
 From there much understanding of the particular functions of individual 
cortical regions came observations of patients having incurred brain damage.  
Perhaps a most famous example is that of Phineas Gage, the railroad worker 
whose frontal lobe was damaged by a rod in 1848 which provided 
understanding of the how connections from the prefrontal cortex drive 
executive functions including behaviour and personality (Macmillan, 2001). 
Triggering movement of particular muscle sets through electrical stimulation 
coupled with lesions to specific cortical regions inducing defects to motor 
functions allowed researchers to build maps of the motor cortex (Fritsch and 
Hitzig, 1870; Ferrier, 1886). It is these, and many other, insights of 
researchers and anatomists throughout history, and constantly ongoing 
research, that has presented the cerebral cortex as a vastly complex brain 
region responsible for so much of our higher level cognitive functions 
including our consciousness, language, movement and ability to perceive 
and interpret the world around us.  
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The human cerebral cortex accounts for 40% of the brain’s mass (Saladin, 
2011). It is a 3-4mm thick stratified tissue structure containing around 15 
billion neurons (Roberts, 1992; Saladin, 2011) divided into functional regions 
which can be identified and characterised by their regional specific 
cytoarchitecture. This variation of cellular composition, or cytoarchitecture, in 
different cortical regions was first noted in the 1860s by Theodor Meynert 
who developed histological staining of brain slices for visualisation.  
 
This histological staining method allowed for the work of Korbinian Brodmann 
who comprehensively described the cytoarchitecture of the cerebral cortex 
(Brodmann, 1910). His work described 52 areas, identified by the 
arrangement of cells in each region, which were later linked to specific 
functions including the auditory and visual systems. 
 
1.2 The structure of the cerebral cortex 
 
The developed, adult cerebral cortex is a highly folded structure comprising 
two cerebral hemispheres separated by the medial longitudinal fissure. The 
cortex is organised into a 6-layed structure with each layer characterised by 
different neuronal populations and neuronal connections. All of the cortical 
layers contain neurons one of two types; the majority (70-80%) are excitatory 
glutamatergic neurons and the minority (20-30%) are GABAergic inhibitory 
interneurons (DeFelipe and Farinas, 1992). Correct balance of the numbers 
and connectivity of these two cell types is critical to correct cortical function.  
 
1.3 Developmental terminology 
For clarification, there are two different terms to describe the progression of 
human fetal development: post-conceptual weeks (pcw) and gestational 
weeks (GW). While the work described in this thesis uses pcw, the 
bioinformatics dataset used, and other descriptions in the literature, use GW. 
The difference between them is approximately two weeks: gestational weeks 
are counted from the date of the mother’s last menstrual period and includes 
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about two weeks where she was not pregnant. Post-conceptual weeks (pcw) 
is the actual number of weeks since the conception and is more accurate and 
is determined by ultrasonography. It is important to consider the slight 
differences in these timescales throughout this thesis, particularly when we 
describe the dataset used for bioinformatics analysis. 
 
 
1.4 Mice as models for the human cerebral cortex 
 
In this thesis, and particularly the introduction, we are describing human fetal 
cortex development. However, much of our knowledge of human 
development is derived from work in non-human models, in particular mice. 
Perhaps the most physically obvious difference between mice and human 
cortices (besides the size), is the smooth brains of the lisencephalic mice 
compared to the folded cortices of gyrencephalic humans and other species 
including primates and ferrets. However simply increasing the size of the 
brain does not scale to increased volume or neuron number (reviewed in 
(Herculano-Houzel, Manger and Kaas, 2014) Cortical folding is a fascinating 
topic in itself (reviewed here (Llinares-Benadero and Borrell, 2019)), however 
in humans it does not begin until after 20pcw, an age past the scope of this 
thesis so any schematics of human brains are shown as predominantly 
smooth. The folded brain of humans allows for a considerable increase in 
neuron number in relation to brain size, and it is the presence of a second 
fibre layer, the outer sub-ventricular zone (oSVZ) which acts as a secondary 
proliferative hub in humans (and primates) taking over from the ventricular 
zone (VZ) later in development as the primary proliferative hub. It is thought 
that the presence of this secondary proliferative hub in the larger brained-
humans and primates contributes in part to the massive increase of the 
neocortical size in these species (Lui, Hansen and Kriegstein, 2011). The 
germinative regions of the primate brain is divided into distinct 
compartments: The ventricular zone (VZ) and the sub-ventricular zone 
(SVZ). In primates the SVZ is divided into two parts – the inner sub-
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ventricular zone (iSVZ) and the outer sub-ventricular zone (oSVZ) with these 
two layers separated by an inner fibre layer (IFL) (Smart et al., 2002). No 
oSVZ has been described in rodents (Smart et al., 2002).  
  The differences in cortical structure between mice and humans are 







Figure 1: Comparison of mouse and human cortical development 
A comparison of mouse and human cortex development. The primary 
difference is the outer subventricular zone in humans which acts as a 
secondary proliferative hub contributing to a large increase in neuron 
number. 
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1.5 Forebrain development 
 
Gastrulation begins around 3 weeks after fertilisation (3pcw) in humans and 
is the very beginning of the development of the nervous system. Here the 
embryo is organised into three germ layers: the outer ectoderm layer, the 
middle mesoderm layer and the inner endoderm layer. It is the ectoderm on 
the outside that forms the neural plate, the precursor to the nervous system. 
This neural plate is a flat sheet of neuroepithelial cells that folds inwards 
dorsally to form the neural tube, the process is termed neurulation and 
occurs during 3-4pcw. Following neural tube closure, distinct swellings 
appear in the rostral part of the tube. These bulges result in formation of 
three primary vesicles.  
 
1.5.1 Embryonic forebrain structures 
 
Initially there are three primary vesicles which form the embryonic brain: the 
prosencephalon (forebrain), mesencephalon (midbrain) and the 
rhombencephalon (hindbrain) (Vaage, 1969; Martinez and Puelles, 2000; 
Price et al., 2011) The prosencephalon then subdivides into the 
telencephalon which will go on to form the cerebrum, and the more caudal 
diencephalon (Figure 2).  
 
The dorsal part of the telencephalon (the pallium) will eventually form the 
cerebral cortex, the region of study for this thesis, while the ventral part (the 
subpallium) will form the basal ganglia (Sur and Rubenstein, 2005).  
 
The vast majority of the developing cortex comprises the 6 layered 
neocortex, however there are also the phylogenetically older allocortex 
areas: the paleocortex and the archicortex which includes the hippocampal 
cortex (N Filimonoff, 1947; Goulas et al., 2019). These older areas typically 
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comprise of three or four layers in adults. This thesis will focus on 







Figure 2: Formation of the three primary vesicles 
The three primary vesicles: The prosencephalon (forebrain) which 
goes on to form the telencephalon and diencephalon. The 
mesencephalon (midbrain). The rhombencephalon (hindbrain) which 
forms the metencephalon and the myelencephalon. There is also 
shown on this figure the spinal cord. 
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1.6 Development of the human cortex 
 
Development of the human neocortex is a vastly complex procedure that 
requires precise temporal and spatial regulation to ensure correct cortical 
size and architecture.  The process is summarised in Figure 3 (based on 
diagram from (Budday, Steinmann and Kuhl, 2015)) and is described in detail 
throughout this section. 
  
  
Figure 3: Process of human cortex development over time 
Schematic showing the process of cortical development until the 
end of neurogenesis. VZ = ventricular zone, MZ = marginal zone, 
SVZ = subventricular zone, IZ = intermediate zone. GW = 
gestational weeks. The cortex forms in an inside out manner with 
the earlier born neurons (teal green) migrating to the innermost 




1.6.1 Cortical development occurs in waves 
 
Cortical development (corticogenesis) can be divided into three main stages 
as visualised in Figure 4 which will be described in greater detail in this 
chapter. These are: proliferation, characterised by rapid expansion of cell 
numbers, neurogenesis and gliogenesis. Ensuring the cells switch to 
undertake different types of cell division is critical to ensuring both the correct 
number of neurons at the end of development and correct proportions of 






Figure 4: Stages of human cortical development 
Schematic showing human cortical development divided into the 
main stages. Graph is not to scale, the numbers of cells generated 
at each stage is not proportional to the graph. Y axis indicates 
which stage the majority of cells are in.  
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1.6.2 Germinative zones in human cortex development  
 
The complete cortex is made up of a variety of distinct cell types, which can 
be sorted into two basic classes of excitatory neurons and inhibitory 
interneurons. The progenitor cells which create these separate populations 
are located in spatially specific germinal zones within the developing cortex 
(Goulas et al., 2019). A schematic of the developing cortex (based on a 
12pcw brain) is shown in Figure 5 with the germinative zones shown in 
green. The excitatory glutamatergic neurons are born in the cortex itself, in 
the VZ and SVZ, and migrate out radially (indicated by pink arrow) to their 
appropriate layer in an inside-out manner (Rakic, 1974; Bystron, Blakemore 
and Rakic, 2008). Their counterparts, the inhibitory interneurons, are born in 
the sub-pallial ganglionic eminences (GE) and they tangentially migrate up to 
the neocortex through the IZ and CP to their final position and integration into 
circuitry (dark blue arrows) (Porteus et al., 1994; Bystron, Blakemore and 
Rakic, 2008). In this thesis we are focusing on the germinative zones of the 
cortex: the VZ and SVZ. 
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Figure 5: Schematic of a coronal section showing the different 
germinative regions of the 12pcw human fetal cortex 
The VZ and SVZ (green) are the primary birth site of excitatory 
neurons which migrate radially out through the intermediate zone (IZ) 
to their final destination of the cortical plate (CP) where they form the 
six cortical layers in an inside out manner.  
 
Inhibitory interneurons are mostly born in the ganglionic eminences 
(GE) of the subpallium of the brain where they tangentially migrate 
through the IZ and CP to their final position in the cortex where they 
integrate into cortical circuitry.  
 
Other structures shown are the cortical hem (CH), the hippocampal 





1.6.3 Initiation of corticogenesis in pre-natal brain 
development 
 
Following closure of the neural tube, the first wave of corticogenesis, the 
proliferative wave, is initiated at 4-6pcw by the division of highly polarized, 
actively mitotic neuroepithelial cells (NECs). These symmetric divisions occur 
at the ventricular margin and are characterised by the process of interkinetic 
nuclear migration (IKNM). In this process the nuclei of the cells “bounce” up 
and down through the cytoplasm during the cell cycle: they move from the 
basal surface, where they undergo DNA synthesis during S phase, down to 
the apical ventricular margin where they divide producing two identical 
daughter cells and they migrate back up towards the basal abventricular 
surface to repeat the process (Figure 6) (Sauer and Walker, 1959; Bystron, 
Blakemore and Rakic, 2008).  
 
These NECs are the earliest progenitors in the cortex and the origin of all 
neocortical neurons. The NECs undergo proliferative symmetric divisions 
producing proliferative daughter cells thus rapidly increasing the committed 
neural precursor population and resulting in rapid increase of cortical 






Figure 6: Interkinetic nuclear migration 
Schematic showing interkinetic nuclear migration (IKNM) of an 
aRGC during cortical development. As the cells go through the cell 
cycle their nucleus migrates within the VZ allowing for a much 
greater number of cells to be present and creating a pseuo-stratified 
layer. The cell nucleus moves away from the ventricular edge as it 
goes through G1 phase transitioning to S phase as it reaches the 
basal surface of the VZ. Entering G2 phase it migrates back down 
towards the ventricular edge where it undergoes mitosis producing 
two daughter cells. In aRGCs the centrosome (yellow circle) is 
located near the ventricular edge and the nucleus moves towards it 
for cells to undergo mitosis. 
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1.6.4 Onset of cortical neurogenesis 
 
Next is the continuation of proliferative corticogenesis and the onset of the 
neurogenic wave of cortical development. This begins when the proliferative 
NECs switch from a symmetric to asymmetric division and the establishment 
of the radial glial system. The process of neurogenesis is highly complex and 
described in some detail below, the compartments and cell types in the 




Figure 7: Schematic of the human cortex during neurogenesis 
Schematic showing the different compartments of the human 
cerebral cortex during the neurogenesis stage of development.  
 
The ventricular zone harbours proliferative apical radial glia cells 
and their daughter intermediate progenitor cells. The subventricular 
zone contains basal radial glia cells which also produce 
intermediate progenitor cells. These proliferating cells will also 
produce neurons which migrate outwards along the radial glia fibres 
to their final position in the cortical plate.  
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1.6.4.1 Establishment of the radial glial system 
 
The NECs gradually express the transcription factor PAX6 and adopt an 
apical radial glial cell (aRGC) identity (Walther and Gruss, 1991; Stoykova 
and Gruss, 1994; Kriegstein and Alvarez-Buylla, 2009; Manuel et al., 2015). 
These aRGCs exhibit an elongated morphology and span the cortical wall 
with their basal process extending to the pial surface and their shorter apical 
process connecting to the ventricular edge. Similar to their NEC precursors, 
these aRGCs also exhibit apical to basal polarity and undergo IKNM and 
divide at the ventricular edge (Götz and Huttner, 2005). Unlike NECs 
however, the aRGCs do not migrate the entire length of their fibres which 
span the width of the cortex, only through the ventricular zone.  
 
1.6.4.2 Key functions of aRGCs during corticogenesis 
 
aRGCs have several key functions during cortical development, the two most 
relevant are described: 
1) Through their asymmetric divisions producing one identical daughter 
cell and one fate-restricted progenitor or neuron they act to contribute 
to both generation of neurons, ensuring correct final neuron number 
and ensuring maintenance of a sufficient progenitor pool to ensure 
correct cortical size. 
2) Their basal processes span the cortex to the pial surface and provide 
a scaffold for cells such as neurons to migrate to the outer layers of 




1.6.5 Progenitor division, diversity and differentiation 
 
The proliferative zones can be considered the factories of the cortex, 
responsible for production of cellular number and variety and are shown in 
Figure 5. In humans the first proliferative zone, the ventricular zone (VZ), 
emerges with the onset of neurogenesis and cells undergo IKNM through it 
(see Figure 6). The cell bodies of aRGC cells are confined to the VZ with 
their centrosomes located in the apical region of their fibre (Chenn et al., 
1998). As neurogenesis progresses, dividing cells from the VZ congregate at 
the basal edge of the VZ thus forming the second proliferative hub of the 
cortex, the subventricular zone (SVZ) (Smart, 1973; Smart et al., 2002; 
Bystron, Blakemore and Rakic, 2008). As neurogenesis progresses, more 
progenitors switch from the proliferative to neurogenic divisions as shown in 
Figure 8 with the timescales for human and mouse described in the legend 
(Picco et al., 2018). Maintenance of this balance of proliferation and 
differentiation is essential for correct cortical formation. 
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Figure 8: The balance of proliferation and differentiation 
As neurogenesis proceeds the types of division cells undergo 
changes accordingly, initially there is huge amounts of proliferation 
to build cortical numbers followed by generation of neurons to 
increase numbers of neurons in the final complete cortex. To give 
some scale to the time axis; in humans, neurogenesis starts around 
E40 and continues for approximately 80 days while in mouse it 
occurs from around E11 until E19.  
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1.6.5.1 Types of progenitor division  
 
There are a variety of types of division progenitor cells can undergo during 
cortex development. Cells undergoing correct division at the appropriate time 
is essential for correct cortical formation. The division types are as follows 
(Götz and Huttner, 2005; Florio and Huttner, 2014) and summarised in 




1) Symmetric proliferative – cell produces two identical proliferative 
daughter cells, the same type as the parent cell. This is a self-
amplifying division. 
2) Symmetric differentiative – cell produces two identical proliferative 
daughter cells, a different type to the parent cell. This is a self-
consuming division 
3) Symmetric neurogenic – cell produces two identical post-mitotic 





1) Asymmetric bi-differentiative – cell produces two non-identical 
proliferative daughter cells. This is a self-consuming division. 
2) Differentiative/neurogenic – cell produces one proliferative cell 
(different to the parent cell) and one neuronal cell. This is a self-
consuming division. 
3) Differentiative – cell produces two proliferating daughter cells, one of 
the same type as the parent cell and the other different. This is a self-
renewing division.  
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4) Neurogenic – cell produces one proliferating daughter cell of the 
same type as the parent cell and one neuronal cell. This is a self-








Figure 9: Different types of progenitor divisions in the 
developing cortex 
Schematic showing the different types of progenitor divisions; 
however, it should be noted that not all types of cell produced by 
each kind of division are shown, only an example. Based on figure 
from (Florio and Huttner, 2014) 
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1.6.5.2 Different progenitor subtypes 
 
After establishment of the radial glial system and formation of the proliferative 
VZ and SVZ, progenitor cells in the developing human cerebral cortex can be 
divided into two main classes; apical progenitors and basal progenitors. 
 
1.6.5.2.1 Apical progenitors 
 
The first apical progenitor cell class to appear is the described above 
neuroepithelial cell (NEC) which undergoes predominantly proliferative 
symmetric division. 
 
Next is the emergence of apical radial glial cells (aRGCs) (also called 
ventral radial glial cells (vRGCs), the cell bodies of which reside in the 
ventricular zone where they undergo IKNM during G1 and G2 phases of their 
cell cycle with mitosis occurring at the apical surface (Figure 6) (Götz and 
Huttner, 2005). These aRGCs express the transcription factor PAX6 and 
astroglial markers such as GFAP (Levitt and Rakic, 1980; Bystron, 
Blakemore and Rakic, 2008). As shown in Figure 9, aRGCs have a huge 
capacity for many different types of division however their proliferation and 
differentiation must be tightly controlled to produce the required number and 
subtypes of neurons.  
 
One daughter type produced by aRGC division is apical intermediate 
progenitors (aIPs). These cells are similar to their aRGC parent cells in that 
they are located in the ventricular zone, express PAX6 and undergo IKNM to 
divide at the apical surface (Gal et al., 2006; Tyler and Haydar, 2013). In 
other aspects they differ from their parent cell: most strikingly that they lose 
self-renewing potential and can only perform a self-consuming, symmetric 
neurogenic division producing a pair of neurons (Gal et al., 2006; Tyler and 
Haydar, 2013; Florio and Huttner, 2014). 
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1.6.5.2.2 Basal progenitors 
 
Basal radial glia cells (bRGCs), also known as outer radial glia cells 
(oRGCs) are born from differentiative divisions of their mother aRGC from 
which they inherit their basal process. Located in the SVZ they lack the 
apical connection of aRGCs and undergo asymmetric self-renewing divisions 
ensuring a continuous pool of undifferentiated bRGCs as well as sufficient 
neuron production (Hansen et al., 2010; LaMonica et al., 2012).  
 
In contrast to aRGCs, which divide by undergoing IKNM, bRGCs divide by 
the process of mitotic somal translocation (MST). During MST, in the hour 
before cytokinesis the cell soma rapidly ascends its radial fibre towards the 
pial surface (Hansen et al., 2010; Wang et al., 2011). Conversely to aRGCs, 
the centrosome in bRGCs is located in the fibre on the pial side of the 




Basal intermediate progenitors (bIPs) are born from either bRGCs or 
aRGC divisions, they migrate to the SVZ losing their apical and basal 
processes and begin expressing TBR2 (Miyata et al., 2004; Noctor et al., 
2004; Englund et al., 2005). These bIPs can undergo two different types of 
division.  
1) The first type is similar to that of aIPCs, undergoing a self-consuming, 
symmetric neurogenic division to produce two neurons (Miyata et al., 
2004; Noctor et al., 2004). 
2) The second type increases the number of bIPs, they undergo multiple 
symmetric proliferative divisions producing two daughter bIPs before 
undergoing a final self-consuming, symmetric neurogenic division 
(Noctor et al., 2004).  
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1.6.6 The cell cycle in cerebral cortex development 
 
1.6.6.1 The cell cycle 
 
The cell cycle is the process by which a cell replicates its DNA and divides its 
organelles and cytoplasm to produce two daughter cells. It comprises four 
distinct phases: G1 phase, S phase, G2 phase and M phase (mitosis) (in 
addition there is G0 phase which is cell cycle exit) and is shown in Figure 10. 
 
G1 Phase is a period of immense cellular growth and G1 phase has a highly 
variable duration. During G1 the cell grows in size and increases organelle 
number. 
S Phase is the stage of DNA replication, during this phase all chromosomal 
DNA is replicated. 
G2 Phase is the second growth phase during which there is rapid cell growth 
and protein synthesis.  
M Phase comprises chromosome separation and cytokinesis. M phrase is a 
highly regulated, complex sequence of events divided into six phases each 
with key events: 
- Prophase: chromatin condenses, and the nucleolus disappears  
- Prometaphase: the nuclear membrane breaks down; the 
chromosomes form kinetochores and kinetochore microtubules 
attach to the kinetochores. 
- Metaphase: The chromosomes line up on the metaphase plate of 
the cell. 
- Anaphase: Chromosomes are split at the centromeres and move 
to opposite poles of the cell. 
- Telophase: Nuclear envelope re-assembles around each set of 
chromatids and the chromosomes unfold to chromatin.  
- Cytokinesis: The cytoplasm of the cell cleaves in two, separating 
the cell into two daughter cells. 
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Figure 10: The cell cycle and M phase 
Interphase of the cell cycle comprises G1, S and G2 phase before 
entering M phase where cells divide to produce two daughter 
cells. S phase can be marked with BrdU – a thymidine analogue 
taken up by cells in S phase and then stained with an antibody 




1.6.6.2 The cell cycle in corticogenesis 
 
To ensure the precise temporal and spatial control required to produce the 
complete cortex, strict regulation of progenitor division in the proliferative 
regions of the cortex is essential.  Major controlling factors of neuron number 
and final brain size is cell cycle length, exit from the cell cycle and 
differentiation to neurons. Any changes to this carefully orchestrated balance 
of proliferation and differentiation can have many cascading effects leading 
to a wide range of neurodevelopmental disorders.  
 
1.6.6.2.1 Cell cycle length and neural progenitor fate 
 
As neuroepithelial cells transition to radial glial cells and these radial glial 
cells switch from neurogenic to proliferative divisions with neural 
development progression, there in an increase in the cell cycle length of 
these cells from (in mice) 10.2 hours (E12) to 18 hours (E16)  (Takahashi, 
Nowakowski and Caviness, 1995).  As neurogenesis progresses there are 
increasing proportion of progenitor cells undergoing neurogenic divisions 
correlating with increasing cell cycle length (Takahashi, Nowakowski and 
Caviness, 1995). Strikingly this is predominantly due to increased G1 length 
(Takahashi, Nowakowski and Caviness, 1995) leading to the “cell cycle 
length hypothesis” proposed initially by Calegari and Huttner from studies in 
mice cortex development (Calegari and Huttner, 2003). This hypothesis 
proposes that lengthening the time of G1 phase is sufficient to induce the 
switch between proliferative and neurogenic fates.  
 
In this model of how cell cycle length determines progenitor division type, 
summarised in Figure 11, there is a threshold of exposure to a cell fate 
determinant (e.g. a differentiation factor) that cells must reach to make a 
neurogenic vs differentiative division. The exposure to this factor can be 
increased by increasing the cell cycle length, thus increasing the chance the 
threshold will be reached. If it is not reached (red cell) then the cell will 
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undergo a proliferative division, if it is reached or surpassed (green cell) then 
the cell will undergo a neurogenic division. 
 
  
Figure 11: Summary of the cell cycle length hypothesis 
The cell cycle length hypothesis states that cell fate is dependent on 
the cell being exposed to a certain amount of a differentiative factor. 
The longer the cell cycle, specifically G1 phase, the more exposure 
the cell has and the greater the chance of it reaching this threshold. 
If G1 phase is relatively short, it does not reach the threshold and 
undergoes a proliferative division. However, as neurogenesis 
progresses and the cell cycle and therefore G1 length increases, 
the cell is exposed to the factor for longer and eventually it will 




This was evidenced by knockdown of known components of the G1 
checkpoint mechanisms in mice, cdk4/cyclinD1, to artificially induce 
lengthening of the G1 phase which was sufficient to induce premature switch 
of progenitors to neurogenic divisions (Calegari and Huttner, 2003). In 
addition, in 2009, it was shown that shortening G1 produced the opposite 
effect; inhibiting neurogenesis and increasing the progenitor pool resulting in 
a larger brain size (Lange, Huttner and Calegari, 2009). This fits with the 
model (Figure 11) which proposed that reduced G1 length reduces exposure 
to factors required for the neurogenic switch and thus the exposure threshold 
for a neurogenic division is not met.  
 
In summary, the decision of neural progenitor cells to remain proliferating or 
to exit the cell cycle to form neurons is tightly controlled by a range of factors, 
including the cell-cycle length and the factors which govern this. These 
factors act to govern the number of cell divisions and final cell number and 
type. Any disruption to this process will have dramatic effects on final cortex 
size, structure and function.  
 
1.6.7 Neurogenesis and the formation of cortical layers 
 
The layers of the human cerebral cortex form in an inside-out manner, with 
early born neurons from the germinative zones of the cerebral cortex 
migrating radially out to form the innermost layer six of the cortex and 
subsequently born neurons migrating past them to form the outer layers. This 
is illustrated in Figure 3.  
 
These first born Cajal-Retzius cells (appearing around 8pcw in humans) 
migrate tangentially from their birth-site in the cortical hem (Takiguchi-
Hayashi et al., 2004; Bystron, Blakemore and Rakic, 2008) to form the 
transient preplate (PP) at the pial surface of the cortex (Marin-Padilla, 1983; 
Luskin and Shatz, 1985; Ayala, Shu and Tsai, 2007). With this first wave of 
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neuronal migration the Intermediate Zone (IZ) emerges; a sparse area 
comprising mainly of axon tracts with few cell bodies, separating the 
germinative VZ and SVZ from the post-mitotic neurons (Ayala, Shu and Tsai, 
2007; Bystron, Blakemore and Rakic, 2008; Hoerder-Suabedissen and 
Molnár, 2015) 
 
Subsequent waves of neurons migrating from the germinative zones split this 
preplate into the outer Marginal Zone (MZ) which harbours those first born 
Cajal-Retzius cells which will eventually become layer I, and the transient 
Subplate (SP) (Ayala, Shu and Tsai, 2007; Bystron, Blakemore and Rakic, 
2008; Hoerder-Suabedissen and Molnár, 2015). As waves of neuronal 
migration continue these neurons fill the space between the MZ and SP to 




As described above, neuronal migration resulting in neurons arriving in their 
appropriate position is essential for correct cortical formation and occurs in 
successive waves. In the developing cortex there are two main forms of 
neuronal migration: radial and tangential as shown in Figure 5.  
 
1.6.7.1.1 Radial migration 
 
During radial migration, excitatory neurons born in the cortex migrate out 
from their germinal zones (Noctor et al., 2004; Ayala, Shu and Tsai, 2007) to 
their final position in the cortex. This process accounts for the vast majority of 
neurons in the cortex (80-90%) (Ayala, Shu and Tsai, 2007). Initially neurons 
are able to migrate by somal translocation, in which they extend a long 
process to the pial surface and pull themselves up through the cortex to the 
appropriate position (Nadarajah et al., 2001). As neurogenesis progresses 
and perhaps as the distance required for travel increases with the thickening 
cortex, neurons rely more on locomotion for transport, in which they attach to 
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the apical-basal spanning processes of the radial glial cells still in the 
germinative zones and migrate up them to their final position (see Figure 3) 
(Rakic, 1972, 1990; Marín and Rubenstein, 2001; Nadarajah et al., 2001; 
Ayala, Shu and Tsai, 2007).  
 
 
1.6.7.1.2 Tangential migration 
 
The second, and much smaller in number, migratory stream of cortical 
neurons is the tangential migration of inhibitory interneurons. Born in the 
ganglionic eminences they migrate tangentially up through the CP and IZ 
(see Figure 5) where they then migrate radially to their final position in the 
cortex for integration into cortical circuitry. It is thought that any disruption to 
migration will affect the inhibitory-excitatory balance of neuronal circuitry 
causing a range of neurodevelopmental disorders such as Autism Spectrum 
Disorder (ASD). However in human cortex development the birth-place of 
interneurons is thought to be more complex than the mouse and is an area of 
conflicting research opinions, with some studies suggesting that some 
cortical interneurons may arise from the dorsal, rather than ventral, 
telencephalon (Zecevic, Hu and Jakovcevski, 2011). One 2015 study 
identified evidence in favour of this theory - cells expressing Nkx2.1 were 
found in the germinative zones of the human and monkey fetal cortex 
(Radonjić et al., 2014). However several additional studies have been unable 
to corroborate these findings (Hansen et al., 2013; Ma et al., 2013). Thus, 
this still remains a topic of controversy and will likely require detailed long-
term slice culture experiments to fully resolve. 
 
At this point of development, the neurogenesis wave begins to decrease as 






Glia cells comprise at least 50% of the human brain (Rowitch and Kriegstein, 
2010), and act as a non-neuronal support system for the brain. They have 
many diverse roles and are essential for ensuring correct neurological 
function through maintaining homeostasis, neuronal protection and support 
and formation of myelin (Jessen and Mirsky, 1980; Kessaris, Pringle and 
Richardson, 2001; Rowitch and Kriegstein, 2010). The incorporation of these 
glial cells by the process of gliogenesis is essential for the neuronal 
maturation of the cerebral cortex.  
 
The process of gliogenesis in human cerebral cortex can be divided into 
early, intermediate and late gliogenesis. Early gliogenesis, beginning with 
early neurogenesis, features the establishment of the radial glial system. 
During intermediate gliogenesis, oligodendrocytes and fibrous astrocytes 
are generated and incorporated into the expanding white matter. Lastly, late 
gliogenesis in which first lamina astrocytes and grey matter protoplasmic 
astrocytes are generated (Marín-Padilla, 2011).  
 
The switch of progenitor cells in the cortex from producing neurons to 
producing glial cells must be tightly controlled to ensure gliogenesis occurs at 
correct times in relation to neurogenesis. In early neurogenesis, NECs do not 
respond to cytokines, and the promotors of the astrocytic genes, GFAP and 
S100B are methylated causing repression of astrocyte development. When 
neurogenesis commences with emergence of RGCs, these RGCs become 
capable of responding to the cytokines as the astrocytic gene promotors are 
demethylating, giving them the potential to generate astrocytes earlier than 
required. To prevent early generation of astrocytes, extrinsic signals such as 
FGF2 repress gliogenesis ensuring that RGCs keep producing neurons. 
Gliogenesis is also repressed by Neuregulin 1 which activates the nuclear 
signalling pathway which involves ERBB2, the pathway which also 
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antagonizes astrogenesis-promoting signals. When neurogenesis ends, 
ERBB2 expression increases coinciding with the transformation of RGCs to 
astrocytes (Molne et al., 2000; Takizawa et al., 2001; Temple, 2001; 
Hermanson, Jepsen and Rosenfeld, 2002; Fox and Kornblum, 2005; Sardi et 
al., 2006; Britsch, 2007; Sanosaka et al., 2008; Rowitch and Kriegstein, 
2010; Marín-Padilla, 2011).   
 
 
This is a description of one of the possible mechanisms by which the neuron 
to glial switch is controlled, others include bHLH factors, NOTCH signalling, 
cytokines secreted by neurons, BMPS and OLIG2 (Mabie, Mehler and 
Kessler, 1999; Mehler, 2002; Barnabe-Heider et al., 2005; Fox and 
Kornblum, 2005; Marshall, Novitch and Goldman, 2005; Sanosaka et al., 
2008; Chenn, 2009; Hirabayashi et al., 2009; Namihira et al., 2009; Rowitch 
and Kriegstein, 2010; Wilkinson, Dennis and Schuurmans, 2013). This 
variety of mechanisms for regulating gliogenesis allow for transition of these 
RGCs into a variety of glial cell types. The two principal types of 






The key role of oligodendrocytes is to create the myelin sheath, essential for 
axonal insulation and conduction of action potentials (Barres and Barde, 
2000; de Castro and Bribian, 2005). Oligodendrocytes arise during neural 
development, starting at 10pcw and continuing until adulthood. During 
development oligodendrocytes are born in discreate anatomical niches which 
causes them to adopt specific migration patterns resulting in them migrating 
to highly regionally specific parts of the brain (de Castro and Bribian, 2005).  
 
During development, oligodendrocyte progenitors become oligodendrocyte 
precursor cells (OPCs) which transform into pre-oligodendrocytes, all three of 
these cell types within the oligodendrocyte lineage have the capacity for self-
renewal. This self-renewing capacity is lost as pre-oligodendrocyte cells 
become immature oligodendrocytes before reaching their final adult form as 
mature oligodendrocytes (de Castro and Bribian, 2005; Rowitch and 
Kriegstein, 2010). The process of axonal myelination by oligodendrocytes 





Astrocytes are the stars of the glial system: they have a variety of roles in the 
nervous system including maintaining extracellular ion balance and water 
balance, structural support and modulating synaptic transmission to highlight 
a few and their dysfunction has been implicated in Fragile X and Rett 
Syndrome autism models (Rowitch and Kriegstein, 2010; Sofroniew and 
Vinters, 2010; Molofsky and Deneen, 2015). Unlike oligodendrocytes, 
astrocytes are rather enigmatic and the stages of astrogenesis are not so 
clearly understood as the individual stages lack specific markers. However 
they are still known to arise from RGCs undertaking the gliogenic switch 
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producing astrocyte precursors which then migrate through the cortex to their 
terminal location and transform to mature astrocytes (Rowitch and Kriegstein, 
2010; Molofsky and Deneen, 2015).  
 
1.6.7.3 Termination of the radial glial system 
 
As pre-natal development draws to a close, neurogenesis has long ended, 
and neuronal and glial migration is complete making the radial fibres 
redundant. The remains of the proliferative RGC populations undergo final 
terminations into glial cells. Some proliferative populations do remain into 
adulthood and are an area of intense research in regenerative medicine. This 
includes the hippocampus where there are conflicting studies with one 
showing undetectable levels of adult hippocampal neurogenesis (Sorrells et 
al., 2018) while another suggested that hippocampal neurogenesis persisted 
long into adulthood (Boldrini et al., 2018). The extent of this neurogenesis is 
controversial and while it has been shown to occur in several species 
(reviewed in (Gage, 2002)), its occurrence in humans has not been 
extensively proven (reviewed in (Kempermann et al., 2018)). Interesting as it 
is this topic far outside the scope of this thesis which will focus on 




1.7 Autism Spectrum Disorder 
 
1.7.1 Introduction to Autism Spectrum Disorder 
 
First described in 1943 by Leo Kanner (Kanner, 1943), Autism Spectrum 
Disorder (hereafter abbreviated to ASD) is a neurodevelopmental disorder 
characterised by impaired social interaction and communication, repetitive 
and restricted behaviours and interests with typical (although not exclusive) 
early childhood onset of symptoms (WHO, 2019) which continue to persist 
without remission.  
 
1.7.1.1 The umbrella of autism  
 
As stated in the name, ASD is a spectrum of disorders, and the autism 
umbrella term is used to encompass five main subtypes of autistic disorders.  
1) Pervasive developmental disorder 
2) Asperger syndrome 
3) Rett syndrome 
4) Childhood disintegrative disorder 
5) Autism disorder 
 
The terminology of these is often changing and a source of disagreement 
among clinicians, as of the time of writing in the UK these are now classed 
under the broader autism diagnosis as per DSM-5 (Association and Force, 
2013). In this thesis the individual subtypes of autism will not be discussed in 




1.7.1.2 Clinical features of ASD 
 
Typically noticed in the first three years of life, the clinical features of ASD 
are highly variable between individuals however there is a convergence on 
impaired social communication. The behaviours most commonly associated 
with ASD, the so called core symptoms, are impaired social interests, 
impaired communication skills and highly rigid, specific interests (Nazeer and 
Ghaziuddin, 2012). As well as these stereotyped social impairments there 
are many secondary symptoms associated with ASD including 
hyperactivity, aggression, with some patients with ASD also being diagnosed 
with intellectual disability and epilepsy (Nazeer and Ghaziuddin, 2012).  
 
1.7.1.3 Prevalence of ASD 
 
The estimates for prevalence of autism does vary drastically depending on 
factors such as diagnostic criteria used, age of children, and geographical 
location. In general for the UK it is estimated to be around 1% of the 
population (Newschaffer et al., 2007; Park et al., 2016). While there has been 
attention focussed onto the increased prevalence of ASD within the last 20 
years, this increase is likely to changes in diagnostic criteria and earlier 
diagnosis, however increased risk factors cannot be ruled out (Newschaffer 
et al., 2007; Fisch, 2012; Park et al., 2016).  
The prevalence of ASD diagnoses is highly skewed between the sexes 
affecting four times as many boys than girls, however it is suspected that 
there is severe under-recognition in girls and the true number is much 




1.7.1.4 Heritability of ASD 
 
ASD is a highly hereditary disorder, even in early case studies of the disorder 
the presence of a second autistic child in a family containing one was 50-100 
times greater than expected by chance (Rutter, 1968). Twin studies further 
solidified this link, monozygotic twins have autism concordance rates of up to 
70% (Folstein and Rosen-Sheidley, 2001).  
 
Coupled with studies that showed autistic-like traits (although not reaching 
the threshold for diagnosis) were more prevalent in parents of children 
affected by ASD than those unaffected (Folstein and Rosen-Sheidley, 2001) 
(although it is important to note that in non-severe cases the diagnosis of 
ASD is “soft” and dependent upon the opinion of the clinician, and lack of 
diagnosis does not mean absence) this suggested some genetic 
underpinnings for ASD. The search for the genetic cause of autism is, and 
has long been, an area of intense research and will be summarised later in 
this chapter. 
 
1.7.2 Neuroanatomy of ASD 
 
While ASD commonly presents as a variable set of behavioural phenotypes, 
there have also been neuroanatomical changes identified in ASD patients 
encompassing structure, functions and connectivity, however it is important 
to note that none of these neuroanatomical changes have been identified as 
causative to ASD.  There are many areas of the brain that are linked to the 
functions implicated by autism highlighting the complexity of the disorder. 
They are shown in Figure 12 and include regions throughout the brain 
including the thalamus, cerebellum and cortex. While it is likely they all to 
contribute to ASD in different ways through their different functions, in this 





Figure 12: Brain regions implicated in autism 
Shown are the brain regions implicated in the three core 




Interestingly a leading theory of the neuropathology of ASD, and one of the 
most replicated findings as well as a described feature in the original 1943 
Kanner paper, is that of altered brain growth. This suggests that ASD begins 
much earlier than the onset of clinical symptoms. Many patients exhibit 
accelerated brain growth in early post-natal life, as evidenced by rapid 
increase in head circumference (a proxy for brain size) peaking to 10% 
greater than normal from 18 months to two years (Courchesne, Carper and 
Akshoomoff, 2003; Amaral, Schumann and Nordahl, 2008; Sacco, Gabriele 
and Persico, 2015). A key issue in MRI studies of ASD is the small sample 
sizes and age variability coupled with the fact that they tend to focus on 
higher-functioning individuals (most likely as they are willing to enter a 
scanner) (Amaral, Schumann and Nordahl, 2008; Lord and Jones, 2012). 
Regardless, MRI studies still provide valuable targets for identifying 
neuroanatomical changes in ASD patients.  
 
1.7.3 Genetics of ASD 
 
Autism was originally reasoned to be a disorder of neuropathological origin, a 
view which shifted in in the 1950s to consider it a psychiatric disorder 
stemming from deficiencies in parenting; so-called “refrigerator mothers”. 
This view has been relatively discarded and we circle back to the present day 
idea of autism as genetic neurodevelopmental disorder with a neurobiological 
explanation (Folstein and Rosen-Sheidley, 2001). While rogue theories do 
continue to persist surrounding the causes of autism, with one of the most 
harmful being the 1998 study linking the MMR vaccine to autism which was 
unequivocally refuted by a number of studies (DeStefano, 2007; Taylor, 
Swerdfeger and Eslick, 2014), the general consensus is for autism as a 
genetic disorder.  
 
This section will discuss a little of the genetics of autism. There is some 
standard terminology used throughout which, before diving into the 





Table 1: Table of terminology 
Term Definition Example 
Syndrome Collection of 
uncorrelated symptoms 




Monogenic syndrome A disorder arising from 
a mutation to a single 
gene 
Fragile X 
Polygenic syndrome A disorder arising from 
the combined mutation 




Idiopathic Disorder which arises 
spontaneously and/or 
has no known genetic 
basis 
Idiopathic epilepsy 
De novo disorder Disorder that arises for 
the first time in a family 
- often during meiosis 
Angelman Syndrome  
Inherited disorder Disorder that has been 
passed down from 
parents 





1.7.3.1 Genetic Studies of ASD  
 
Autism is a disease with a complex and highly heterogeneous nature, while it 
tends to converge on a rather limited set of symptoms, there is no single 
genetic cause, making it a particularly intriguing area for study. Instead it can 
be considered to be multi-factorial arising from many different genetic risk 
factors (Packer, 2016). Even the most common genetic mutation associated 
with ASD, the 16p11.2 CNV,  accounts for only 1% of ASD cases highlighting 
just how vast the autism aetiological landscape is (Abrahams and 
Geschwind, 2008). To try to further understand the genetics of ASD, in 2008 
the Autism Gene Database was created, providing a database of causative 
and candidate ASD genes. There are many different types genetic changes 
(summarised in Table 1), which are associated with autism: the mutation of a 
single gene or mutation to a larger region, whether it occurs de novo or is 
inherited and whether the genetic cause is known or not.  
 
1.7.3.1.1 Monogenic causes of ASD 
 
The “traditional” identification of autism genes involved identifying a patient 
with a syndrome of which the features included autism, thus linking the 
mutation in that gene to autism. Within the past 20 years things have moved 
rapidly as genome sequencing has become easier and cheaper, as well as 
datasets becoming more widely available and larger cohort availability. This 
has allowed the field to expand from studying a small number of monogenic 
disorders, to consider the vast genetic landscape of autism. The advent of 
next generation sequencing (NGS) allows for unbiased interrogation into the 
genome of a patient with autism to identify mutations that may be associated 
with the autism diagnosis. Uploading this to databases will allow multiple 
researchers to correlate many cases worldwide to identify frequently 
occurring mutations in ASD patients.  
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Around 5-10% of ASD patients have been shown to have monogenic ASD; 
where a single gene mutation produces a syndrome, which includes autism 
as a symptom – also classing it as syndromic ASD (Benger, Kinali and 
Mazarakis, 2018; Wisniowiecka-Kowalnik and Nowakowska, 2019). The 
most common single-mutation (monogenic) syndrome associated with ASD 
is Fragile X syndrome and other monogenic disorders with ASD as a 
frequent symptom include Rett Syndrome, Angelman Syndrome and 
tuberous sclerosis (Sztainberg and Zoghbi, 2016; Benger, Kinali and 
Mazarakis, 2018; Wisniowiecka-Kowalnik and Nowakowska, 2019). Some of 
these, like Fragile X syndrome, are typically inherited (Saldarriaga et al., 
2014), others such as Angelman Syndrome frequently occur de novo 
(Clayton-Smith and Laan, 2003). These and other monogenic syndromes 
with high ASD prevalence are summarised in Table 2 however this is by no 
means an exhaustive list of genes, nor non-ASD clinical features. These 
single-gene mutations occur at a very low prevalence in the population and 
individually account for no more than 1% of ASD, however being able to link 
specific gene mutations to ASD in these patients provides a pathway to begin 




Table 2: Most common causes of monogenic ASD 
Syndrome Gene Occurrence of ASD in 




Fragile X FMR1 30-60% (males only) ID, epilepsy, 
hyperactivity 












































1.7.3.2 Copy number variations in autism  
 
The search for the underlying genetic causes of ASD gained a new avenue 
of research with the use of array comparative genomic hybridisation (array 
CGH), a tool to detect microduplication and microdeletions in the 
chromosomes that would not be detected by traditional karyotyping. This 
identified de novo copy number variations (CNVs) as being strongly 
associated with ASD (Sebat et al., 2007). A CNV is the duplication or 
deletion of a greater than 1000bp region of a chromosome. CNVs are 
relatively common in the human genome and have important functions for 
increasing biodiversity and be either inherited or occur de novo (Yoo, 2015).  
 
The significance of CNVs in ASD came from studies which identified a 
greater occurrence of CNVs in idiopathic ASD patients (in whom there was 
no inherited autism-implicated genetic mutation) compared to controls (Vicari 
et al., 2019) suggesting that presence of a CNV is a significant risk for ASD 
(Sebat et al., 2007). CNVs can be classed as recurrent or nonrecurrent. 
Recurrent CNVs occur when the region of DNA is flanked by two almost 
identical (95-97% sequence homology) low copy repeats. This similarity 
makes the region predisposed to non-allelic homologous recombination 
(NAHR) resulting in duplications or deletions with reciprocal changes to gene 
dosage (Wisniowiecka-Kowalnik and Nowakowska, 2019). Nonrecurrent 
CNVs come from fork stalling and template switching (FoSTeS) and non-
homologous end joining (NHEJ). This thesis will be focusing on the recurrent 
CNVs. As these CNVs contain many genes identifying which contribute to 
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the ASD phenotype is a challenge. Some of the recurrent CNVs most 
commonly identified in ASD patients are shown in Table 3. In addition, many 
of these CNVs have incomplete penetrance for ASD suggesting that the 
individual’s genetic background will impact susceptibility for ASD. 
 
Table 3: CNVs most frequently associated with ASD 
Locus CNV Occurrence 











Inherited or de 
novo 
1q21.1 Duplication 8-50% 
(Brunetti-









Inherited or de 
novo 
2q37 Deletion ~25% ID, seizures, 
hypotonia 
De novo (very 
very rarely 
inherited) 
3q29 Deletion ~30% 






















75% de novo, 
25% inherited 







85% de novo, 
15% maternal 
inherited 





25% de novo 












16p11.2 Duplication ~25 % 
(Niarchou et 
al., 2019) 

























17p11.2 Deletion 90% (Laje et 
al., 2010) 








17p11.2 Duplication ~80% 
(Molina et 
al., 2008) 








17q12 Deletion ~66% 
(Moreno-De-
Luca et al., 
2010) 
Schizophrenia, 


















17q21.31 Duplication unknown ID (mild to 
moderate), 
microcephaly 











90% de novo, 
10% inherited 
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30% de novo 
 
 
1.7.4 Autism as a synaptic disorder 
 
Despite its vast and somewhat confusing genetic landscape, ASD has a 
rather convergent profile of symptoms. Autism has historically be considered 
to be a synaptic disorder, not least of which because some genes first 
identified and most consistently reported in ASD patients such as SHANK3, 
NRXN and NLGN2 are genes with direct synaptic roles (Zoghbi and Bear, 
2012; Yoo, 2015; Packer, 2016). The synaptic hypothesis of ASD is outwith 
the scope of this thesis and will not be discussed.   
 
1.7.5 Disruptions to neurogenesis in ASD 
 
Despite the more traditional view of ASD as a synaptic disorder, there is a 
complimentary view that ASD begins much earlier during neurodevelopment, 
during neurogenesis and migration during cortical development (Casanova, 
2014; Casanova and Casanova, 2014; Reiner et al., 2016). As stated earlier, 
one of the hallmarks of ASD is early brain overgrowth, implying changes to 
proliferation earlier in neurogenesis (Amaral, Schumann and Nordahl, 2008). 
This section will summarise the evidence that the underpinnings of ASD 




1.7.5.1 Evidence from patient brains 
 
Some of the most compelling evidence for changes to proliferation and 
neuron number in ASD patients comes from study of post-mortem brains. 
One small study in 2011 using post-mortem brain tissue from 7 boys with 
ASD and 6 controls showed a 67% increase in neuron numbers in the 
prefrontal cortex (Courchesne et al., 2011), implying that excess 
neurogenesis may be occurring in ASD brain. This was further evidenced in 
2012, a study showed differential expression of genes involved in controlling 
cell cycle and neural patterning in brains from young ASD patients compared 
to controls (Chow et al., 2012). In addition in 2014 Stoner et al showed 
disruption to cortical lamination in ten out of eleven ASD post-mortem brains 
(Stoner et al., 2014).  
 
1.7.5.2 Alternative models for studying the 
neurodevelopmental basis of ASD 
 
While a powerful tool, a key issue with post-mortem tissue is its availability. 
However, researchers are developing methods to circumvent this each of 
which provides their own advantages and caveats. The more traditional 
method from which some of our early understandings of ASD (and almost 
every other disease) have emerged are animal models. The somewhat 
newer approach is to use cells cultured from ASD patients and control 
individuals, induced pluripotent stem cells (iPSCs). iPSCs are an 
exceptionally powerful tool to allow us to understand ASD at the molecular 
level, and as a tool it is only growing with the rise of cerebral organoids, a 3-
D assembly of cells in a dish that accurately recapitulate some aspects of 




1.7.5.2.1 Animal models and the neurodevelopmental 
hypothesis of ASD 
 
Mouse models have provided a powerful tool to understand the roles of 
autism associated genes play in neurodevelopment. As described above, 
ASD patients often present with brain overgrowth (macrocephaly), however 
microcephaly does also present in some ASD cases, typically more 
frequently in cases with more severe ASD and ID (Gilbert and Man, 2017). 
Table 4 summarises some ASD genes and CNVs implicated in disruption to 
neural progenitors and what we have learnt from the mouse model, this is by 
no means an exhaustive list. 
 
Table 4: Studies using mice have provided insight as to how many ASD 
implicated genes may contribute to altered brain size 
















(Chen et al., 
2015; Gilbert 
and Man, 2017) 
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(in 80% of CHD8 
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(Orosco et al., 
2014) 
Ankrd11 Microcephaly Regulates 
transcription by 
histone binding 





































et al., 2009) 
32 genes in this 
region 












Macrocephaly This CNV is the 
focus of this 
thesis  
Enlarged brain 
size (Horev et 






While mice provide a powerful tool to study genetic mutations contributing to 
ASD, they, like any model, have some caveats. Firstly, there are fundamental 
differences in the cortical structure of mice and humans; the outer SVZ (see 
Figure 1). Another is that they can only be easily used to study syndromic 
ASD, where there is a known genetic cause such as FMR1. In addition most 
identified gene mutations associated with ASD are heterozygous which rarely 
induces ASD symptoms instead requiring a homozygous mutation 
suggesting that mice cannot accurately recapitulate the roles of these genes 
in ASD (Ey, Leblond and Bourgeron, 2011). Therefore, it is necessary to use 




1.7.5.2.2 What we have learned from cell culture systems 
about ASD and neurogenesis 
 
One powerful approach to study both idiopathic ASD and to take a different 
approach to studying syndromic ASD is the use of human induced pluripotent 
stem cells (hIPSCs). These can be taken from ASD patients from skin 
biopsies or blood and differentiated to neural progenitor cells (NPCs) to 
understand the effects of ASD genes on early proliferation. This system 
provides researchers with a 2-D system to study neurogenesis, or it can be 
transformed into a 3-D organoid system; cortical organoids recapitulate some 
aspects of human cortical development. They are both powerful systems and 
can be utilised in different ways depending on the questions of the research. 
This proved a particularly powerful tool in a 2017 study that showed NPCs 
derived from idiopathic ASD individuals showed faster proliferation than 
controls suggesting a proliferative defect that could underlie part of the ASD 
phenotype (Marchetto et al., 2017). Regarding syndromic ASD, studies have 
also showed using hiPSCs derived from Rett syndrome patients to have 
delayed neuronal maturation (Kim, Hysolli and Park, 2011) and studies with 
hiPSCs from Williams Syndrome (associated with ASD and schizophrenia) 
patients showed incomplete neural commitment and altered cell cycle genes 
(Lalli et al., 2016).  
 
In conclusion there are many tools available that can provide powerful 
insights into the genetic landscape of ASD. As discussed above there are 
many genetic disorders with ASD as an associated symptom. This thesis is 




1.8 The 16p11.2 CNV 
 
The 16p11.2 CNV has been implicated in ~1% of ASD cases making it tied 
with 15q11-q13 duplication as the most frequent aetiologies of ASD (Cook 
and Scherer, 2008). This frequency makes it a promising area of research 
into how its genetic changes contribute to ASD and the focus of this thesis. 
 
1.8.1 The 16p11.2 locus  
 
The 16p11.2 locus is a 593kpb region at the p11.2 region of human 
chromosome 16 (BP4-BP5). It encompasses 29 protein coding genes. The 
region is flanked by two homologous 147kpb sequences that arose after the 
evolutionary divergence of humans from primates, generating a misalignment 
hotspot for this region (Nuttle et al., 2016). The structure of the region is 
shown in Figure 13 and the non-identical genes (BOLA2, GIYD2, SULT1A4 
and SULT1A3 are repeated at either end) within the region are summarised 
in Table 5. 
  
Figure 13: The 16p11.2 region 
The 16p11.2 locus comprises 29 protein coding genes and 
is located on the p arm of the 16th chromosome in humans. 
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SPN Protein is a highly 
sialylated 
glycoprotein required 
for antigen specific T 
cell activation 
Low levels Wiskott-Aldrich 
syndrome 
QPRT Key enzyme in the 
catabolism of 
quinolinate 
Yes High quinolinate in the 
brain associated to 
epilepsy, Alzheimer’s 
and Huntington’s 
KIF22 Microtubule motors 
which move 
chromosomes during 






















Yes Evidence of its 
upregulation in epilepsy 
(Balan et al., 2013) 
 57 




SEZ6L2 Encodes a seizure 
related protein on 
the cell surface 
Yes Epilepsy 




TMEM219 IGFBP3 specific cell 
death receptor 
Yes  
TAOK2 Encodes a protein 
kinase 
Yes Mice have dose 
dependent changes in 
head size (Richter et al., 
2018) 
HIRIP3 Complexes with 













C16orf92 Protein coding gene   




ALDOA Encodes a glycolytic 
enzyme catalyses 































MAPK3 Encodes member of 
the ERK family 
which has many 
roles in proliferation 
and cell cycle 
Yes  











1.8.2 16p11.2 Copy Number Variation 
 
Large, recurrent CNVs are implicated in many neuropsychiatric disorders 
including ASD, epilepsy, ID and schizophrenia (Girirajan and Eichler, 2010; 
Kirov, Rees and Walters, 2015). CNVs are not causative to any of these 
disorders; while carrying a particular CNV will increase the risk of developing 
the associated disorder it is not guaranteed. Even among siblings with the 
same CNV, there are incomplete penetrance of phenotype and high 
phenotypic variability of symptoms (Levy et al., 2011; Giaroli et al., 2014; 
Qureshi et al., 2014). The homozygous deletion or duplication (Figure 14) of 
the 16p11.2 locus can be inherited but it  predominantly occurs de novo 
during meiosis (Shinawi et al., 2010) and is implicated in a wide range of 
neurodevelopmental and neuropsychiatric disorders (Kumar et al., 2008; 
Bijlsma et al., 2009; Rosenfeld et al., 2010; Shinawi et al., 2010; Hanson et 
al., 2015). 
 
The 16p11.2 deletion was first described in 2007 in male monozygotic twins 
who presented with seizures, ID and aortic valve abnormalities (Ghebranious 
et al., 2007). Its implication in ASD was proposed shortly after by Sebat et al 
who identified its de novo deletion in a screen of simplex families (a simplex 
family is a family where only one member has ASD) (Sebat et al., 2007). 
Since then a range of studies have rapidly implicated the 16p11.2 CNV in a 
range of neurodevelopmental and neuropsychiatric disorders (Kumar et al., 
2008; Bijlsma et al., 2009; Rosenfeld et al., 2010; Shinawi et al., 2010; 
Hanson et al., 2015). The clinical features of this CNV extend beyond the 
neuropsychiatric - including changes to body mass, and are highly variable in 
their presentation with incomplete penetrance of CNV; 46.8% for the deletion 





   
  
Figure 14: The 16p11.2 copy number variation 
This CNV can result in the heterozygous duplication or 
deletion of the 16p11.2 locus of chromosome 16 
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1.8.2.1 Dosage changes in the 16p11.2 CNV 
 
The 16p11.2 CNV is heterozygous not homozygous and therefore will cause 
a change in gene dosage rather than complete ablation of the gene. Altering 
the gene dosage will alter mRNA levels and subsequent protein levels 
(Figure 15). This expression change is the potential driving pathogenic 
mechanism in CNVs (Blaker-Lee et al., 2012). This change in gene dosage 
has been confirmed in mice (Horev et al., 2011; Blumenthal et al., 2014) and 
human lymphoblasts (Blumenthal et al., 2014) showing that gene dosage 
disruption predictably impacts mRNA expression levels; increasing to 1.5 
times that of the control in the microduplication and decreasing to 0.5 times 




Figure 15: Effect of changes of gene dosage on 
transcription and translation 
Altering the numbers of copies in the gene by heterozygous 
deletion will result in less mRNA being transcribed and 
subsequently less protein being translated. Conversely, in a 
heterozygous duplication more mRNA will be transcribed, and 




1.8.2.2 Clinical features associated with the 16p11.2 CNV 
 
There is growing evidence that the opposing duplication and deletion of the 
16p11.2 region produce mirrored phenotypes. This section will briefly discuss 
the various clinical features associated with the duplication and deletion.  
 
One of the most striking features in many patients that appears well before 
the onset of clinical neuropsychiatric symptoms is the changes to head size 
at birth, a clear example of the mirrored phenotype of this CNV. Both 
McCarthy et al in 2008 and Shinawi et al in 2010 showed increased head 
size (macrocephaly) in deletion patients and decreased head size 
(microcephaly) in duplication patients (McCarthy et al., 2009; Shinawi et al., 
2010). As suggested earlier in this chapter changes to head size are 
indicative of altered brain size which is often due to altered neural 
proliferation. Continuing the mirror phenotype the deletion is associated with 
a highly penetrant form of obesity while duplication patients are often 
underweight (Walters et al., 2010; Maillard et al., 2015).  
 
Regarding neuropsychiatric disorders, their occurrence also differs between 
microdeletion and microduplication patients.  Meta-analysis of several 
studies evidenced that the microduplication to be strongly associated with 
multiple psychiatric disorders including schizophrenia, bi-polar disorder and 
autism. The microdeletion is strongly associated with autism, developmental 
delays but not schizophrenia (McCarthy et al., 2009; Hanson et al., 2015). In 
addition, both the microdeletion and the microduplication, but more strongly 
the microduplication, are associated with ADHD (Shinawi et al., 2010) and 
both are heavily associated with speech delays and motor delays (Shinawi et 
al., 2010).  
 
Epilepsy and seizure disorders are also frequent in both the microduplication 
and the microdeletion (Shinawi et al., 2010). In addition, many microdeletion 
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patients share facial features including broad forehead, hypertelorism and 
micrognathia and while microduplication patients present with facial 
dysmorphia, there is no consistent pattern (Shinawi et al., 2010). Several 
studies have also identified altered brain structures in a subset of patients, 
including corpus callosum hypoplasia (Bedoyan et al., 2010), enlarged 
ventricles with thinned corpus callosum and thinned periventricular white 
matter (Filges et al., 2014), cerebral cortical atrophy (Ghebranious et al., 
2007) and partial left temporal lobe agenesis (Bijlsma et al., 2009).  
 
1.8.3 16p11.2 CNV and the neurogenic basis of autism  
 
The changes in head size in 16p11.2 patients implicate neurogenic defects 
during prenatal development that may contribute to the patient phenotype. 
There is range of evidence from different models supporting this hypothesis.  
 
Murine models generated to harbour the 16p11.2 CNV exhibit autism-like 
behaviours with opposing changes to the size of some brain regions in the 
duplication and deletion in one study (Horev et al., 2011). Notably this has 
been contradicted by later studies showing reversed head size phenotypes 
(Pucilowska et al., 2015). However, this may well be due to the difference in 
human and mouse brain development (Figure 1) or it may be that the 
different backgrounds of the mice strains used induce this difference. Despite 
this, the murine model shows clear disruption to cortex development, 
supporting the contribution of altered neurogenesis in 16p11.2 pathogenesis. 
The deletion mouse shows increased mitosis of apical and basal progenitors, 
with increased IP mitosis increasing neuron production mid-neurogenesis 
and the progenitor pool prematurely being depleted causing microcephaly 
(Pucilowska et al., 2015).  
 
In addition, while not thoroughly investigating changes to neural progenitors 
such as analysing changes to cell cycle length, a 2017 study from 
Deshpande et al deriving cortical neurons from 16p11.2 patient iPSCs 
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showed altered neuron size which mirrored the opposing patients brain size 
as well as diminished synapse production (Deshpande et al., 2017). 
Therefore, it is possible that changes in cell size may explain the patient 
head size phenotypes rather than changes to cell numbers.  
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1.8.3.1 Effect of individual 16p11.2 genes on neurogenesis 
 
The 16p11.2 CNV harbours 29 genes, to understand how this region 
contributes to the patient phenotype, studies to understand the individual 
roles of these genes during brain development are essential. These are 
summarised in Table 6 and suggest that changes to at least some of the 
16p11.2 genes are likely to contribute to neurogenic causes of ASD. 
 
Table 6: Evidence implicating some of the 16p11.2 locus genes in 
altered proliferation 
Gene Model Effect Reference 







(Haslinger et al., 
2018) 





(B. Liu et al., 
2016) 







(Y.-T. Liu et al., 
2016) 
KCTD13 Knockdown in 
zebrafish 
Altered head 
size (note this 
finding has been 
disputed) 
(Golzio et al., 
2012) 












MAPK3 Deletion of Erk 










1.8.3.2 The 16p11.2 phenotype is likely polygenic  
 
It is unlikely to be one single gene from the 16p11.2 region causative for the 
neuroanatomical phenotype, instead the phenotype is likely to be polygenic 
with the phenotype stemming from the altered dosage of several 16p11.2 
genes. This is supported by several lines of evidence including a study 
systematically knocking down each gene in zebrafish embryos reporting 
neuroanatomical phenotypes for the vast majority of genes, although 50% 
knockdown only induced phenotypes in two genes; ALDOA and KIF22 
(Blaker-Lee et al., 2012). In addition systematic deletion of all combinations 
of the genes in drosophila showed complex interactions between all of the 
genes to contribute to the phenotype (Iyer et al., 2018). 
 
1.8.4 Summary of evidence  
 
Evidence indicates that multiple 16p11.2 transcript levels are affected by the 
16p11.2 CNV and the pathology of the 16p11.2 CNV could stem from altered 
dosage of either one of them. Altered proliferation during cortex development 
is observed in mouse models, however it is unknown which of the proteins 
produced by 16p11.2 CNV genes are expressed by progenitor cells in the 




1.9 Aims of Thesis 
 
This thesis has the following aims: 
 
1) To perform an unbiased screen of an existing scRNA-seq dataset 
from the developing human cerebral cortex to identify genes from the 
16p11.2 locus whose transcripts are expressed in progenitors, in 
particular genes whose mRNA levels are then reduced as cells 
become post-mitotic. This bioinformatics analysis was performed by 
Yifei Yang. 
 
2) To describe the mRNA expression of these genes expressed in 
progenitors using sections of the developing human fetal cerebral 
cortex during the late first and early second trimester.  
 
3) Having identified genes highly expressed in cortical progenitors and 
down regulated as cells become postmitotic we aim to describe their 




2 Materials and Methods 
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2.1 Human tissue 
 
Human tissue was obtained either from the Human Developmental Biology 
Resource (hereafter referred to as HDBR) or the Royal Edinburgh Infirmary 
(hereafter referred to as RIE). 
 
2.1.1 Samples obtained from HDBR 
 
Samples obtained from HDBR were collected and processed by the staff at 
HDBR. The processes used are described here but is work performed by 




All samples were collected from women >16 years old undergoing 
termination of pregnancy. Donation was voluntary and written consent given 
by donors only after they received counselling regarding termination of 
pregnancy. Following collection all information was anonymised.  
 
2.1.1.2 Staging of fetuses 
 
Staging of foetus was estimated based on patient information and ultrasound 
prior to termination procedure and then confirmed upon arrival at HRBR 
based on length measurements and other developmental guides e.g. facial 




2.1.1.3 Dissection and fixation 
 
Small slits were cut in the skull of the head and fixed overnight in formalin or 
methacarn to preserve tissue morphology. The brain was then dissected out 
and cut into pieces depending on size of sample and further fixed for 24-48 




Following fixation and washing brain pieces were embedded in paraffin using 




The paraffin blocks where then sectioned at 8µm using a wax microtome and 
mounted onto superfrost plus slides where they were stored at room 
temperature prior to shipping to Edinburgh for use in this project.  
 
2.1.2 Samples obtained from RIE 
 
Collection of fetal samples from Edinburgh was coordinated by Richard 
Anderson and day to day collection and coordination was by Anne 
Saunderson and Norma Forson. They performed all clinical duties regarding 
consent and collection and brought the specimen to RIE for collection by 
researchers.  
Ethical approval for this study was obtained from Lothian Research Ethics 
Committee (study code LREC 08/S1101/1), and women gave informed 
written consent. Human fetuses were obtained after elective termination of 
pregnancy, and all fetuses used in this study were morphologically normal. 
 72 
Gestational age was determined by ultrasound scan, and confirmed (for 
second trimester fetuses) by direct measurement of foot length 
Patients deemed suitable for the study were required to be <16 years old, 
without any known infection (HIV, Hepatitis B/C/E or chlamydia) and without 
any identified fetal/pregnancy abnormality. Patients were also excluded from 
study if nursing staff had any concerns about their emotional state, they had 
learning disabilities, or if the patients was not fluent in English when there 
were no adequate translation services available at the time. Patients were 
approached by research midwifes and provided a patient information sheet, if 
they wished to proceed with sample donation, they signed a consent form 
with the understanding they could change their mind at any time. Following 
collection all information was anonymised.  
 
2.1.2.1 Dissection and fixation 
 
Dissection of specimens from RIE was performed by Sarah. Briefly the head 
was removed and transported back to Hugh Robson Building on ice. There, 
small slits were cut in the skull in the soft membrane where the four unfused 
skull plates meet, and the specimen placed in 4% paraformaldehyde 
(hereafter termed 4% PFA) overnight at 4ºC to preserve brain morphology.  
 
The next day the sample was washed 10x15 minutes in 1 x PBS on a rocker 
to remove PFA. The sample was then placed in a 10cm petri dish, the skin 
removed, and skull plates removed to expose the brain. Cutting the 
brainstem (or as close to possible) allowed removal of the brain from the 
skull which was then placed in PFA at 4ºC overnight. Skull fragments and 
any leftover tissue were returned to RIE to be respectfully disposed of with 
the rest of the sample 
 
The following day the brain sample was again washed 10 x 15 minutes with 1 
x PBS on a rocked to remove all PFA. The brain was then divided down the 
 73 
middle and cut into 8 pieces (as shown in Figure 16). These sections were 
transferred to individually labelled specimen jars with PFA and fixed at 4ºC 









2.1.2.2 Cryoprotection and embedding 
 
After the final fixation step, brain sections were washed 5 x 15 minutes in 1 x 
PBS on a rocker at room temperature. Following this the PBS in each 
specimen jar was replaced with 30% sucrose/1 x PBS and left at 4ºC for 3 
days to cryoprotect the tissue.  
 
Following cryoprotection each section was transferred to a mould 
(Thermofisher scientific) and covered with a 50:50 mix of OCT and 30% 
sucrose/1 x PBS and allowed to equilibrate for 30 minutes at room 
temperature. Samples were then flash frozen on dry ice and transferred to     
-80ºC for long term storage until sectioning. 
 
Figure 16:  How tissue was divided up for sectioning 
We cut down the middle of the sample and then divided 
each hemisphere into four blocks for secondary fixation. 





Samples were transported on dry ice from -80ºC storage to the cryostat. OCT 
was used to attach the tissue block to the chuck and sections were coronally 
cut at 14µm and mounted on Superfrost positively charged slides. Slides 
were allowed to air dry for 2 hours before storage at -20ºC.  
 
2.1.3 Haematoxylin and Eosin Staining 
 
For the H&E staining cryostat sections were used and allowed to warm to 
room temperature for 30 minutes. The staining was performed on adjacent 
sections to those used for in situ hybridisation and all developmental ages 
stained simultaneously. To try to reduce tissue loss, a secondary fixation 
step was performed using Formalin-acetic-acid-alcohol (FAA). Here sections 
were immersed in FAA for 30 seconds at RT and then rinsed under running 
water for two minutes before being immersed in Haematoxylin for two 
minutes. Sections were then rinsed under running water for two minutes and 
then immersed in water-based Eosin and then rinsed in running water for one 
then immersed in potassium aluminium for two minutes. Next slides were 
rinsed for two minutes under running water and then dehydrated by 
immersion in increasing alcoholic concentrations: 70%, 90%, 95% followed 
by two changes of 100%. Sections were then immersed in xylene and 




2.2 In situ hybridisation  
 
2.2.1 Probes used 
 
The probes were used in this thesis are for KIF22, ALDOA, HIRIP3, PAGR1, 
MAZ and SPN. All were designed and generated in house.   
 
2.2.2 Probe preparation 
 
The pGEMT easy kit was used for creation of plasmids. All cDNA used was 
converted from RNA extracted from the NAS2 cell line, with the exception of 
the KIF22 and ALDOA plasmids which used purchased Image cDNA (source 
bioscience). KIF22 and ALDOA probes were made with the help of Kathy 
Howe. 
 
2.2.2.1 Primer design  
 
The following primers were designed using primer3 software to target all 
known splice variants of each gene according to BLAST and are shown in 
Table 7. Oligos were ordered dry from Thermo Fisher scientific. Upon arrival 





Table 7: Primers used for in situ hybridisation probes 
Gene Forward Primer Reverse Primers 
KIF22  CGA CGA CGG ATG 
GTG CTA AT 
GAG ACC CAG GAT 
GTT TGC CT 
ALDOA CTG TCA CTG GGA 
TCA CCT T 
GTG ATG GAC TTA 
GCA TTC AC 
PAGR1 ATG ATG AGC CAG 
TGA CAC CA 
TCT GCC TCT CCC 
TTC AAG TG 
HIRIP3 TGG TGC CCA TCG 
AAA CTA CA 
TGG CCC AAA ATA 
CAG GAG GT 
MAZ CAC GAG GAG AAA 
GTG CCA TG 
GAG AGA AGA GGA 
CCG TCG AG 
SPN TGA TCT TTC CCA 
GGG CAC AT 
GAG AGA GAG AGA 




2.2.2.2 Extraction of human cDNA 
 
For amplification of target DNA sequence human cDNA was required. This 
was obtained from the NAS2 hIPSC line gifted from John Mason. Briefly cells 
were cultured at 37ºC in Stem Max IPS Brew XF in 6 well plates until 70-80% 
confluency. RNA was extracted using the RNeasy kit from Qiagen and 
nanodropped to determine RNA concentration. 
 
RNA was then converted to cDNA as follows: RNA was diluted to 2µg/13µl in 
RNAse free water and 2µl random primers (500ng/µl) added and then the 
mixture heated at 70ºC for 5 minutes then rapidly cooled on ice. 10µl of 
Promega M-MLV reverse transcription mix was added and the mixture heated 
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at 37ºC for 60 minutes to produce cDNA at a final concentration of 80ng/µl. 
cDNA was then diluted to 5ng/µl in ddH2O and stored at -20ºC. 
 
2.2.2.3 Amplification of target DNA sequence 
 
Primer mix was made as shown in Table 8  
 
Table 8: Primer mix used for PCR 
Forward Primer Reverse Primer ddH20 
10µl of 25µM primer 10µl of 25µM primer 80µl 
 
 
The target sequence was amplified by PCR prior to transfection into pGEMT 
Easy vectors using the following reagents in Table 9. 
 
Table 9: Reagents used for PCR amplification of target sequence 
Reagent Volume 
ddH20 16.3µl 
DNTP mix 2.5µl 
Promega PCR buffer 5µl 
Taq polymerase 0.2µl 




The PCR mix was then run on the PCR cycle shown in Table 10. 
 
Table 10: PCR cycle times and temperatures 
Temperature Time 
96ºC 2 minutes 
96ºC 30 seconds  
28 Cycles 59ºC 30 seconds 
72ºC 30 seconds 
 
PCR product was then cleaned up using the QIAGEN gel extraction kit and 
nanodropped to confirm concentration. 
 
2.2.2.4 DNA clean up 
 
To clean up DNA the QIAgen gel extraction kit was used. 200ul of DNA was 
used and 200µl of isopropanol and 600µl of buffer QC were added. The 
mixture was added to a QIAquick spin column and placed into a 2ml 
collection tube. This was then centrifuged at 13000rpm (speed used 
throughout) for 60 seconds to bind DNA to column and the flow through 
discarded. 500µl of buffer QG was added to column and centrifuged for 60 
seconds and flow through discarded. Then 750µl of buffer PE was added, 
allowed to stand for 5 minutes then column centrifuged for 60 seconds and 
flow through discarded. The column was then centrifuged for 60 second, flow 
through discarded and centrifuged for another 60 seconds to dry the filter. 
Column was placed into a 1.5ml centrifuge tube and 20ul of sterile ddH20 
added directly to the centre of the column and allowed to stand for 5 minutes 
before being centrifuged for 60 seconds. Eluted DNA was collected in the 






2.2.2.5 Agarose Gel 
 
After amplification and clean up the mix was run on a 1.5% agarose gel 
(Table 11) for 30 minutes to confirm a band indicating successful 
amplification.  
 
Table 11: Reagents used for a 1.5% agarose gel 
TBE 
Buffer 
Agarose Voltage Syber Safe 
50ml 0.75g 260mV 1.5µl 
 
The reagents for x5 stock TBE buffer are shown in Table 12, this was diluted 
to x1 in ddH20 prior to use. 
 
Table 12: Reagents for x5 stock TBE buffer 
Reagent Volume 
Tris base 54g 
Boric acid 27.5g 
0.5M EDTA 20ml 
H20 Make up to 1l 





Ligation was performed as per the instructions in the pGEMT easy kit. A 1:1 
ration of insert:vector ratio was used for all plasmids. The following in Table 
13 was used for the ligation reaction: 
 
Table 13: Reagents and volumes used for ligation reaction 





5µl 5µl 5µl 





on insert size 
- - 
Control DNA - 2µl - 
T4 ligase 1µl 1µl 1µl 





Solutions were thoroughly mixed, and ligation allowed to occur overnight at 
4ºC.  
 
2.2.2.6.1 Ampicillin Plates 
 
Ampicillin plates were used to grow transformed cells on. 250µl of ampicillin 
was added to 250ml of autoclaved agar and poured into petri dishes. As the 
vector contained an ampicillin resistant insert this ensured only bacteria 
which had taken up the plasmid could grow. Plates were allowed to set and 
then stored upside down at 4ºC to prevent condensation contamination. Just 
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prior to use plates were coated with 100µl XGAL/BTP solution (Sigma) and 
incubated at 37ºC for 30 minutes. 
 
 
2.2.2.7 Transformation  
 
Transformations required the pGEMT easy vector to be heat shocked into 
JM109 competent cells (Promega) as per the instructions. The reaction 
reagents used are shown in Table 14. 
 
Table 14: Reagents for transformation of competent cells 
Component Volume (µl) 






Cells were thawed on ice and following addition of reagents the reaction 
mixture was incubated on ice for 20 minutes before being heat shocked for 
45 seconds in a 42ºC water bath then returned to ice for 2 minutes.  
 
950µl of SOC medium (Invitrogen) was added to transformation mix and 
incubated 1.5 hours at 37ºC shaking at ~150rpm.  
100µl of each culture was streaked onto plates using sterile rods and 




2.2.2.8 Identification of transformed colonies 
 
 The next day the effectiveness of the ligation was confirmed as background 
plates were all blue and control were all white. To preserve transformed 
colonies a grid system was used. A grid was drawn and placed under a new 
dish (see Figure 17) and one white colony streaked to each square of the 




Figure 17: Schematic of colony selection and streaking 
onto grid 
Blue colonies had not taken up the plasmid so were not 
used; white colonies had taken up the plasmid so where 
used for streaking to the grid plate. 
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2.2.2.9 Plasmid mini-preps 
To set up for the mini-preps, a dot of each bacterial colony was added to 4ml 
of sterile LB broth and incubated overnight at 37ºC on a shaker ~160rpm.  
Next day tubes were removed from shaker and the mini-prep performed with 
the Qiagen mini-prep kit. Cultures were centrifuged at 13000rpm at room 
temperature (RT) using a table top centrifuge for 3 minutes. The supernatant 
was removed, and pellet resuspended in 250µl of buffer P1 with added 
RNase A and LyseBlue. 250µl of buffer P2 was added and tube thoroughly 
mixed by inverting 6 times until the solution turned blue. 350µl buffer P3 was 
added immediately by inverting the tube 6 times until the solution turned 
clear. Mixture was centrifuged at RT at 13000rmp (standard speed for this 
protocol) for 10 minutes. The supernatant was carefully removed and 
transferred to a QIAprep spin column and the pellet discarded. Column was 
centrifuged for 60 seconds and flow through discarded. 500µl of buffer PB 
was added and column centrifuged for 60 seconds to wash the DNA then 
flow through discarded. 750µl of buffer PE was added and centrifuged for 60 
seconds and flow through discarded. Column was centrifuged for 60 seconds 
and flow through discarded then centrifuged for another 60 seconds and flow 
through discarded to thoroughly dry column. The column was transferred to a 
new 1.5ml centrifuge tube and 40µl of sterile ddH20 added directly to the 
centre of the column and left for 5 minutes. Column was then centrifuged for 
60 seconds and then 5ul of the DNA run on a 1.5% agarose gel to confirm 
DNA. 1µl of samples that produced a band were used for nanodrop and the 
two with the strongest concentration of DNA used for sequencing.  
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2.2.2.10  Sequencing of plasmids 
 
Sequencing of the vector was Sanger Sequencing performed by Edinburgh 
Genomics. Forward and reverse sequencing was performed separately, and 
two samples were sequenced for each gene. The reagents provided to 
Edinburgh Genomics are shown in Table 15 and were provided in a 0.2ml 
strip tube with the DNA and primer combined to final volume of 6µl. 
 
Table 15: Reagents provided for sequencing 
Reagent Forward Sequencing Reverse Sequencing 
 Volume Concentration Volume Concentration 
Clean 
DNA 
5µl 300-400ng 5µl 300-400ng 
Primer 1µl 6.4µM 1µl 6.4µM 
 
Sanger sequencing standard Big Dye reaction was performed by Edinburgh 
Genomics using the following Big Dye master mix (Table 16) and then the 
Big Dye reaction mix (Table 17). 
 
Table 16: Reaction components for BigDye master mix 
Reaction Components 1 x reaction 
5x sequencing buffer 2µl 
BigDye 1µl 
Molecular grade water 1µl 





Table 17: Reagents for BigDye Reaction 
Reaction 
Components 
1 x reaction 
Big Dye master mix 4µl 
DNA 5µl 
Primer at 6.4µM 1µl 
Total Volume 10µl 
 
The following PCR reaction in Table 18 was performed by Edinburgh 
Genomics to amplify the DNA prior to sequencing: 
 
Table 18: PCR settings for BigDye Reaction 
Temperature Time 
96ºC 60 seconds 
96ºC 10 seconds  
Repeat for 24 cycles 50ºC 5 seconds 
60ºC 60 minutes 
12ºC Hold 
 
The BigDye reaction mix was then column purified, dried in a vacuum, 
resuspended in HiDi and denatured prior to sequencing run on the 3730XL 
sequencing machine. 
 
Sequencing data was then returned and compared to BLAST to ensure DNA 




2.2.2.11  Amplification of sequenced plasmid 
Following confirmation of sequencing results the best colony (best meaning 
clearest and longest sequencing result) of each gene was selected from the 
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grid and a dot added to 150ml of LB broth with 150µl of Ampicillin added and 
incubated at 37ºC overnight shaking at ~160rmp.  
 
2.2.2.12 Midi-prep of plasmid 
 
The next day cultures were removed, and the plasmid extracted using the 
Qiagen HiSpeed plasmid midi kit. Cells harvested from culture were spun 
down at 6000 x g for 15 minutes at 4ºC. All supernatant was removed, and 
the pellet resuspended in 6ml of chilled buffer P1 (with RNase solution A and 
LyseBlue reagent already added to buffer) by vortexing. 6ml buffer P2 was 
added and the mixture inverted 6 times until the solution turned blue and 
then allowed to incubate for 5 minutes at RT. 6ml of chilled buffer P3 was 
added and the solution inverted 6 times until the solution turned clear. The 
lysate was transferred to the barrel of a QIAfilter cartridge and incubated at 
RT for 10 minutes. During this incubation a HiSpeed tip was equilibrated with 
4ml of buffer QBT and the column allowed to empty by gravity flow. After the 
10 minutes incubation the plunger was fitted into the QIAfilter cartridge and 
the lysate filtered into the previously equilibrated HiSpeed tip which was then 
washed with 20ml buffer QC by gravity flow. The bound DNA was then eluted 
into a 15ml falcon tube using 5ml buffer QF. 3.5ml of isopropanol was added, 
mixed and incubated for 5 minutes at RT to precipitate the DNA.               
The elute-isopropanol mix was then transferred into the syringe with a QIA 
precipitator, the plunger inserted, and the mixture filtered with constant 
pressure on the plunger. The QIA precipitator was then removed from the 
syringe, 2ml of 70% ethanol added, the QIA precipitator re-attached and the 
mixture filtered. To dry the membrane the QIA precipitator was removed, 
plunger removed, precipitator reattached and pressing air through the filter. 
This was repeated several times to thoroughly the membrane and then the 
membrane dried with absorbent paper. The QIA precipitator was attached to 
a new 5ml syringe, 1ml of buffer TE was inserted to the syringe, the plunger 
inserted, and mixture filtered into a clean 1.5ml centrifuge tube. QIA 
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precipitator and plunger were removed, eluted mixture transferred back to 
the syringe and re-filtered into the same 1.5ml tube.  
 
DNA was then nanodropped and stored at -20ºC until required.  
 
 
2.2.2.13 Plasmid linearization 
 
To determine the appropriate enzyme for linearization of the plasmid it was 
first necessary to determine the orientation of the plasmid in the vector using 
the sequencing data, from this the correct restriction enzyme for linearization 
can be identified and this information is shown in Table 19: 
 
 
Table 19: Orientation of plasmids and restriction enzymes used for 
digest 
Plasmid Orientation in vector Restriction enzyme 
KIF22 5’-3’ NCO1 
ALDOA 3’-5’ SAL1 
HIRIP3 3’-5’ SACII 
MAZ 3’-5’ SACII 
PAGR1 5’-3’ PST1 
SPN 5’-3’ PST1 
 
The reaction mixture for the digest is shown in Table 20, restriction enzymes 
and buffers are from New England Biolabs and the digest mixture was 





Table 20: Reagents used for digest 
Reagent Volume 
Plasmid DNA Required volume for 
concentration of 10µg 
Enzyme 5µl 
BSA (1000x) 2µl 
10x Buffer 20µl 
ddH20 To final volume of 200µl 
 
2µl of the digested plasmid was run for 30 minutes on a 1.5% agarose gel 
with 2µl of the unlinearised plasmid to confirm the digest was successful. The 
DNA was then cleaned up using the QIAgen gel extraction kit and eluted with 
20µl of sterile ddH20 and stored at -20ºC. 
 
2.2.2.14 Transcription and DIG labelling of Plasmid 
 
To make a DIG labelled anti-sense probe the reagents used are shown in 
Table 21 and were made up in 1.5ml tubes and incubated for two hours at 
37ºC. Due to the different plasmid orientation in the vector different RNA 




Table 21: Reagents used for transcription and DIG labelling 
Reagent Volume 
Linearized probe 14µl 
10x transcription buffer 2µl 
DIG labelling mix (Roche) 2µl 
RNA polymerase 2µl 
 
Table 22: Polymerases used for each of the probes 








Following incubation 2µl of DNAse1, RNAse free (10units/µl) was added and 
the mixture incubated at 37ºC for 15 minutes. Then 2µl of 0.2M EDTA (pH8) 
was added to stop the reaction. Then 2.5µl of 4M LiCl and 75µl ice cold 
EtOH were added and the probe left at -20ºC overnight to precipitate.  
 
Next day the probe was spun at 13000rpm at room temperature using a 
tabletop centrifuge (used throughout this protocol) for 15 minutes and then 
supernatant removed. 100µl of RT 70% EtOH was added and the tube spun 
for another 15 minutes. All supernatant was carefully removed, and the tube 




The pellet was then resuspended in 50µl sterile ddH2O and 2µl of the probe 
run for 20 minutes on a 1.5% agarose gel and quickly imaged to prevent 
RNA degredation to confirm successful transcription. Probe was then stored 
at -20ºC until needed.  
 
2.2.3 In situ hybridisation staining 
 





Three sections, rostral, middle, caudal, were used for each age. Preliminary 
optimisation runs included PAX6 as a positive control (which has been 
previously validated by the lab). A no probe control was used as a negative 
control during optimisation. Slides were defrosted and allowed to stand at RT 
for 15 minutes and then were placed into a 37ºC oven for 4 hours to prevent 
tissue falling off prior to hybridisation. 
 
 A sealed plastic box was lined with two sheets of white Tork roll which was 
then soaked in 100ml of 50% formamide/1x Salt. Reagents for 10x salt are 
shown in Table 23 and 1x salt was made from diluting 10x stock solution. 




Table 23: Reagents for 10x salt solution 
Reagent Amount 
NaCl 22.8g 
Tris HCl (pH7.5) 2.8g 
NaH2PO4•2H2O 1.56g 
NaH2PO4 1.42g 
0.5M EDTA (pH8) 20ml 
ddH2O Make up to 200ml  
Autoclave and store 
 
 
The probes were thawed quickly and diluted in hybridisation mix (reagents 
for hybridisation mix shown in Table 24) using 1.5ml RNAse free screw cap 
tubes. Optimisation was required for each probe with test concentrations of 
1:1000, 1:2000. 1:4000 and 1:8000 used to find optimum concentration. 
Hybridisation mix and probes were vortexed vigorously and the diluted 
probes denatured at 95ºC for 10 minutes using a hot block before being 
returned to ice.  
 
A hydrophobic pen was used to delineate sections, probe mix was vortexed 
and 300µl added to each slide and carefully distributed across the tissue 
sections using a p200 pipette tip (note no coverslips were used to minimise 
tissue damage). Slides were then placed in the pre-heated hybridisation box 





Table 24: Reagents for hybridisation mix 
Reagent Amount 
10x Salt 1ml 
Deionized formamide 5ml 
50% dextran sulfate 2ml 
tRNA (50mg/ml) 200µl (tRNA denatures 
at 85ºC for 10 mins 
before use) 
100x Denhardts 100µl 
RNAse free water To total volume of 10ml 
 
2.2.3.2 Post hybridisation washes 
 
Following hybridisation, slides were transferred from hybridisation box to a 
glass colpin jar where they were washed in wash buffer (pre-warmed to 
65ºC), reagents shown in Table 25, for 30 minutes at 65ºC. Washes were 
repeated another 2 x 30 minutes at 65ºC with fresh wash buffer used each 
time. 
 
Table 25: Reagents for wash buffer 
Reagent Amount 
20x SCC 15ml 
50% formamide 150ml 
0.1% Tween-20 300µl 
ddH2O 135ml 
 
Next 3x 30 minutes washes were performed with 1x MABT (reagents for 
buffer in Table 26 at RT on a rocker. 
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Table 26: Reagents for 1x MABT 
Reagent Amount 
ddH2O 600ml 
0.5M Maleic acid 11.64g 
NaOH pH to 7.5 after addition 
of Maleic acid 
0.75M NaCl 8.76g 
0.5% Tween 20 1ml 
 
 
2.2.3.3 Blocking and antibody staining  
 
A box was lined with Tork roll soaked with ddH2O to ensure a humidified 
environment. Slides were removed from MABT and a hydrophobic pen used 
to re-delineate the edges of sections as much of the pen was lost during 
hybridisation. The sections were blocked using 200µl blocking solution (see 
Table 27) per slide and incubated in the humidified box at RT for 1 hour.  
 
Table 27: Reagents for blocking solution 
Reagent Amount 
Heat inactivated sheep serum 1ml 
1x MABT 4ml 
Blocking reagent 0.1g 
 
Following blocking 200µl of anti-DIG antibody diluted 1:1500 in blocking 
solution was added to each slide to detect RNA expression. Slides were 
returned to the humidified box and incubated at 4ºC overnight. 
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2.2.3.4 Post antibody washes and colour reaction 
 
The next day slides were moved to a glass colpin jar and washed 5x 20 
minutes in 1x MABT at RT on a rocker. Sections were then equilibrated in 
pre-staining buffer (Table 28) for 2x 10 minutes at room temperature on a 
rocker. 
 
Table 28: Reagents for pre-stain buffer 
Reagent Amount 
5M NaCl 6ml 
1M MgCl2 15ml 
1M Tris (pH 9.5) 30ml 
0.1% Tween-20 300µl 
ddH2O 250ml 
 
Following equilibration of slides staining buffer was used to visualise RNA 
expression. Staining buffer reagents are shown in Table 29, with the nitro-
blue tetrazolium and 5-bromo-4-chloro-3”-indolyphosphate (NBT/BCIP) 
added directly before reaction. Staining reaction was incubated in the dark in 
the humidified box at RT until colour developed (different development times 













Table 29: Table of reagents for staining buffer 
Reagent Amount 
5M NaCl 0.2ml 
1M Tris (pH 9.5) 1ml 
ddH2O 8.3ml 
PVA 0.9g 
Heat to 85ºC with constant stirring, when dissolved allow to cool 
1M MgCl2 0.45ml 




After the colour developed, slides were transferred to a colpin jar and 
washed many times in 1x PBS to stop the colour reaction and left overnight 
in 1x PBS at 4ºC. Slides where then mounted with coverslips using Aquatex 
mounting medium, allowed to dry and stored at 4ºC until imaging. 
 
2.2.4 Imaging of in situ hybridisations 
Imaging of in situ hybridisation was performed using a Zeiss Axioscan z.1 
slide scanner, access to which was kindly provided by the Nolan lab. Slides 
were cleaned and loaded into the scanner trays and imaging was calibrated 
using the ZEN software provided by Zeiss. ROI was delineated manually 
around each section and the focal plane chosen for each section. Scanning 
was performed at x20 objective allowing for single cell resolution and tiling 
was performed by the ZEN software. Images were viewed and exported from 
the ZEN software. Individual regions at high magnification were selected and 







For immunohistochemistry all sections used were paraffin sections provided 
by the HDBR except the PAX6 immunofluoresence which used cryostat 
sections.   
 
2.3.1 Immunofluorescence  
 
2.3.1.1 Dewaxing and antigen retrieval of sections 
 
Sections were dewaxed by immersion for 15 minutes in 2 changes of xylene. 
They were then rehydrated with 5 minutes in each of the following: 2 
changes of 100% IMS, 95% IMS, 90% IMS, 70% IMS and then placed in a 
glass colpin jar under running water for 10 minutes.  
 
Antigen retrieval was used by washing sections for 10 minutes in 10mM 
sodium citrate (diluted from 100mM stock, see Table 30 before being heated 
in a microwave for 5 minutes on high, topped up with ddH2O to ensure buffer 
concentration was not altered by evaporation and then heated for another 5 
minutes on high and topped up again. The slides were kept in solution and 
placed on ice to cool for a minimum of half an hour. 
 
Table 30: Reagents for 100mM stock sodium citrate solution 
Reagent Amount 
Sodium citrate 29.4g 
ddH2O Up to 1 litre 
NaOH To pH6 
  
Sections were then washed 3x 15 minutes in 1x TBS (diluted from 10x stock 
solution of TBS pH7.6 see Table 31 at RT on a rocker.  
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Table 31: Reagents for 10x TBS stock solution 
Reagent Blocking 
NaCl 87.6g 
Trizma base 60.5g 
ddH2O Up to 1litre volume 
Conc HCl pH to 7.6 
 
2.3.1.2 Blocking and antibody incubation 
 
A hydrophobic pen was used to delineate sections and then sections were 
incubated with 200µl of blocking solution comprising 20% heat-inactivated 
serum in TBS for 1 hour at RT in the previously described humidified box. 
Next sections were incubated with primary antibody diluted to the required 
concentration in blocking solution overnight at 4ºC in the humidified box.  
 
2.3.1.3 Post antibody washes and secondary incubation 
  
Next day sections were washed 3x15 minutes in TBS at RT on a rocker. 
Sections were then incubated for 1 hour at RT in the dark humidified box with 
200µl of the appropriate fluorescent secondary antibody diluted 1:200 in 
blocking solution.  
From this point on all sections were kept in the dark by wrapping colpin jars 
in foil. Sections were washed 3x 15 minutes at RT on a rocker in TBS. Next 
the sections were incubated with 200µl of DAPI diluted 1:1000 in ddH2O for 
10 minutes at RT in the humidified box. Sections were then washed 1x 15 
minutes in PBS before being mounted in H1400 Vectashield hardset 




2.3.1.4 Imaging of sections 
 
Sections were imaged using a Leica DM5500B epifluorescence microscope 
with a DFC360FX camera. Confocal images were obtained using a Nikon 
AIR FILM microscope and analysed in ImageJ. Details of imaging and 
analysis are provided in the relevant chapter. 
 
2.3.2  Immunocytochemistry 
 
2.3.2.1 Dewaxing, peroxidase blocking and antigen retrieval 
of sections 
 
Sections were dewaxed by immersion for 15 minutes in two changes of 
xylene, and then 5 minutes in two changes of 100% IMS. To ensure blocking 
of endogenous peroxidases sections were transferred to a glass colpin jar 
and incubated with 3% H2O2 in methanol at RT for 10 minutes. Sections were 
then washed in running tap water for 10 minutes.  
 
Antigen retrieval was used by washing sections for 10 minutes in 10mM 
sodium citrate (diluted from 100mM stock) before being heated in a 
microwave for 5 minutes on high, topped up with ddH2O to ensure buffer 
concentration was not altered by evaporation and then heated for another 5 
minutes on high and topped up again. The slides were kept in solution and 
placed on ice to cool for a minimum of half an hour. 
 






2.3.2.2 Blocking and antibody incubation 
 
Sections were delineated with a hydrophobic pen and then incubated with 
200µl blocking solution (10% heat inactivated serum diluted in 1x TBS) in a 
humidified box at RT for 1 hour. Next sections were incubated with primary 
antibody diluted to the required concentration in blocking solution overnight 
at 4ºC in the humidified box. 
 
2.3.2.3 Post antibody washes, secondary antibody incubation 
and amplification 
 
Next day sections were transferred to a glass colpin jar and washed 3x 15 
minutes at RT on a rocker in 1x TBS. Next sections were incubated with 
200µl of the appropriate biotinylated secondary antibody diluted 1:200 in 
blocking solution for 1 hour at RT in the humidified box. While this incubation 
was performed, Avidin-Biotin Complex (ABC) solution was made up in 1x 
TBS at least 30 minutes prior to use to allow the complex to form.  
 
After blocking sections were moved to glass colpin jar and washed 3x 15 
minutes in 1x TBS at RT on a rocker. Next each section was incubated with 
200µl of the ABC solution in the humidified box at RT for 30 minutes. Next 
sections were moved back to the glass colpin jar and washed 3x 15 minutes 
in TBS at RT on a rocker.  
 
2.3.2.4 Colour reaction 
 
Colour was developed using the 3,3’-Diaminobenzidine (DAB) kit. The 
solution was made up using ddH2O and pipetted onto slides. Due to the low 
concentration of antibody used development took longer than expected and 
sections were incubated with the solution for 30 minutes at RT until colour 
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developed. When staining a range of ages sections were all incubated for the 
same amount of time.  
 
After colour developed sections were washed in running tap water for at least 
10 minutes.  
 
 
2.3.2.5 Counterstaining with NFR 
 
To enable visualisation of cytoarchitecture sections were then counterstained 
with Nuclear Fast Red (NFR) (vector labs). NFR solution was kept in the dark 
from day of opening and filtered before use. NFR was applied to sections for 
30 sections at RT and then washed off in running water until only nuclear 
staining remained.  
 
2.3.2.6 Mounting of sections 
 
Sections were then dehydrated by immersion for 1.5 minutes in each of the 
following concentrations: 70% IMS, 90% IMS, 95% IMS, 2x changes of 100% 
IMS and 2 changes of Xylene. Sections were then mounted using DPX 
mountant and allowed to dry. Slides were then stored at RT until imaging.  
 
2.3.2.7 Imaging of sections 
 
Sections were imaged using a Leica DMNB microscope with an attached 
Leica DFC480 camera and analysed in ImageJ. Specific details of analysis 




3 Identification of progenitor-enriched 
16p11.2 transcripts by bioinformatics 




As described in the introductory chapter one (1.8), there are 29 protein-
coding genes within the 16p11.2 locus. This thesis focuses on the 
neurogenesis hypothesis of ASD, the idea that changes during neural 
development impact cortical architecture and function leading to 
manifestation of ASD in some patients in early life. This is strongly evidenced 
by the mirrored head size phenotype of many 16p11.2 patients, 
macrocephaly in the deletion and microcephaly in duplication patients. 
Changes to head size are a proxy for changes to brain growth, and changes 
to head size are one of the most replicated findings when investigating the 
neuropathology of ASD (Courchesne, Carper and Akshoomoff, 2003; 
Amaral, Schumann and Nordahl, 2008; Sacco, Gabriele and Persico, 2015).  
This suggests that final cell numbers are altered and disruptions to the 
balance of proliferation and differentiation early in neurodevelopment is a 
potential cause. Therefore, studying the effects of the 16p11.2 CNV, the 
most frequent aetiology of ASD, and the roles of each of its genes in 
neurogenesis is a particularly important avenue of research.  
 
Very little is known about the roles of many of the 16p11.2 locus genes in 
neurogenesis, especially in the developing human cerebral cortex. It is 
unknown which of the proteins produced by the 16p11.2 locus genes are 
expressed by progenitor cells in the developing human cerebral cortex and 
are therefore candidates for regulating neurogenesis, and the potential 
disruptive effects on neurogenesis when their level is altered as a result of 
the 16p11.2 CNV.  
 
Here we aim to identify candidate genes from the locus: genes which will 
potentially specifically affect neurogenesis in the developing human cerebral 
cortex, by identifying 16p11.2 locus genes which are highly expressed in 
cerebral cortex progenitors and are downregulated as cells become post-
mitotic. Genes that are expressed in progenitors and then switched off (or 
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downregulated) as cells exit proliferation are likely to have important 
proliferative functions and therefore are ideal candidates for our study. 
 
To identify candidate genes we made use of a previously published single 
cell RNA-sequencing (scRNA-seq) dataset of the germinative VZ and SVZ of 
the 16-18GW human cerebral cortex (Pollen et al., 2015). This provided us 





3.1.1 Chapter aims. 
 
The aims of this chapter were as follows: 
 
1) Use bioinformatics analysis of sc-RNAseq data (Pollen et al., 2015) 
from the developing human cerebral cortex to perform an unbiased 
screen and identify 16p11.2 locus transcripts enriched in progenitors, 
and ideally down-regulated in post-mitotic cells. This analysis was 
performed by Yifei Yang. 
 
2) In vivo validation of identified progenitor enriched transcripts by in situ 
hybridisation on sections of human fetal cortex.  
 
3) By combining the results of these two approaches we will select 
candidates for further analysis. 
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3.2 Materials and methods 
 
All bioinformatics analysis was performed by fellow PhD student Yifei Yang.  
 
3.2.1 scRNA-seq dataset 
 
The scRNA-seq dataset of 16-18GW human cortical tissue was generated 
and published by Pollen et al in 2015 (Pollen et al., 2015). Briefly the VZ and 
SVZ of 16-18GW (three brains were used in total) human cerebral cortex 
samples were microdissected, dissociated and sequenced with data from 
393 cells included in the final published dataset.   
 
3.2.2 scRNA-seq analysis 
 
The Pollen et al (Pollen et al., 2015) dataset was used to identify candidate 
genes. Prior to dataset publication the reads were aligned, we normalized the 
RPKMs as log(x+1) to give zero reads a meaningful value for log 
transformation. Analysis was performed by Yifei Yang using R studio. To 
determine genes with significant changes a Wilcox test by FindAllMarkers in 
Seurat package was used. Monocle2 R package was used to order cells in 
pseudotime. To identify cell-cycle phase specific transcripts we used function 
CellCycleScoring from Serurat R package.  
 
3.2.3 Fetal samples used 
 
For the in situ hybridisation the cryostat tissue obtained from The Royal 
Edinburgh Infirmary (RIE) was prepared as described in 2.1.2, with the 
exception of the 12pcw sample which was obtained from HDBR as a PFA 
fixed brain and processed in the same way as RIE samples. One sample of 
each age was used, and the ages of tissue were used for the in situ 
hybridisations shown in this chapter are explained in Table 32. The rostral 
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Table 32: Table of ages used for this chapter 
Age Rostral Middle Caudal 
12pcw ü ü ü 
14pcw ü ü ü 
15pcw ü ü ü 





3.2.4 Immunofluorescence of PAX6 
 
The immunofluorescence stain of PAX6 was performed in the same way as 
described in 2.3.1, however it was performed on cryostat tissue rather than 
paraffin. Therefore, we made the slight change to heat the tissue at 37ºC for 
several hours before proceeding the protocol and the dewaxing in xylene 
step was not required. The PAX6 antibody used here was the rabbit 
polyclonal PAX6 antibody purchased from Biolegend used at a concentration 
of 1:500 with an Alexa Fluor Goat anti-rabbit 488 secondary antibody. 







3.3.1 Identification of genes expressed in progenitors 
 
We used the scRNA-seq dataset to identify candidate genes of interest from 
the 16p11.2 locus whose transcripts are enriched in progenitors. 
 
3.3.1.1 Dimensional reduction to cluster cells  
 
First, we performed dimensional reduction of the scRNA-seq dataset to 
separate the 393 cells into three distinct classes based on their transcriptome 
similarity. This is shown in Figure 18, the three classes were subsequently 
identified as the three cardinal cell classes: progenitors, post-mitotic/principal 











Figure 18: tSNE plot separating cells into three clusters 
 
Dimensional reduction allowed classification of each cell into one of 
three classes: progenitors = red, principal cells = green and 




 The following genes were used to identify the three cardinal cell classes. 
They are shown overlaid on the tSNE plot for progenitors (Figure 19), 
principal cells (Figure 20) and interneurons (Figure 21).  
 
Figure 19: The four genes used to identify progenitor cells 
overlaid to the tSNE plot 
 Four genes were used to identify progenitor cells: PAX6, SLC1A3, 
HES1 and VIM. Each dot represents an individual cell and highest 
expression is indicated by dark purple, cells with no expression are 
grey. PAX6 is a transcription factor expressed by neural progenitor 
cells. SLC1A3 expression is downregulated by basal progenitors. 
HES1 is expressed in neural progenitors and its absence 
accelerates neurogenesis (Kageyama, Ohtsuka and Kobayashi, 




Figure 20: The four genes used to identify principal cells 
overlaid to the tSNE plot 
Four genes were used to identify principal cells: NEUROD2, 
NEUROD6, RBFOX1 and SATB2. Each dot represents an 
individual cell and highest expression is indicated by dark purple, 
cells with no expression are grey. NEUROD2 is expressed in 
cortical projection neurons during cortical neurogenesis. 
NEUROD6 is involved in neuronal differentiation. RBFOX1 is 
expressed in neurons and heart tissue. SATB2 is expressed in 
upper layer neurons. 
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Figure 21: The four genes used to identify interneurons 
overlaid to the tSNE plot 
Four genes were used to identify interneuron cells: DLX1, DLX2, 
GAD1 and GAD2 Each dot represents an individual cell and highest 
expression is indicated by dark purple, cells with no expression are 
grey. DLX1 and DLX2 promote GABA-ergic interneuron 





3.3.1.2 Pseudotime analysis of gene expression 
 
Next, we wanted to identify how the expression pattern of each of the 
16p11.2 locus genes changed in pseudotime as cells changed from 
progenitors towards postmitotic cells. Here, pseudotime acts to provide us a 
relative measure of transcript expression level at different “time-points” 
through the process of progenitor cells differentiating into post-mitotic cells 
(Campbell and Yau, 2018). This technique is particularly useful for our work 
as it allows us to recapitulate temporal dynamics of transcript levels through 
changing cell fates despite only having access to tissue from one time point. 
 
We used the monocle2 R package to order the cells in pseudotime using the 
normalized expression of levels of selected differentially expressed genes 
(DEGs) as input to order the cells (Trapnell et al., 2014; Qiu et al., 2017) 
moving from the progenitor state (left) to the post-mitotic stage (right). We 
plotted the average expression of each 16p11.2 transcript at each 












Figure 22: Changing mRNA expression levels of 16p11.2 genes 
across pseudotime 
Pseudotime analysis showing how mRNA expression levels of each 
of the 16p11.2 locus genes change as cell state moves through 
pseudotime from progenitor to post-mitotic. In this figure the six genes 
which we selected for initial study are shown in colour, with the colour 
for each gene shown in the key. The other genes are all coloured 




  From this pseudotime analysis we identified two genes, KIF22 (blue line) 
and ALDOA (maroon line) which were notable for having high mRNA 
expression in progenitors which then declined as cells became post-mitotic. 
We used a Wilcox test which identified ALDOA and KIF22 as the only 
16p11.2 transcripts that were significantly higher in progenitor than neuronal 
populations (p<<0.05). Four other genes, HIRIP3 (orange line), MAZ (red 
line), PAGR1 (green line) and SPN (turquoise line), were not significantly 
enriched in progenitors but their transcripts were expressed in progenitors at 
higher levels than the remaining 16p11.2 transcripts (shown as grey lines), 
many of which were barely expressed at all.  
 
To obtain a little insight into what the functions of these genes may be in 
progenitors we looked up their GO terms; Gene Ontology provides 
information about the functions of the products of these genes. GO terms of 




Table 33: GO terms associated with each of the six candidate 16p11.2 
locus genes 
Gene GO Term 




KIF22 DNA binding  
Microtubule motor activity 
ATP binding 
ATPase activity  
HIRIP3 Chromatin assembly or disassembly  
PAGR1 Protein binding 
Oestrogen receptor binding  
Histone H3-K4 methylation (chromatin remodelling) 
MAZ DNA binding 
Nucleic acid binding 
SPN Heat shock protein binding 





3.3.2 Expression of the candidate genes in the clustered 
populations 
 
To add to the findings of the pseudotime analysis, we wanted to visualise the 
expression levels of each of these genes in the cells of each of the three 
cardinal cell classes. To do this we mapped the expression levels of each of 
the genes as shown in Figure 23 onto the previously shown tSNE plot. These 
tSNE plots have the advantage that they allow us to visualise heterogeneity 
in transcript levels between single cells which wasn’t possible from the 
pseudotime analysis.  
 
 This data showed ALDOA and KIF22 to be expressed at the highest 
(although variable cell to cell) levels, with KIF22 restricted almost completely 
to progenitor cells. ALDOA is strongly expressed in progenitors but also 
expressed at lower levels in the other two cardinal cell classes.  
MAZ, HIRIP3 and PAGR1 appear to be expressed at lower levels and in 
fewer cells and also their expression is scattered throughout the cell classes, 
although HIRIP3 does appear predominantly in the progenitor class. SPN 
expression is also scattered throughout the cell classes, appearing to be 
expressed in more principal cells and interneurons that any of the other six 
genes in line with the pseudotime analysis. 
For all the genes (although less so for ALDOA), all six of these transcripts 






Figure 23: Gradient plots of the six candidate genes 
The gradient plots show the expression levels of each of the six 
candidate genes overlaid to the tSNE plot indicating the 
expression level of the gene in each cell; grey is lowest and dark 
purple is highest. Each dot represents an individual cell. 
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With our initial scRNA-seq analysis we have identified two highly promising 
candidate genes and four other potentially interesting genes. To build on this 
foundation we wanted to next take a complementary in situ hybridisation 
approach. This allowed us to visualise the transcripts identified; gaining more 
information about their spatial expression in vivo and to validate the results of 
our scRNA-seq experiment by an independent method.  
 
 
3.3.3 mRNA expression of the six candidate genes using in 
situ hybridisation of human fetal cortex sections 
 
To build on our bioinformatics foundations, our next step was to visualise the 
expression of our six candidate genes in vivo by performing in situ 
hybridisation for mRNA of each of these genes in sections of human fetal 
cerebral cortex at several ages. Due to the limited previous research into 
these genes in the brain, particularly the human brain, it was necessary to 
design probes from scratch (see 2.2.2 for details of cloning) as there were 
none publicly available.  
 
3.3.3.1 Design and sequencing of in situ probes 
 
This section will briefly describe the genomic regions identified for use in the 
in situ probes. For all six probes we used human RNA which was converted 
to cDNA (except KIF22 and ALDOA see 2.2.2). We designed primer pairs to 
amplify sequences selected from the cDNA by PCR and the amplified PCR 
products were then cloned into a pGEMT easy vector and their identity 
confirmed by sequencing and BLAST. For each gene we ensured the probes 









KIF22 has three transcript variants, the structure of the three variants and the 





Figure 24: Gene structure of KIF22 and region used for probe 
Schematic showing the three variants of the KIF22 gene and the 
619bp region spanning 1443-2062 of the KIF22 splice variant one 
region. Exons are shown in green: dark green = protein coding, light 
green = untranslated region (UTR). Black line = introns. 
Gel showing KIF22 PCR fragment estimated to be ~600bp on the 
left side of an agarose gel, on the right side there is the 100bp 
ladder run simultaneously with 500bp and 1000bp indicated by 
arrows. 
Pink rectangle contains the sequence of the PCR product which 








ALDOA has four transcript variants, the structure of the four variants and the 





Figure 25: Structure of ALDOA gene and probe region 
Schematic showing the four variants of the ALDOA gene and the 
464bp region spanning 1798-2262 of the ALDOA splice variant 
one region. Exons are shown in green: dark green = protein 
coding, light green = untranslated region (UTR). Black line = 
introns.  
Gel showing ALDOA PCR fragment estimated to be <500bp on 
the left side of an agarose gel, on the right side there is the 100bp 
ladder run simultaneously with 500bp and 1000bp indicated by 
arrows. 
Pink rectangle contains the sequence of the PCR product which 








HIRIP3 has two known transcript variants, the structure of the two variants 






Figure 26: Structure of HIRIP3 gene and probe region 
Schematic showing the two variants of the HIRIP3 gene and the 
618bp region spanning 1978 - 2416 of the HIRIP3 splice variant one 
region. Exons are shown in green: dark green = protein coding, light 
green = untranslated region (UTR). Black line = introns.  
Gel showing HIRIP3 PCR fragments, unlike the other genes, two 
bands estimated to be between 600-800bp were identified as 
indicated by the blue arrows on the right side of the gel. On the left 
side there is the 100bp ladder run simultaneously with 500bp 




Our primers were carefully designed to amplify a 618bp sequence that was 
common to both HIRIP3 splice variants. This would ensure that our probe 
would detect all splice variants of HIRIP3. However, upon running the 
amplified PCR product on a 1.5% agarose gel we observed two bands as 
seen in Figure 26 which, based on their position relative to the ladder we 
estimated one to be 600-700bp and the other to be 700-800bp in length.  
 
This result was unexpected, as we were predicting to only see one band as 
we had for the other five genes. This result of two bands meant that we could 
not be sure any probe created from these PCR products would be specific to 
HIRIP3 and detect all splice variants. There were two possible explanations 
for this: it could be due to off target effects, where our primers also amplified 
an unknown region of a different gene, or the presence of another HIRIP3 
splice variant which had not been previously predicted by BLAST. 
  
To confirm which of these possibilities was the case here, we cloned each of 
the two PCR products into the pGEMT easy vector and sequenced the DNA. 
When we compared the sequences to BLASTN, our shorter band (estimated 
to be 600-700bp on the DNA ladder) showed 99% similarity for both HIRIP3 
splice variants one and two as seen in Figure 27 making it the most 
appropriate PCR product to use for generating the HIRIP3 probe. The longer 
sequence only showed to have 77% similarity to the HIRIP3 splice variants 
one and two and no similarity to any other genes. It also matched 99% to the 
chromosome 16 reference genomic sequence confirming that the transcript 
is encoded by the HIRIP3 gene as seen in Figure 27. Therefore, we can 
strongly conclude that we have identified a new HIRIP3 splice variant that 






Figure 27: Sequence alignments of HIRIP3 PCR products 
The two HIRIP3 PCR products visualised to the HIRIP3 genome 
within the region targeted by the PCR primers. In the top figure the 
overlapping aligned sequences between the shorter and longer PCR 
products are shown with a blue background while those that differ 
are shown with a pink background. 
 
Below, the pink box shows the sequence of the shorter PCR 
product, which matched to both the reference genome and the two 
known HIRIP3 splice variants. Based on its high specificity for both 
known HIRIP3 splice variants we decided it was the most 
appropriate of the two PCR products to use to generate the HIRIP3 
probe. 
 
 In the green box is the sequence of the longer PCR product, this 
matched to the reference genome however only 77% of it matched 
to known HIRIP3 splice variants and to the shorter PCR product. 
The sequence regions which matched these are shown in blue while 






MAZ has four transcript variants, the structure of the four variants and the 







Figure 28:Structure of MAZ gene and probe region 
Schematic showing the four variants of the MAZ gene and the 
642bp region spanning 1335 - 1976 of the MAZ splice variant one 
region. Exons are shown in green: dark green = protein coding, 
light green = untranslated region (UTR). Black line = introns. 
Gel showing MAZ PCR fragment estimated to be ~600bp on the 
left side of an agarose gel, on the right side there is the 100bp 
ladder run simultaneously with 500bp and 1000bp indicated by 
arrows. 
Pink rectangle contains the sequence of the PCR product which 








PAGR1 has only one splice variant; its structure and the region used for the 









Figure 29: PAGR1 gene structure and region used for probe 
Schematic showing the PAGR1 gene and the 672bp region 
spanning 886 – 1557 of the gene. Exons are shown in green: dark 
green = protein coding, light green = untranslated region (UTR). 
Black line = introns. 
Gel showing PAGR1 PCR fragment estimated to be ~600bp on the 
left side of an agarose gel, on the right side there is the 100bp 
ladder run simultaneously with 500bp and 1000bp indicated by 
arrows. 
Pink rectangle contains the sequence of the PCR product which 







SPN has two transcript variants, the structure of the two variants and the 




Figure 30: SPN gene structure and region used for probe 
Schematic showing the SPN gene and the 673bp region 
spanning 2280 - 2952 of the gene. Exons are shown in green: 
dark green = protein coding, light green = untranslated region 
(UTR). Black line = introns. 
Gel showing SPN PCR fragment estimated to be ~600bp on the 
left side of an agarose gel, on the right side there is the 100bp 
ladder run simultaneously with 500bp indicated by an arrow. 
Pink rectangle contains the sequence of the PCR product which 







Having confirmed all the cloned regions, it was possible to make DIG-





3.3.4 Optimisation of processing human cortex tissue 
 
As human fetal cerebral cortex samples had not previously been used in our 
lab some optimisation of the tissue preparation was required.  
 
  To best preserve the morphology of the tissue it was fixed overnight still in 
the skull, this was determined to be the best method, as not fixing and 
dissecting at RIE resulted in significantly greater tissue damage, especially 
during transport method consisting of a half hour bike ride, as shown in 
Figure 31. 
 
Due to tissue size, complete fixation of the whole intact brain was not optimal 
here as it would result in over fixed tissue outside and under-fixed inside. 
Therefore, the tissue was cut into sections as described in 2.1.2.1 to ensure 
complete fixation.  
Figure 31: Comparison of fixation techniques for preserving 
brain morphology 
The fixing tissue overnight in the head as shown right, proved to be 
much better for preserving brain morphology and reducing damage 




3.3.5 In situ hybridisation of the six candidate genes 
 
We performed in situ hybridisation of our six candidate genes as described in 
the methods. We used four ages of tissue and one slide from rostral, middle 
and caudal with the exception of the 16pcw sample where the rostral brain 
tissue was damaged beyond use during dissection.  
 
3.3.5.1 H&E Staining to determine cytoarchitecture 
 
Prior to performing the in situ hybridisation, we first wanted to be able to 
determine the different compartments of the telencephalic wall based on 
cellular density. This also had the advantage of, as none of the samples from 
RIE were karyotyped, allowing us to confirm each sample used had 
approximately normal brain structure for its age (Bayer and Altman, 2002, 
2005). H&E was performed as described in the methods 2.1.3. In Figure 32, 
Figure 33, Figure 34 and Figure 35 we can see schematics of the region of 
the brain sections used in part a-a*, and low magnification image of the entire 
brain sections in part b-b*. On the low magnification we have indicated 
various anatomical locations of the brain such as the ganglionic eminences 
and where possible the different lobules. The high magnification images of 
the cortex were always taken from the ventral telencephalon.  
 
At high power (c-c*) we can determine the ventricular zone as the highly 
dense pseudostratified layer at the apical edge of the cortical section. Basally 
from this ventricular zone we can determine the less dense sub-ventricular 
zone, however based on cell density we cannot easily differentiate between 
the inner and outer sub-ventricular zone. Further towards the pial edge the 
SVZ transforms into the intermediate zone as indicated by sparse purple 
nuclei and very dense pink fibres. Next, we can see the IZ become the 
cortical plate/subplate regions, this is characterized by a change to dense 
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purple nuclei indicating the dense populations of neurons in their final 
position of the cortical plate that will go on the form the cortical layers. 
Although not indicated in the figures, adjacent to the pial surface we can 
observe a thin layer with very few nuclei, this is the marginal zone which 
mostly comprises of RGC pial end-feet and fibres, however, will eventually 
form layer 1 of the cortex. The nuclear densities used to determine each 
cortical region are summarised in Table 34. 
 
Table 34: Summary of nuclear density in each cortical region 
Cortical Region Cell Nuclear Density 
Ventricular zone Very high 
Sub-ventricular zone Moderate 
Intermediate zone Low 
Sub-plate/Cortical plate High 
 
These H&E stains act to provide a guide for the different cortical regions 
when studying the in situ hybridisation data.  
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Figure 32: 12pcw H&E Stain 
12pcw brain sections stained with H&E stains. a-a* show schematic of 
brain location taken for section. At low power (b-b*) scale bar = 2mm 
and high power (c-c*) scale bar = 100µm. Purple stain indicates cell 
nucleus and pink stain shows extracellular matrix and cytoplasm.  
b-b*) regions of brain indicated: LGE = lateral ganglionic eminence, 
MGE = medial ganglionic eminence, IC = internal capsule, LV = lateral 
ventricle, OF = orbitofrontal neuroepithelium and subventricular zone, 




Figure 33: H&E Stain at 14pcw 
14pcw brain sections stained with H&E stains. a-a* show schematic 
of brain location taken for section. At low power (b-b*) scale bar = 
2mm and high power (c-c*) scale bar = 100µm. Purple stain 
indicates cell nucleus and pink stain shows extracellular matrix and 
cytoplasm. 
b-b*) regions of brain indicated: GE= ganglionic eminence 
 
 140 
    
Figure 34: 15pcw H&E stain 
15pcw brain sections stained with H&E stains. a-a* show schematic 
of brain location taken for section. At low power (b-b*) scale bar = 
2mm and high power (c-c*) scale bar = 100µm. Purple stain 
indicates cell nucleus and pink stain shows extracellular matrix and 
cytoplasm. b-b*) regions of brain indicated: GE= ganglionic 




Figure 35: H&E stain at 16pcw 
15pcw brain sections stained with H&E stains. a-a* show schematic 
of brain location taken for section. At low power (b-b*) scale bar = 
2mm and high power (c-c*) scale bar = 100µm. Purple stain indicates 
cell nucleus and pink stain shows extracellular matrix and cytoplasm. 
b-b*) regions of brain indicated: DH = dorsal hippocampus, VH = 
ventral hippocampus, LGE = lateral ganglionic eminence, MGE = 
medial ganglionic eminence, CGE = caudal ganglionic eminence  
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3.3.5.2 Confirmation of the germinative zones using PAX6 
 
As the focus of this thesis is the proliferative germinative zones of the cortex, 
the VZ and SVZ, we wanted to be sure we had correctly identified them. 
Therefore, we stained a 12pcw brain section for PAX6 protein, the 
transcription factor expression by glial cells in both the VZ and SVZ. Our 
result in Figure 36 showed that PAX6 protein is strongly expressed in almost 
all cells of the VZ and is expressed in a subset of cells in the SVZ. There is a 
change in nuclear density between the SVZ and IZ which is also identifiable 






Figure 36: PAX6 protein expression at 12pcw 
PAX6 protein at 12pcw. a) the nuclear DAPI stain allowing us to 
see nuclear cytoarchitecture of the telencephalic wall. b) PAX6 
(green) stain overlaid to DAPI (blue). Non-specific antibody 
binding to blood vessels is indicated by pink arrow. White boxes 
indicate higher region shown for higher magnification. a, b) 
scale bars = 50µm. c-c”) high magnification images for the c) 





 The first transcript we stained for was KIF22. The scRNA-seq data predicted 
the mRNA to be expressed highly in progenitor cells and greatly decreased 
in post-mitotic cells as shown in Figure 37. We stained rostral-middle-caudal 
sections at four ages as described in the methods (with the exception of 
16pcw where the rostral part of the brain was damaged beyond use) and the 
results are shown for 12pcw (Figure 38), 14pcw (Figure 39), 15pcw (Figure 
40) and 16pcw (Figure 41). Our in situ hybridisation produced staining for 
mRNA first confirming that the KIF22 mRNA is expressed in brain tissue at 




At lower magnification (all KIF22 figures parts b-b*) we can see the 
expression of KIF22 mRNA across the entire section, it is expressed at all 
ages studied across the rostral-middle-caudal axis. It looks to be restricted to 
Figure 37: KIF22 mRNA expression through pseudotime 
Pseudotime analysis as described above showing only KIF22 
mRNA as cells move from progenitor to post-mitotic expression 
profile. 
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the germinative zones of the cortex with a clear blue band visible around the 
innermost edge of the cortex. Additionally, extremely strong KIF22 mRNA 
staining is observed at the ganglionic eminence of several sections 
(specifically Figure 38 part b’ and b*, Figure 39 part b’ and b*, Figure 39 part 
b’ and Figure 41 part b’). In some sections we can observe a small region of 
strong highly localised KIF22 mRNA staining (Figure 38 parts b’ and b*), this 
is the region around the lateral ventricle. 
 
We then studied the KIF22 mRNA expression at higher magnification, (all 
KIF22 figures part c-c*) examining across the cortex as indicated by the box 
in part b-b*. Using the H&E sections above as a guide for cortical lamination 
we observed at all ages and rostral-middle-caudal sections KIF22 mRNA 
staining to be most prominent in the germinative VZ and SVZ of all sections 
while there is very few or complete absence of expressing cells in the IZ and 
SP/CP. We also note the “speckled” appearance of the stain suggesting that 
KIF22 mRNA is present in a subset of cells within the germinative zones.  
This similarity of KIF22 mRNA expression in vivo to our result of the scRNA-
seq analysis, coupled with its restrictive expression to germinative zones in 
vivo make it a good candidate for further protein studies. 
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Figure 38: in situ hybridisation of KIF22 at 12pcw 
12pcw brain sections stained with a KIF22 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 39: in situ hybridisation with KIF22 probe at 14pcw 
14pcw brain sections stained with a KIF22 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 40: in situ hybridisation with KIF22 probe at 15pcw 
15pcw brain sections stained with a KIF22 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 41: in situ hybridisation with KIF22 probe at 16pcw 
16pcw brain sections stained with a KIF22 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 





The second probe used was for ALDOA mRNA. The scRNA-seq analysis 
showed this gene to be highest expressed in progenitors and decreasing 
significantly but still expressed, albeit at lower levels, as cells become post-
mitotic as shown in Figure 42. As previously described, we stained four ages 
and data is shown for 12pcw (Figure 43), 14pcw (Figure 44), 15pcw (Figure 
45) and 16pcw (Figure 46) across the rostral-middle-caudal axis with the 




Our staining at low magnification (all ALDOA figures parts b-b*) show 
ALDOA mRNA staining to be present in all sections at all ages. Like KIF22 
there is a strong staining band around the inside, the germinative zones of 
Figure 42: ALDOA mRNA expression through pseudotime 
Pseudotime analysis as described above showing only ALDOA 




the cortex. However, unlike KIF22, ALDOA mRNA staining is also present 
throughout the rest of the cortex. We also can observe high ALDOA staining 
in the ganglionic eminences (particularly in Figure 43 parts b’ and b*, Figure 
44 parts b’ and b*, Figure 45 part b’ and Figure 46 part b’). As with the KIF22 
mRNA we can also see high ALDOA mRNA expression in the ventricular 
zone surrounding the lateral ventricle (Figure 43 part b’ and b* and Figure 45 
part b’).  
 
Looking at the higher magnification across the cortex (as indicated by the 
black box on all ALDOA figures part b-b*) we can see the expression of 
ALDOA mRNA in the different parts of the cortex (seen in all ALDOA figures 
parts c-c*). We observe at all ages and rostral-middle-caudal sections 
ALDOA staining to be most prominent in the proliferative ventricular and sub-
ventricular zones, however there are also substantial numbers of ALDOA 
expressing cells in SP/CP and some in the IZ (however as shown by H&E 
there are very few nuclei in the IZ). This matches what was predicted by the 
scRNA-seq data and we also note that, particularly in the VZ, ALDOA seems 
to be present in many more cells than KIF22 matching the gradient plot 
shown in Figure 23. 
 
This similarity of ALDOA mRNA expression in vivo to that shown by the 
scRNA-seq analysis, coupled with its high expression in germinative zones in 
vivo make it a good candidate for further protein studies.   
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Figure 43: in situ hybridisation with ALDOA probe at 12pcw 
12pcw brain sections stained with an ALDOA probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 44: in situ hybridisation with ALDOA probe at 14pcw 
14pcw brain sections stained with an ALDOA probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 45: in situ hybridisation with ALDOA probe at 15pcw 
15pcw brain sections stained with an ALDOA probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 46: in situ hybridisation with ALDOA probe at 16pcw 
16pcw brain sections stained with an ALDOA probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




The third gene used for in situ hybridisation was HIRIP3. This gene was 
shown by the scRNA-seq analysis to be expressed in progenitor cells, 
although at lower levels than ALDOA and KIF22 and to decrease as cells 
move to post-mitotic state (as shown in Figure 47)  but not significantly. As 
before we stained rostral-middle-caudal sections at four ages as described in 
methods, except 16pcw rostral. The results are shown for 12pcw (Figure 48), 
14pcw (Figure 49), 15pcw (Figure 50) and 16pcw Figure 51). Our in situ 
hybridisation staining was successful confirming that the HIRIP3 mRNA is 




First looking at lower magnification (all HIRIP3 figures parts b-b*) we see 
HIRIP3 mRNA expression across the entire section and it is expressed at all 
ages studied across the rostral-middle-caudal axis. Unlike the KIF22 and 
Figure 47: HIRIP3 mRNA expression through pseudotime 
 Pseudotime analysis as described above showing only HIRIP3 




ALDOA mRNA stains there is not the clear band of staining around the 
ventricular zone, the increased staining that can be seen here is likely due to 
increased cell density in the ventricular zone. We also do not observe the 
very strong staining in the ganglionic eminences with the exception of 14pcw 
caudal (Figure 49 part b*).  
 
Moving to HIRIP3 mRNA expression at higher magnification (all HIRIP3 
figures part c-c*) we looked at expression across the cortex as indicated by 
the box in parts b-b*. Using the H&E sections above as a guide to the cortical 
lamination we observed HIRIP3 to be expressed (when taking varying cell 
density into account), rather uniformly across the cortex at all ages and 
locations in the rostral-middle-caudal axis. It appears to be more strongly 
expressed in the ventricular zone, however that may be an artefact of the 
high nuclear density in this region. We also observe a speckled pattern of 
staining suggesting that HIRIP3 mRNA is in a subset of cells. This staining 
shows that, as demonstrated by the scRNA-seq data, HIRIP3 mRNA is not 
restricted to, or significantly higher expressed in the germinative zones of the 
human fetal cortex in vivo. This lack of progenitor enrichment from 
bioinformatics analysis and strong staining in germinative zones in vivo does 
not make HIRIP3 a good candidate for further protein studies.  
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Figure 48: in situ hybridisation with HIRIP3 probe at 12pcw 
12pcw brain sections stained with a HIRIP3 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 49: in situ hybridisation with HIRIP3 probe at 14pcw 
14pcw brain sections stained with a HIRIP3 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 50: in situ hybridisation with HIRIP3 probe at 15pcw 
15pcw brain sections stained with a HIRIP3 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 51: in situ hybridisation with HIRIP3 probe at 16pcw 
16pcw brain sections stained with a HIRIP3 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 






The fourth gene we studied mRNA expression of was PAGR1. PAGR1 was 
shown by the scRNA-seq analysis to be expressed in progenitor cells at 
about the same level as HIRIP3 and at lower levels than ALDOA and KIF22. 
It then decreased midway through the pseudotime and then increased again, 
although to lower levels than progenitors, as cells became post-mitotic as 
shown in Figure 52. PAGR1 mRNA did not change significantly between 
progenitor and post-mitotic cell classes. Again, we stained rostral-middle-
caudal sections at four stages, except 16pcw rostral. Our results for the 
PAGR1 in situ hybridisation are shown for 12pcw (Figure 53), 14pcw (Figure 
54), 15pcw (Figure 55) and 16pcw (Figure 56). Our in situ hybridisation 
staining was successful despite requiring a long incubation time of four days 
and confirmed that PAGR1 mRNA is expressed in human brain tissue at the 
ages studied.  
Figure 52: PAGR1 mRNA expression through 
pseudotime 
Pseudotime analysis as described above showing only 
PAGR1 mRNA as cells move from progenitor to post-mitotic 
expression profile 
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 First looking at lower magnification (all PAGR1 figures parts b-b*) we can 
see PAGR1 appears to be uniformly expressed at low levels across the 
entire section at all ages and across the rostral-middle-caudal axis. 
Accounting for cell density PAGR1 does not seem to show particularly high 
expression in the ganglionic eminences at any ages.  
Considering now PAGR1 at higher magnification (all PAGR1 figures part c-
c*), we looked at its mRNA expression across the cortex as indicated by the 
boxes in parts b-b* and again used the H&E sections as a guide for cortical 
lamination. We observed some variation in staining intensity at some ages, 
most notable at 14pcw (Figure 54) where the middle has noticeably less 
staining than the rostral or caudal sections. Overall, it appears PAGR1 
mRNA is not restricted to any particular compartment of the cortex and its 
expression is rather uniform across the cortex, with particularly noticeable 
staining in the SP/CP compared to HIRIP3. This is perhaps indicative of the 
slight increase of PAGR1 expression in post-mitotic cells seen by the scRNA-
seq analysis. As with HIRIP3 staining we also observe a speckled staining 
pattern of PAGR1 mRNA suggesting that it is only expressed in a subset of 
cells.  
This lack of progenitor enrichment in vivo or from bioinformatics analysis 
does not make PAGR1 a good candidate for further studies. 
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Figure 53: in situ hybridisation with PAGR1 probe at 12pcw 
12pcw brain sections stained with a PAGR1 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 54: in situ hybridisation with PAGR1 probe at 14pcw 
14pcw brain sections stained with a PAGR1 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 55: in situ hybridisation with PAGR1 probe at 15pcw 
15pcw brain sections stained with a PAGR1 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 56: in situ hybridisation with PAGR1 probe at 16pcw 
16pcw brain sections stained with a PAGR1 probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




The fifth gene studied in vivo using in situ hybridisation was MAZ. MAZ 
mRNA was shown by the scRNA-seq analysis to be expressed in progenitor 
cells, and to only decrease very slightly, and not significantly, as cells move 
to the post-mitotic state as shown in Figure 57. As with all genes, before we 
stained rostral-middle-caudal sections at four ages except 16pcw rostral. Our 
in situ hybridisation results are shown for 12pcw (Figure 58), 14pcw (Figure 
59), 15pcw (Figure 60) and 16pcw (Figure 61). Our in situ hybridisation 
produced staining for mRNA allowing us to first confirm that the MAZ mRNA 
is expressed in brain tissue at the ages studied. 
  
  
Looking at lower magnification (all MAZ figures parts b-b*), we can see MAZ 
mRNA expression to be expressed across the whole section and expressed 
at all ages across the rostral-middle-caudal axis. For MAZ mRNA its 
expression pattern somewhat mimics that of the purple nuclear part of the 
Figure 57: MAZ mRNA expression through pseudotime 
Pseudotime analysis as described above showing only 
MAZ mRNA as cells move from progenitor to post-mitotic 
expression profile 
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H&E stains above suggesting that its expression pattern mimics cell nuclear 
density patterns across the cortex.  
 
 
Looking now at MAZ mRNA expression at higher magnification (all MAZ 
figures parts c-c*), we examined its expression across the cortex as shown 
by the boxes in parts b-b* and we used the H&E sections above as a guide 
for cortical lamination. We saw MAZ mRNA to be expressed in a very similar 
pattern to that of cell nuclear density; high in the VZ, lower in the SVZ, very 
low in the IZ and increasing again in the SP/CP. This is the same at all ages 
and across the rostral-middle-caudal axis and suggests that, as predicted by 
the scRNA-seq MAZ mRNA expression is relatively consistent across the 
cortex. The speckled staining pattern again suggests that MAZ mRNA is only 
expressed by some cells, matching the gradient plot shown in Figure 23. The 
lack of MAZ mRNA enrichment in progenitors as shown by the scRNA-seq 
analysis coupled with its very general staining pattern in vivo means it is not 
a good candidate for further protein studies into progenitor enriched genes 
from the 16p11.2 locus.  
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Figure 58: in situ hybridisation with MAZ probe at 12pcw 
12pcw brain sections stained with a MAZ probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 59: in situ hybridisation with MAZ probe at 14pcw 
14pcw brain sections stained with a MAZ probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 60: in situ hybridisation with MAZ probe at 15pcw 
15pcw brain sections stained with a MAZ probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 61: in situ hybridisation with MAZ probe at 16pcw 
16pcw brain sections stained with a MAZ probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




The final gene studied for in situ hybridisation was SPN. Unlike the other five 
genes, SPN was shown by the scRNA-seq analysis to be expressed in 
progenitor cells at similar levels to HIRIP3, PAGR1 and MAZ and then 
increase as cells become post-mitotic as shown in Figure 62. Our in situ 
hybridisation staining produced staining for SPN mRNA allowing us to first 
confirm that it is expressed in human brain tissue at the ages studied: 12pcw 
(Figure 63), 14pcw (Figure 64), 15pcw (Figure 65) and 16pcw (Figure 66). 
  
  
At lower magnification (all SPN figures parts b-b*) we can see SPN mRNA 
expression across the whole section and it is expressed at all ages studied 
across the rostral-middle-caudal axis. Most notable is the clear band of 
staining we can see around the outer edge of the cortex; this is particularly 
evident at 12pcw (Figure 63). In addition to this there is staining across the 
rest of the width of the cortex.  
 
Figure 62: SPN mRNA expression through pseudotime 
Pseudotime analysis as described above showing only SPN 
mRNA as cells move from progenitor to post-mitotic 
expression profile. 
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At higher magnification (all SPN figures part c-c*) we examined expression 
across the width of the cortex as shown by the boxes in parts b-b* and used 
H&E sections above as a guide to the cortical lamination. Here we saw 
staining that very closely matched that seen in the scRNA-seq analysis: SPN 
mRNA staining in all regions of the cortex, but particularly (especially when 
compared to stains such as MAZ) increased staining in the SP/CP. This is 
seen at all ages and across the rostral-middle-caudal axis. This mirrors our 
result from the scRNA-seq analysis and shows that in vivo, SPN is 
expressed in by cells in the proliferative regions and its level increases in the 
post-mitotic regions. This result means that SPN is not a good candidate for 
further protein studies into progenitor enriched genes in the 16p11.2 locus.   
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Figure 63: in situ hybridisation with SPN probe at 12pcw 
12pcw brain sections stained with a SPN probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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Figure 64: in situ hybridisation with SPN probe at 14pcw 
14pcw brain sections stained with a SPN probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 65: in situ hybridisation with SPN probe at 15pcw 
15pcw brain sections stained with a SPN probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 




Figure 66: in situ hybridisation with SPN probe at 16pcw 
16pcw brain sections stained with a SPN probe. a-a* show 
schematic of brain location taken for section. At low power (b-b*) 
scale bar = 2mm and high power (c-c*) scale bar = 100µm. 
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3.3.6 Selection of candidate genes for further studies  
 
Based on the results from our unbiased screen using the scRNA-seq dataset 
to present six candidate genes from the 16p11.2 locus whose transcripts 
were expressed in progenitors, and the complimentary in vivo expression 
study of the mRNA of these six genes in human fetal cerebral cortex 
sections, we identified two candidate genes. These two candidate genes 
showed significantly increased mRNA expression in progenitors compared to 
post-mitotic cells in the scRNA-dataset, and high mRNA expression in 
proliferative regions in vivo. The two candidate genes used for future study 
were ALDOA and KIF22.  
 
 
3.3.6.1 Cell cycle variability of target genes  
 
We wanted to consider what these genes may be important for. Considering 
the literature that cell cycle disruption has been implicated in the 16p11.2 
mouse model (Pucilowska et al., 2015), and that disruption to cell cycle can 
alter brain size and architecture we wanted to see if mRNA expression of 
these genes changed with the cell cycle. Therefore, we returned to the 




3.3.6.1.1 KIF22 mRNA fluctuates with cell cycle 
 
First, we asked if KIF22 mRNA expression level was related to cell-cycle 
phase. We used the expression of cell-cycle phase specific transcripts as 
described in methods (3.2.2) to divide the cells into three classes, G1/S, 
G2/M and post-mitotic neurons. We then compared KIF22 transcript levels 
between these three groups using a violin plot as shown in Figure 67. This 
analysis showed us that the majority of cells in G2/M phase expressed higher 
levels of KIF22 mRNA (red plot), cells in G1/S expressed lower levels (blue 
plot) and the vast majority of post-mitotic cells expressed low levels of KIF22 











Figure 67: KIF22 mRNA at different cell cycle stages 
Violin plot showing KIF22 mRNA distribution at three 
different cell cycle stages: G1/S, G2/M and postmitotic. 
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3.3.6.1.2 ALDOA mRNA does not fluctuate with cell cycle 
 
We performed the same analysis for ALDOA transcripts. Comparison of 
ALDOA transcript levels between the three cell cycle state groups is shown 
in Figure 68. In contrast to KIF22, there is no clear difference in the 
partitioning of ALDOA mRNA expression level between different phases of 
the cell cycle.  
   
 
  
Figure 68: ALDOA mRNA at different cell cycle stages 
 Violin plot showing ALDOA mRNA distribution at three 





3.3.7 Conclusions of results  
 
The results of this chapter are summarised here:  
 
We performed an unbiased screen of previously published scRNA-seq data 
from the VZ and SVZ of human fetal cerebral cortex and identified six genes 
whose transcripts were expressed in progenitors. We then used in situ 
hybridisation using sections of human fetal cortex to examine expression 
patterns of these genes in vivo. The results of this are briefly summarised in 
Table 35.  
 
From this we identified the two best candidates for further studies: KIF22 and 
ALDOA. They were determined as the best candidates as their mRNA was 
highly expressed in progenitors and significantly downregulated as cells 
became post-mitotic suggesting a progenitor-specific role for these genes.  
KIF22 mRNA was tightly restricted to germinative zones in vivo and we found 
it to vary with the cell cycle. ALDOA mRNA was not restricted to the 
germinative zones in vivo, however its expression was much stronger there 
than its expression in the post-mitotic IZ and SP/CP and its transcript did not 










Table 35: Summary of results from scRNA-seq analysis and in situ 
hybridisation 
Gene scRNA-seq analysis Expression in vivo Candidate for 
protein 
studies? 
KIF22 Significantly enriched in 
progenitors compared to 
post-mitotic cells 
Present in the 
germinative VZ and 
SVZ, very low or 
absent from IZ and 
SP/CP 
Yes 
ALDOA Significantly enriched in 
progenitors compared to 
post-mitotic cells, still 
expressed in post-mitotic 
cells but lower 
Strong staining in 
the germinative VZ 
and SVZ, lower but 
substantial staining 
in the IZ and SP/CP 
Yes 
HIRIP3 Higher expression in 
progenitors than post-
mitotic, but not 
significantly changed 
Expressed 
throughout the width 
of the cortex, not 
especially high in 
germinative zones 
No 
PAGR1 Higher expression in 
progenitors than post-
mitotic, but not 
significantly changed 
Expressed 
throughout the width 
of the cortex, not 
especially high in 
germinative zones 
No 
MAZ Very slightly higher 
expression in 
progenitors than post-
mitotic, but not 
significantly changed 
Expressed across 
the width of the 
cortex, staining 
pattern matches 
nuclear density of 
H&E staining  
No 
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SPN Expressed in progenitors 
and increases as cells 
become post-mitotic 
Expressed across 
the width of the 
cortex, strong 












3.4.1 The 16p11.2 transcript expression during human 
neurogenesis  
 
The 16p11.2 CNV is a polygenic mutation strongly associated with 
neurodevelopmental disorders including Autism Spectrum Disorder. This 
chapter has used an unbiased screen of existing human fetal scRNA-seq 
data identified a number of the 29 16p11.2 genes as being expressed in 
progenitor cells of the cerebral cortex and confirmed their expression in vivo 
using in situ hybridisation. We identified ALDOA and KIF22 as significantly 
enriched in progenitors and four other transcripts; HIRIP3, PAGR1, MAZ and 
SPN as also expressed in progenitors but at lower levels and not significantly 
down regulated as cells become post-mitotic. We have also confirmed this 
expression pattern in vivo to validate our two candidate choices as the best 
two for further studies.  
 
This section of the chapter will discuss the results we obtained and the 
caveats of this work.  
 
3.4.2 Analysis of scRNA-seq data 
 
All technical analysis of the scRNA-seq dataset was performed by Yifei 
Yang. This used the previously published dataset generated from single cell 
RNA sequencing of micro-dissected VZ and SVZ regions from three 16-
18GW human fetal cortices (Pollen et al., 2015).  
 
From this dataset we were able to group cells based on their transcripts to 
determine the expression levels of the 16p11.2 genes in each of the cell 
classes. This proved to be a powerful tool for producing candidates, allowing 
us to identify progenitor enriched genes.  
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When we were considering which human fetal scRNA-seq dataset to use for 
this study our decision to use the one generated by Pollen et al was made 
with the following considerations. In this study we are interested in 
proliferating cells, this cell class is found within the germinative zones of the 
developing brain, therefore using this dataset which uses cells exclusively 
from the germinative zones focuses our analysis. In addition, it uses ages 
available to us in the UK; 16-18GW (roughly equivalent to 14-16pcw), which 
allowed us to perform complementary in vivo experiments on tissue obtained 
here. One limitation of this dataset could be the low cell number: 393 cells, 
and it can be postulated that analysing datasets with more cells could 
produce a stronger result. However, our conclusions of this chapter do not 
rely solely on the results of the scRNA-seq analysis, we follow this analysis 
with an in vivo in situ hybridisation study providing two different approaches 
to identify our top two candidate genes. 
 
 
3.4.3 Fetal Samples used 
 
We used human fetal samples collected from the RIE (with the exception of 
the 12pcw sample which was obtained from HDBR in Newcastle) for the H&E 
stains and in situ hybridisations shown in this chapter. Screening of patients 
was performed by research midwife nurses as described in the methods, 
however in using this tissue we did make some assumptions. As there was 
no karyotyping of our samples, we had no way to know if the samples would 
have been affected by any neurodevelopmental disorders having proceeded 
to term. In particular there was no way to know if they could have been 
affected by the 16p11.2 CNV. Based on its prevalence at only 3 in 100,000 of 
the population we determined the risk of this to be negligible.  
 
Another potential caveat is the lack of replicates for each age. This is a 
general problem associated with working with human tissue and one we 
encounter throughout this thesis. We are able to compensate for this to some 
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extent by comparing rostral-middle-caudal of each age and using a wide 
range of ages, and as this chapter is a purely qualitative expression study in 
this chapter it does not affect statistical power. Therefore, the tissue samples 
used were sufficient for this descriptive gene expression study. 
 
 
3.4.4  Using H&E staining and nuclear density to determine 
cortical lamination 
 
We used H&E staining on adjacent sections to those used for the in situ 
hybridisation to guide our determination of the cortical architecture. This 
allowed us a rudimentary guide to identify the different parts of the cortex 
based on their nuclear cell density. In addition, our IF stain for PAX6 protein 
allowed us to more clearly identify the VZ and SVZ, the regions of interest for 
this study. This method was sufficient for this as we were not looking to 
precisely identify individual regions although ideally, we would have used 
other region-specific markers to determine the different parts on adjacent 
sections. In addition for our indication of key anatomical locations at low 
magnification, many of these are approximate based on atlases (Bayer and 
Altman, 2002, 2005) and are only indicative. To be sure of the various 
regions we would need to stain with individual markers such as NKX2.1 for 
the medial ganglionic eminence, and COUP-TFII for the caudal ganglionic 
eminence. However, while we notice mRNA expression of some of our 
genes, particularly KIF22 and ALDOA, their potential role in interneurons is 
outwith the scope of this thesis. 
 
If possible we would have used layer specific markers for some of the 
regions that were more difficult to delineate by eye such as the boundary 
between the inner and outer SVZ could have been determined using a oSVZ 
specific marker such as HOPX (Pollen et al., 2015). In addition it can be 
difficult to determine the boundary between the IZ and SP (and we combined 
the SP and CP for our data as these post-mitotic regions was not our focus), 
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we could have better identified these using GAP-43 to identify the SP at our 
time-points of interest and MAP2 to determine the cortical plate (Bayatti et 
al., 2008). However, as this thesis is focused primarily on the germinative 
zones, the VZ and SVZ, this does not significantly impact our findings.  
 
One issue we encountered when staining sections for H&E was the fragility 
of the cryostat sections, particularly the highly nuclear dense VZ. Despite 
secondary fixing in FAA as described in methods we noticed large amounts 
of damage to the sections, however this was not detrimental enough to 
prevent identifying individual cortical regions.  
 
3.4.5 In situ hybridisation results  
Our in situ hybridisation data provides a detailed atlas of the mRNA 
expression of our six candidate genes across key developmental timepoints. 
It validates the candidates selected by our unbiased screen of the scRNA-
seq data and allowed us to identify the top two candidate genes for further 
studies. Having identified two genes: ALDOA and KIF22 as having mRNA 
enriched in progenitors and being significantly downregulated as cells 
become postmitotic, and four other genes HIRIP3, PAGR1, MAZ, and SPN 
as having mRNA expressed in progenitors but at lower levels and not 
significantly down regulated as cells became post-mitotic. Our in vivo results 
confirmed that, for our study looking to identify 16p11.2 locus progenitor 
enriched transcripts, HIRIP3, PAGR1, MAZ and SPN while their mRNA were 
expressed in the progenitor regions of the brain, it was not at a particularly 
high level compared to other regions excluding them as candidates for this 
study and therefore they will not be discussed further in this thesis.  
 
3.4.6 Candidates for further study 
Out of our unbiased bioinformatics screen and follow-up in situ hybridisation, 
we identified two strong candidate genes from the 16p11.2 locus for further 
study: ALDOA and KIF22. These two genes emerging as our study genes is 
particularly interesting, as they were previously identified as the only two 
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genes from the 16p11.2 locus to induce head size changes in zebrafish when 
their mRNA levels were reduced 50% as in the 16p11.2 CNV patients 
(Blaker-Lee et al., 2012). Therefore, there is already some evidence for these 
two genes as important in proliferation and brain growth during neural 
development, and altering their dosage affects neural development, albeit in 
the slightly smaller and simpler zebrafish brain.  
 
It is important to consider that while we can learn a lot from mRNA 
expression, it is the protein that exerts effect in the cell. Therefore, having 
achieved the aim of this chapter to identify progenitor enriched genes from 
the 16p11.2 locus, in the next chapters of this thesis we will investigate 




4 KIF22 protein expression is restricted to 
proliferating cells and varies with the 





4.1  Introduction 
 
From our work in chapter three we identified two candidate genes from the 
16p11.2 locus whose transcripts were enriched in progenitors and 
downregulated in post-mitotic cells: KIF22 and ALDOA. These progenitor-
enriched genes were of particular interest to us as they are likely to 
specifically affect neurogenesis. In this chapter we will study further the first 
of these two genes KIF22. 
 
 From the scRNA-seq analysis we can summarise using a violin plot (Figure 
69) the numbers of cells expressing different levels of KIF22 mRNA in the 
different cardinal cell classes to show that KIF22 is expressed predominantly 
in progenitors.  
 
  
 We next wanted to study KIF22 protein expression during human cerebral 
cortex development to understand more about its role in neurogenesis. In 
this introduction we will briefly summarise what is known about the KIF22 
protein from the literature and outline the aims of this chapter.  
  
Figure 69: KIF22 mRNA expression 
Violin plot showing the distribution of KIF22 in different cells 
types. Cortical progenitors = blue, post-mitotic neurons = red 
and interneurons = green. 
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4.1.1 Kinesin family 
 
The KIF22 gene encodes a protein which is a member of the kinesin-like 
protein family (Tokai et al., 1996). The first of the kinesin family (Kinesin-1) 
was discovered from the giant axon of the squid in 1985 (Allen et al., 1982; 
Brady, Lasek and Allen, 1982; Vale, Reese and Sheetz, 1985). This protein, 
when isolated, was found to comprise of two main parts: two identical heavy 
chains which act as the motor and associate with the second part; two light 
chains responsible for binding the motor to the cargo for transportation (Vale, 
Reese and Sheetz, 1985). Since the discovery of this first kinesin a whole 
superfamily of kinesins has been identified comprising 15 families and 
organised into three main classes (Hirokawa et al., 2009):  
1) N-kinesins with their motor domain in the amino terminal region which 
drive microtubule plus end-directed motilities. 
2) C-kinesins with their motor domain in the carboxy-terminal region 
which drive microtubule minus end-directed motilities. 
3) M-kinesins with their motor domain in the middle which depolymerize 
microtubules.  
 
There are a vast number of kinesin genes identified since the discovery of 











Table 36: Kinesins ordered by family 
Family Class Members 
Kinesin 1 N-Kinesin KIF5A 
KIF5B 
KIF5C 


















Kinesin 5 N-Kinesin KIF11 
Kinesin 6 N-Kinesin KIF20A 
KIF20B 
KIF23 
Kinesin 7 N-Kinesin KIF10 





Kinesin 9 N-Kinesin KIF6 
KIF9 
Kinesin 10 N-Kinesin KIF22 
Kinesin 11 N-Kinesin KIF26A 
KIF26B 
Kinesin 12 N-Kinesin KIF12 
KIF15 




Kinesin 14A C-Kinesin KIFC1 






4.1.1.1 Kinesin Structure  
While there is some variability in structure between members of the kinesin 
superfamily, there is conservation in the overall structure which is shown in 
Figure 70. The prototypical form of the kinesin-1 protein was identified in 
1989 from electron microscopy studies of bovine brain kinesin. It was shown 
to comprise of two identical heads (which act as the motor domain) which 
each connect to a stalk, a long alpha helix coiled coil domain. The coiled coil 
ends in a tail which associates with the light chain which binds to the cargo. 
Each of the coiled coils of each head intertwine to direct dimerization of the 




Figure 70: Schematic of a kinesin protein 
 Diagram showing a N-kinesin. Arrow on microtubule 
indicates direction of travel towards plus end of microtubule. 
The heavy (124 kDa) chain comprises the two identical 
polypeptide chains dimerize to form the coiled coil α helix 
stalk (the neck) and the globular heads which act as the 
motor domain which hydrolyses ATP to move the protein 
along the microtubules. The light (64 kDa) chain binds to the 




4.1.1.2 Kinesin movement 
Kinesin protein move along the microtubule by “walking”. The exact details of 
this movement are unknown, however there are two current leading theories: 
The “hand-over-hand” mechanism and the “inchworm” mechanism, these are 
shown in Figure 71 (based on diagram in (Hua, Chung and Gelles, 2002)). 
While it is unknown exactly by which method the kinesin protein walks, 
mounting evidence suggests the “hand-over-hand” mechanism as the most 






Figure 71: Proposed mechanisms of kinesin movement 
There are two proposed mechanisms of kinesin movement: 
 Symmetric hand-over-hand: in this mechanism the heads 
alternately move past each other. One head is tightly bound to 
the microtubule while the other uses 1 ATP molecule to move 
forward (black arrow). The coiled domain moves 180º around its 
axis each step (pink arrow). This is the favoured proposed 
mechanism. 
 Inchworm: In this mechanism the leading head always stays in 
the lead (here the purple head) and the heads never swap 
places. The coiled domain does not rotate (pink arrow). This 





Our kinesin of interest for this thesis is KIF22, the kinesin-like microtubule-
based motor which binds to chromosomes and microtubules throughout 
mitosis. The KIF22 protein was first identified in 1996 by Tokai et al (Tokai et 
al., 1996) as a kinesin-like DNA-binding protein in humans, hence its 
protein’s alternative name as KID (throughout this thesis it is referred to only 
as KIF22). Over the years, KIF22 has proved itself a multi-functional protein, 
with many domains that are proposed to facilitate a wide range of its roles. 
These are shown in Figure 72, and its roles can be separated into two main 
classes: its functions in mediating the mitotic spindle as a microtubule motor, 
and its other transcriptional roles. It is known that KIF22 has many roles in 
mitosis through its role as a microtubule-based motor protein, however it also 
has other, transcriptional, roles which make it interesting to study its 




Figure 72: KIF22 domains and associated functions 
The motor domain (pink) harbours an ATP loop allowing for ATP 
hydrolysis and is also capable of bundling microtubules 
The second microtubule binding domain (blue) does not require 
ATP for bundling microtubules. 
The coiled-coil domain (green) plays a role in maintaining the 
spindle 
The DNA binding domain (purple) allows for chromosome binding 
and some transcriptional repressor roles such as repression of 
CDC25C. 
It is shown that some of KIF22 cellular functions require more than 
one domain e.g. spindle size maintenance involves both the coiled 
coil domain and the second microtubule binding domain. 
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4.1.3 KIF22 as a microtubule motor 
 
Originally identified as localised to chromosomes during mitosis (Tokai et al., 
1996), in 2003 three papers by the labs of Toyoshima and Yamamoto 
provided greater insight to this protein (Ohsugi et al., 2003; Shiroguchi et al., 
2003; Yajima et al., 2003) including its role as a plus end-directed 
microtubule-based motor. KIF22 is present throughout the entirety of mitosis, 
although its location varies at different points as shown in Table 37. The 
modulation of the many KIF22 functions and locations has been shown to be 
regulated by CDK1-mediated phosphorylation of Thr463 amino acid (Ohsugi 
et al., 2003). It has been previously shown that, in order for KIF22 to switch 
between its opposing motor actions on chromosomes during the metaphase-
anaphase transition, an alteration of KIF22’s microtubule and chromosomal 
affinities must happen. This happens because CDK1-CyclinB dependent 
phosphorylation of Thr463 activates the second microtubule binding domain 
and suspends generation of the polar ejection force as cells enter anaphase 
(Soeda, Yamada-Nomoto and Ohsugi, 2016). 
 
The known function of KIF22 protein in mediating spindle microtubule 
stability (Tokai-Nishizumi et al., 2005) is of particular interest to our work. The 
mitotic spindle is known to control whether a cell undergoes a symmetric or 
asymmetrical division, therefore contributing to maintaining the balance of 





Table 37: Localisation of KIF22 throughout the cell cycle 
Point in cell 
cycle 
Location Purpose if known Reference 
Interphase Nucleus unknown (Tokai et 
al., 1996) 
Prometaphase Spindles and the 
length of 
chromosomes 
unknown (Tokai et 
al., 1996) 
Metaphase Metaphase plate To provide force to 
move chromosome 
arms to the spindle 






Anaphase Moves with the 
chromosomes to 






















4.1.4 The transcriptional role of KIF22 
 
As its second role which involved transcriptional regulation, KIF22 protein 
acts to regulates the expression of the cell-cycle regulator CDC25C. During 
the cell cycle, in order for cells to enter mitosis they require to reach a 
threshold level of activated cell cycle regulator proteins; CDK1-CyclinB. This 
complex accumulates during G2 phase, but it is kept inactive as it is 
phosphorylated. As cells begin to transition from G2 to M phase, the 
phosphatase cell cycle regulator protein CDC25C is activated, which then is 
able to dephosphorylate the CDK1-CyclinB complex and render it active 
allowing the cell to enter mitosis. KIF22 is involved in regulating this process 




Evidence from a study in cancer tissue in 2014 helped to reveal the feedback 
loop by which KIF22 and the CDK1-CyclinB complex are linked (Yu et al., 
2014). They showed that inhibition of KIF22 supresses cancer cell 
proliferation and reducing KIF22 levels caused cells to exhibit a faster S to 
G2/M progression but to have a slower mitotic exit (Yu et al., 2014). In their 
model; KIF22 transcriptionally and translationally represses CDC25C, a 
primary driver of mitotic entry (Bulavin et al., 2003), and the inhibition of 
KIF22 increased CDK1 activity by transcriptionally upregulating CDC25C 












Figure 73: Schematic of KIF22's transcriptional regulation of 
cell cycle regulators 
 
Schematic showing the result from cancer cell lines that evidenced a 
transcriptional regulatory role for KIF22 in the cell cycle. Here during 
the transition from G1/S phase to G2 phase the CDK1-CyclinB 
complex is highly phosphorylated by CDC25C which allows it to 
phosphorylate KIF22 which transcriptionally represses CDC25C, a 
primary mitotic entry driver. This repression results in the 
dephosphorylation of the CDK-CyclinB complex and subsequently 
KIF22 dephosphorylation which no longer represses CDC25C 
allowing for mitotic entry.  As CDC25C is no longer repressed, the 
CDK1-CyclinB complex phosphorylates CDC25C enhancing its 
phosphatase activity creating a feedback loop to drive cells to 
mitosis. However, this activated CDK1-CyclinB complex also 
phosphorylates KIF22 allowing it to transcriptionally repress 
CDC25C reducing CDK1-CyclinB activity and triggering mitotic exit. 
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4.1.5 KIF22 as a cell cycle regulator 
 
The multiple roles of the KIF22 protein in cell division, transcriptional and as 
a motor protein, make it an intriguing candidate: one of the key determinants 
of NPCs undergoing a neurogenic vs proliferative division is increased cell 
cycle length. Most of the knowledge about KIF22’s functions are from studies 
in cell culture systems or cancer tissues, and nothing is known about its roles 
in neural development. While a KIF22 depleted mouse has been previously 
generated, no investigation has been performed into any changes to neural 
development in these mice and half died in utero (Ohsugi et al., 2008).  
 
As there is much previous evidence as to KIF22’s importance in the cell cycle 
and mitosis, it can be hypothesised that any alteration to its normal level by 
changes to gene dosage has potential to disrupt neural progenitor 
proliferation and differentiation. However, as nothing is currently known about 
KIF22 in human neural development it is important to first describe its normal 
expression in the human fetal cerebral cortex.  
 
4.1.6 Chapter Aims 
 
This chapter has the following aims: 
 
1) To characterise the anatomical expression pattern of the KIF22 
protein during human fetal cortical development using high-level 
immunohistochemistry. 
2) To establish whether the restriction of KIF22 mRNA to progenitor cells 
is also true for the KIF22 protein. 
3) To further investigate whether, like KIF22 mRNA, KIF22 protein levels 





4.2.1 Fetal tissue used 
The fetal tissue for this chapter was paraffin embedded tissue from the 
HDBR. Tissue was used for both colourmetric immunohistochemistry (IHC) 
and immunofluorescence (IF). The ages used are shown in Table 38. Details 
of tissue preparation is provided in 2.1.1. 
 
Table 38: Fetal ages used in this chapter 
Age Rostral Middle Caudal 
12pcw 
sample one 
 IHC and IF  IHC and IF  IHC and IF 
12pcw 
sample two 
IF IF IF 
14pcw  IHC and IF  IHC and IF  IHC and IF 
16pcw IHC IHC IHC 
 
4.2.2 Colourmetric immunohistochemistry of KIF22 
The colourmetric immunohistochemistry (referred to as IHC hereafter) was 
performed as described in 2.3.2. The antibody used for this IHC stain was 
the KIF22/KID polyclonal antibody anti-KID (Invitrogen #PA5-29490) at a 
concentration determined to optimal of 1:5000.  Sections where then 






4.2.2.1 Cell Counting for immunohistochemistry 
 
 Cell counts were performed manually in FIJI with the help of undergraduate 
honours student Erin Boyle. Having taken individual high magnification 
images across the width of the cortex as described in the methods chapter, 
we used FIJI software to stitch them together using the stitching plugin 
(Preibisch, Saalfeld and Tomancak, 2009). Having stitched the images, we 
overlaid a grid of regular counting boxes (34x88μm) onto the images 
extending across the entire width as shown in Figure 74a and aligned with 
the ventricular edge. To ensure cells were not double counted, we used an 
inclusion/exclusion system to systematically determine if cells on the borders 
of grids should be included or not as shown in Figure 74b. We used the 
ImageJ cell counting plugin to count cells which were denoted as either 
KIF22+ (brown) or KIF22- (red) with examples shown in Figure 74b, green 
arrows indicating KIF22+ cells and blue arrows indicating KIF22- cells. The 
distinction between the regions (VZ, SVZ, IZ and SP/CP) was determined 
anatomically by cell nuclear density. The count for each box was averaged 
with other boxes in the region to provide the final value. The size and number 
of bins used was optimised to make sure to include the ventricular edge, 







Figure 74: Counting method for KIF22 IHC 
A = showing the grid overlaid across the cortical width for counting 
aligned with the ventricular edge. Example KIF22+ cells are 
indicated by green arrow and example KIF22- cells are indicated by 
blue arrows. 
B= inclusion/exclusion criteria for cells on the boundaries of grid 
boxes. Cell nuclei which has >50% of their stain in the a box (pink 
cells)  were included for that box count, where there was not a clear 
box and the cell nuclei sat on a boundary line , cells on the top edge 
were included (pink cells) and on the bottom edge were not 
included (grey cells), cells spanning the boundary furthest from the 




4.2.2.2 Data analysis for IHC 
 
First, we identified which boxes corresponded to which region based on 
cellular nuclear density of the nuclear fast red (NFR) counterstain. The 
ventricular edge was considered to be the first box of the counting grid. The 
KIF22+ and KIF22- counts for each box were averaged for the respective 
regions and displayed as graphs showing both the percentage of KIF22 
expression cells and the numbers of both KIF22+ and KIF22- cells. To 
combine our data, we presented the data two ways: first by averaging the 
values for each age but keeping the rostral-middle-caudal values separate, 
and secondly by averaging the values for rostral-middle-caudal and keeping 
the ages separate. No statistical tests were performed on the IHC data as 
one fetal sample was used for each age.  
 
 
4.2.3 Immunofluorescence of KIF22 and KI67 
 
For our immunofluorescence study of KIF22 the tissue from HDBR was again 
used and the IF protocol performed as described in the methods. The 
antibodies used for this part are shown in Table 39. 
 
Table 39: Antibodies used for IF 
Antibody Concentration Vendor Secondary Antibody 
KIF22 rabbit 
polyclonal 







Alexa Fluor Goat anti-




4.2.3.1 Cell Counting for immunofluorescence  
 
For the IF study of KIF22 we only performed high-magnification imaging of 
tissue from the germinative zones: the VZ and SVZ. The images were then 
stitched together in FIJI and a counting grid (20x145μm per box) overlaid 
onto the image in the same style as the IHC. For cell counts performed in 
FIJI, the same inclusion/exclusion criteria were used as for IHC. For 
determining intensity, cells were randomly selected on the DAPI channel, the 
nucleus outlined and the fluorescent intensity of KIF22 and KI67 recorded. 
The counts from the individual boxes were then combined to give final 
values.  
 
4.2.3.2 Data analysis and statistics for IF 
 
First, we determined cells as expressing KI67, KIF22, both or neither. We 
performed this individually for 12pcw (two brains were used, and the results 
kept independent) and 14pcw (one brain used) with individual rostral-middle-
caudal sections. As we saw no difference in expression quantification 
between the ages nor anatomical locations, we then pooled the data. We did 
this by averaging the rostral-middle-caudal values for each age to use as a 
single n value and treating the two 12pcw and one 14pcw values to give n=3 
as explained in Table 40 to perform an ANOVA with a post-hoc test to 









Table 40: Summary of data handling 
Sample n-value 
12pcw brain one - Rostral   
First n value 12pcw brain one - Middle 
12pcw brain one - Caudal 
12pcw brain two - Rostral  
Second n value 12pcw brain two - Middle 
12pcw brain two - Caudal 
14pcw brain - Rostral  
Third n value 14pcw brain - Middle  
14pcw brain - Caudal 
 
 
Next, we examined KIF22 and KI67 levels by recording fluorescent intensity 
as described above. Cells were determined as being KI67- if their expression 
level fell below that of a background reading taken from recording mean 
fluorescence intensity of several clearly KI67- cells and averaging those 
values. To transform the data prior to statistical testing to produce normal 
distribution, we wanted to log transform it, however as some values = 0 it 
was necessary to do a +1(log) transformation where we added a value of one 
to every data point prior to the log transformation. To show KIF22 levels in 
KI67+ cells vs KI67- cells we created boxplots from the individual values in 
each sample (two 12pcw samples treated individually) and performed an 
unpaired t-test to determine statistical significance for each of the rostral-
middle-caudal sections with the clear caveat that any result is derived from 
pseudo replication. As again we saw no difference between ages nor 
anatomical location, we then averaged the values to pool the untransformed 
data, however for the average values were greater than 0.1 we were able to 
perform log transformation rather than +1(log), as described above in Table 




All analysis was performed, and graphs generated in GraphPad prism 
version 6.0, with the exception of the correlation graphs which were created 





4.3.1 KIF22 protein is expressed in the germinative zones of 
the 12, 14 and 16pcw cortex 
 
Here we characterize KIF22 protein expression during human corticogenesis. 
As described in the methods, coronal cortex sections samples from the 
rostral-middle-caudal axis were immunostained for the KIF22 protein and 
counterstained with NFR to show cytoarchitecture. KIF22+ (brown) and 
KIF22- (red) cells were counted for each region in the telencephalic wall (VE, 
VZ, SVZ, IZ and SP/CP) (see 4.2.2.1 for sampling details), and the 
lamination was identified by cell nuclear density (Bayer and Altman, 2002, 
2005).  
 
We investigated three developmental stages across the rostral-middle-caudal 
axis and saw similar expression patterns. The data is shown for 12pcw 
(Figure 75), 14pcw (Figure 76), 16pcw (Figure 77). We use schematics (a, 
a*, a’) to indicate the rostral-middle-caudal region of the brain sections were 
taken from. Next, we show low magnification image of the entire section 
stained (b, b*, b’) on which the cortical region used for high magnification 
imaging and analysis is indicated by a black box. At higher magnification (c, 
c*, c’), we can see that KIF22 protein is most abundant in the germinative 
zones, in a similar pattern seen in the in situ hybridisation stains in chapter 
three. This can be seen more clearly at higher magnification (d-h’) of the 
boxed region shown on (c, c*, c’) where green arrows indicate examples of 
KIF22+ cells. Looking qualitatively at these images it appears as though 
KIF22 protein is predominantly present in cells within the germinative zones 
of the cerebral cortex. We sought to confirm this with quantification, for clarity 
we presented the data two different ways: first as a percentage of total cells 
which express KIF22 (i-k), in this way across the rostral-middle-caudal axis, 
we can see that KIF22 expressing cells are most abundant in the VE, 
followed by the VZ and SVZ with the IZ and SP/CP presenting a very low to 
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complete absence of KIF22. The second way we presented the data (i*-k*), 
shows the total number of cells split to indicate how many are KIF22+ and 
how many are KIF22-. This provides the same result, showing the highest 
abundance of KIF22+ cells in the VE followed by the VZ and SVZ. This way 
of presenting the data also clearly shows us that even in the most KIF22 
abundant region, only a subset of cells expresses KIF22 protein.  In addition 
we can also see high KIF22 protein expression in the ganglionic eminence, 
notably in Figure 76 b* and Figure 77 b*, suggesting KIF22 is not restricted to 
the dorsal cortical germinative zones.  
 
Our observation of KIF22 cortical expression is the same across all ages and 
rostral-middle-caudal ages studied showing that within the ages looked at, 









Figure 75: KIF22 protein expression at 12pcw 
a, a*, a’) showing brain regions sectioned. b, b*, b’) low 
magnification image of the whole brain section, scale bars = 2mm. 
c, c*, c’) sections spanning the rostral-middle-caudal axis showing 
KIF22 protein expression in the telencephalic wall, scale bars = 
100μm. d-h’) high magnification images of different cortical zones 
rostral-caudal. KIF22+ cells in brown and examples indicated by 
green arrows, KIF22- cells in red pink, scale bars = 25μm. i-k) 
quantification of percentage of cells expressing KIF22. i*-k* = 
quantification separating the cell population in each zone into 








Figure 76: KIF22 protein expression at 14pcw 
a, a*, a’) showing brain regions sectioned. b, b*, b’) low magnification 
image of the whole brain section, scale bars = 2mm. c, c*, c’) sections 
spanning the rostral-middle-caudal axis showing KIF22 protein 
expression in the telencephalic wall, scale bars = 100μm. d-h’) high 
magnification images of different cortical zones rostral-caudal. KIF22+ 
cells in brown and examples indicated by green arrows, KIF22- cells 
in red pink, scale bars = 25μm. i-k) quantification of percentage of 
cells expressing KIF22. i*-k* = quantification separating the cell 














Figure 77: KIF22 protein expression at 16pcw 
a, a*, a’) showing brain regions sectioned. b, b*, b’) low 
magnification image of the whole brain section, scale bars = 2mm. 
c, c*, c’) sections spanning the rostral-middle-caudal axis showing 
KIF22 protein expression in the telencephalic wall, scale bars = 
100μm. d-h’) high magnification images of different cortical zones 
rostral-caudal. KIF22+ cells in brown and examples indicated by 
green arrows, KIF22- cells in red pink, scale bars = 25μm. i-k) 
quantification of percentage of cells expressing KIF22. i*-k* = 
quantification separating the cell population in each zone into 
KIF22+ and KIF22- cells. 
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We next pooled the KIF22+ count data as shown in Figure 78 to compare 
between all anatomical regions (Figure 78 a) and all ages (Figure 78b).  This 
concisely summarises the individual values from Figure 75, Figure 76 and 
Figure 77. We found that the percentage of KIF22+ cells in the VE (40-50%) 
was consistently higher than in other regions, followed by the VZ (20-30%) 
and SVZ (10%) with even fewer cells (<10%) in the IZ and SP/CP. This result 
describes KIF22 protein as predominantly restricted to a subset of cells in the 
germinative zones of the developing cortex at all stages studied. 
  
Figure 78: Pooled values for KIF22 protein 
Pooled values for our percentage of KIF22+ cells. 
a) values combined for individual ages with rostral (circle), middle 
(square) and caudal (triangle) separate. 
b) values combined for the anatomical regions with 12pcw (circle), 
14pcw (square) and 16pcw (triangle) kept separate. 
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4.3.2 KIF22 protein expression is restricted to proliferating 
cells 
 
Our results above show us that KIF22 protein expression is almost 
exclusively restricted to a subset of cells within the germinative zones of the 
human fetal cerebral cortex.  From the scRNA-seq data we expect these to 
be progenitor cells (Figure 69), however we wanted to identify in vivo what 
these cells are. To determine what these KIF22 positive cells were, we 
performed double immunofluorescence for KIF22 and KI67. The KI67 protein 
is expressed in all proliferating cells and switched off as cells become post-
mitotic (Scholzen and Gerdes, 2000; Miller et al., 2018) making it an ideal 
tool to identify proliferating cells in our tissue. As our IHC analysis showed 
that the KIF22+ cells were predominantly located in the VE, VZ and SVZ 
(Figure 78), we examined these regions for analysis.   
 
We performed double immunofluorescence as seen in Figure 79 for KI67 
(green) and KIF22 (red) with all cell nuclei stained blue with DAPI at 12pcw 
(a) and 14pcw (b), and a high magnification region of KIF22 and KI67 






Figure 79: Immunofluorescence of KIF22 and KI67 in the cortex 
KI67 = green, KIF22 = red, DAPI = blue 
a) KIF22 and KI67 at 12pcw, low magnification scale bars = 
4mm, high magnification scale bars = 100μm. White box on 
high magnification denotes region for c. 
b) KIF22 and KI67 at 14pcw, low magnification scale bars = 
4mm, high magnification scale bars = 100μm. 




The first analysis we performed was to count if cells expressed KI67 and 
KIF22 (see methods 4.2.3.1 for details of counting method) and the results of 
this analysis are shown in Figure 80. We performed this for two 12pcw brains 
(Figure 80 a and b) and one 14pcw brain (Figure 80 c). Cell counts at all 
ages for KIF22+/KI67+ labelled cells show that the majority (80-90%) of KI67+ 
cells also express KIF22 at both ages and across the rostral-middle-caudal 
axis. We then combined the data for anatomical locations and ages (d) (see 
methods 4.2.3.2 for details) and performed statistical analysis which revealed 
significantly more KIF22+/KI67+ cells than KIF22+/KI67- and KIF22-/KI67+ 
cells (One way ANOVA p<0.0001, F = 604.4, Tukey post hoc test). This 
analysis confirms to us that KIF22 protein expression is restricted to 









Figure 80: KIF22 and KI67 cell count analysis 
Quantification of KIF22 and KI67 expression cells in the cortex. a) 
percentage of cells expressing KIF22, KI67 or both at 12pcw in 
the first brain sample. b) percentage of cells expressing KIF22, 
KI67 or both at 12pcw in the second brain sample. c) percentage 
of cells expressing KIF22, KI67 or both at 14pcw. d) Combined 
data of percentage of cells expressing KIF22, KI67, or both with 
one-way ANOVA followed by post-hoc Tukey test performed. 
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4.3.2.1 KIF22 protein is variable but higher in proliferating 
cells 
 
Next, we considered the importance of the protein level, beyond whether it is 
a binary present or absence. From the scRNA-seq analysis in (3.3.2), we see 
that within the progenitor population there is variability in the mRNA 
expression level. To see if this was the same for the protein, we quantified 
nuclear KIF22 fluorescence level at the single-cell level (Figure 81) at 12pcw 
(brain one= a-a*, brain two = b-b*) and 14pcw across the rostral-middle-
caudal axis, again acknowledging that the statistics for the individual values 
arise from pseudo replication. Combining the data from the two ages and 
locations (see methods 4.2.3.2 for pooling of data), our result showed 
significantly higher KIF22 fluorescence in KI67+ cells (Figure 81 d). Thus, we 
are able to confirm that KIF22+ cells are proliferating, that KI67+ cells have 
higher KIF22 protein levels and that those levels are variable. 
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Figure 81: KIF22 intensity in proliferating vs non proliferating 
cells 
a, a’, a*) 12pcw brain sample one quantification of KIF22 
fluorescence intensity in KI67+/KI67- cells (raw data transformation 
= +1(log), unpaired t-test with Welch’s correction p=<0.0001). 
b, b’, b*) 12pcw brain sample two quantification of KIF22 
fluorescence intensity in KI67+/KI67- cells (raw data transformation 
= +1(log), unpaired t-test with Welch’s correction p=<0.0001). 
c, c’, c*) 14pcw quantification of KIF22 fluorescence intensity in 
KI67+/KI67- cells (raw data transformation = +1(log), unpaired t-test 
with Welch’s correction p=<0.0001). 
d) quantification of KIF22 fluorescence intensity in KI67+/KI67- cells, 
12 and 14pcw combined (raw data transformation =(log), paired t-
test, p=0.0122. 
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4.3.3 KIF22 protein levels vary with the cell cycle 
 
From the scRNA-seq analysis (3.3), and the variable KIF22 protein levels in 
KI67+ cells, we can now hypothesise that KIF22 protein levels change 
throughout the cell cycle. We wanted to test this hypothesis and see how 
they changed during the cell cycle at the single-cell level, so we returned 
again to the double immunofluorescence staining of KIF22 and KI67 in 
Figure 79. We quantified the nuclear immunofluorescence intensity of KIF22 
and KI67 in 300-400 individual cells in two 12pcw brains and one 14pcw 
brain across the rostral-middle-caudal axis (see methods 4.2.3.1 for details of 
sampling procedure). KI67 protein levels vary during the cell cycle as shown 
in Figure 82: they are lowed in G1 phase, increasing through S and G2 
phase to peak in mitosis (Scholzen and Gerdes, 2000; Miller et al., 2018).  
 
Figure 82: KI67 levels throughout the cell cycle 
Schematic showing how KI67 protein levels vary 
throughout the cell cycle to peak in mitosis 
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 We found a strong correlation between KI67 and KIF22 in our three samples 
across the rostral-middle caudal axis and the data for all of these is shown in 
Figure 82. We found a strong correlation between KIF22 and KI67 
fluorescence intensity in both 12pcw brain samples (a, a’ and a* and b, b’ 
and b*) (Brain one rostral R2=0.8095, middle R2=0.8139, caudal R2=0.6691. 
Brain two rostral R2=0.7489, middle R2=0.7447, caudal R2=0.7763). We also 
saw the same strong positive correlation at 14pcw (c, c’ and c*) (rostral 
R2=0.7465, middle R2=0.6668, caudal R2=0.643). These data demonstrate 
that the correlation between KI67 and KIF22 is consistent between ages and 
rostral-middle-caudal location. Combining all values of KIF22/KI67 nuclear 
intensity (Figure 82 d) showed us that KIF22 levels strongly correlated with 
KI67 levels (R2=0.7236)  
 
Although KIF22 expressing cells were scattered throughout the VE, VZ and 
SVZ, there was a general trend for the cells expressing the highest levels of 
KIF22 to be closest to the apical surface (yellow coloured dots on 
scatterplots in Figure 82) with lower expressing cells tending to be further 
from the apical surface (purple coloured dots on scatterplots in Figure 82) 
however there are still some high KIF22/KI67 blue dots noticeable. During 
interkinetic nuclear migration, radial glial cell nuclei move to the apical 
surface to perform mitosis, so this spatial distribution suggests KIF22 is 
expressed at high levels by apical radial glial cells undergoing mitosis at the 
apical surface of the VZ. Basal radial glial cells in the SVZ however do not 
undergo IKNM, instead they undergo mitotic somal translocation as 
described in (1.6.3), and the presence of high KIF22/KI67 in SVZ cells 









Figure 83: Quantification of KI67 and KIF22 levels 
a) Quantification of KIF22 and KI67 fluorescence intensity in 12pcw 
brain sample one with distance from apical surface indicated by 
dot colour. 
b) Quantification of KIF22 and KI67 fluorescence intensity in 12pcw 
brain sample two with distance from apical surface indicated by 
dot colour. 
c) Quantification of KIF22 and KI67 fluorescence intensity in 14pcw 
with distance from apical surface indicated by dot colour. 
d) Intensity correlations of KIF22 and KI67 nuclear fluorescence 
intensity for combined data of three brain samples rostral-middle-
caudal with distance from apical surface indicated by dot colour. 
e) Colour key showing distance from apical surface: yellow dots 




We wanted to confirm that the strong correlation we observed between 
KIF22 and KI67 fluorescence intensity was not simply a result of the nucleus 
size changing with the cell cycle. To do this we confirmed that KIF22 nor 
KI67 protein levels did not correlate with nuclear size by DAPI staining. At all 
samples and ages studied we did not see any correlation at 12pcw (sample 






Figure 84: No correlation between nucleus size and 
fluorescence intensity in 12pcw sample one 
Quantification showing that there is no correlation between 
KIF22 fluorescence intensity and nuclear size nor KI67 
fluorescence intensity and nuclear size across the rostral-
middle-caudal axis in the first 12pcw sample. 
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Figure 85:No correlation between nucleus size and 
fluorescence intensity in 12pcw sample two 
Quantification showing that there is no correlation 
between KIF22 fluorescence intensity and nuclear size 
nor KI67 fluorescence intensity and nuclear size across 






Figure 86: No correlation between nucleus size and 
fluorescence intensity at 14pcw 
Quantification showing that there is no correlation 
between KIF22 fluorescence intensity and nuclear size 
nor KI67 fluorescence intensity and nuclear size across 
the rostral-middle-caudal axis in the 14pcw sample 
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  From these data and our analysis, we show that KIF22 protein levels 
change throughout the cell cycle in a positive correlation with KI67: KIF22 
protein is present in G1 and increases through S and G2 phase to peak in 





Figure 87: KIF22 model 
Model based on our results of 
how KIF22 protein levels 
change throughout the cell cycle 
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4.3.4 Conclusion of results 
Here we summarise the results of this chapter:  
 
We used colourmetric and fluorescent immunohistochemistry to describe 
KIF22 protein expression in the human fetal cortex during neural 
development. First, we used the colourmetric IHC to show KIF22 protein as 
being expressed in a subset of cells in the germinative regions of the cortex; 
highest in the VE followed by the VZ and SVZ. We showed that this 
expression pattern was consistent across the ages studied and across the 
rostral-middle-caudal axis.  
 
Next, we used double immunofluorescence (IF) staining for KIF22 and KI67 
to determine that the subset of KIF22 expression cells in these regions are 
indeed proliferating, a complementary result to that of the scRNA-seq data in 
Figure 69. Our final, and most interesting, finding of this chapter is our 
observation, again complementary to the result of the scRNA-seq analysis, 
that KIF22 protein levels may fluctuate throughout the cell cycle, suggesting 





The 16p11.2 CNV is a polygenic mutation heavily implicated in ASD. 
However, to begin to understand the many ways in which this CNV affects 
development it is critical to understand the roles of each of its individual 
genes in development; here focussing on human fetal cerebral cortex 
development. Based on the scRNA-seq analysis in 3.3.2, we focused on 
KIF22 for further studies. We have showed it to be expressed in progenitors 
of the cortex, and its protein levels to vary with the cell cycle. In this section 
of chapter four we will discuss our results obtained in this chapter and the 
caveats of our work.  
 
4.4.1 KIF22 protein is expressed in progenitor cells in the VZ 
and SVZ at varying levels during the cell cycle 
 
Our results show that KIF22 protein is expressed in proliferating cells of the 
VZ and SVZ. Our data showing the highest proportion of KIF22+ cells in the 
VE, the location of mitosis for apical radial glial cells, and the correlation of 
KI67 and KIF22 proteins in the VZ and SVZ (where cells undergo mitotic 
somal translocation to divide) suggest that KIF22 protein levels peak in 
mitosis and its expression level is closely tied to the cell cycle. This variation 
of KIF22 protein levels during the cell cycle suggests its correct function in 
cell division is dependent on its correct dosage.  
 
Literature tells us that KIF22 is a multifunctional protein that regulates cell 
proliferation through at least two distinct mechanisms. Its first role is as a 
kinesin-like microtubule-based motor which acts to bind microtubules and 
chromosomes during mitosis and regulates mitotic spindle stability and 
symmetric/asymmetric cell division (Tokai et al., 1996; Tokai-Nishizumi et al., 
2005; Sun and Hevner, 2014). Its second function is summarised in Figure 
73, it regulates expression of cell-cycle regulator CDC25 by transcriptionally 
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repressed CDC25C and inhibits mitosis. The transcriptional repression of 
CDC25C depends on KIF22 being phosphorylated on Thr463 (Ohsugi et al., 
2003; Yu et al., 2014) and KIF22 depletion in tumour cell lines has been 
shown to accelerate the G2/M transition and slow M/G1 transition (Yu et al., 
2014). 
 
4.4.2 KIF22 in the 16p11.2 CNV 
 
Based on the literature, it appears that KIF22 protein can act at several 
points in the cell cycle making it difficult to predict how increased or 
decreased dosage of KIF22 in the 16p11.2 duplication or deletion 
respectively would impact cell cycle in the specific context of cerebral cortical 
neural progenitors. However, we can still postulate potential hypotheses in 
the context of our results. We observed complementary results from both our 
scRNA-seq analysis and in vivo protein studies. Our observations, while 
purely correlative at the protein level, suggest that KIF22 mRNA and KIF22 
protein levels may both increase during the cell cycle to achieve highest 
levels in G2/M phase that drop as cells enter G1 phase. These data imply 
that KIF22 protein does not persist for long after it is translated and is 
degraded at the end of M-phase suggesting that both transcriptional and 
post-translational mechanism regulate its levels.  
 
In our results we can clearly see that KIF22 protein levels correlate with KI67 
in neural progenitors and steadily rise as the cell progresses through 
G1>S>G2>M phases, culminating in the maximum level during M-phase. 
One possibility, shown in Figure 88, is that KIF22 is required to reach a 
threshold for mitosis to occur, after which its levels must decrease sufficiently 
to allow mitotic exit. Whether cells undertake proliferative or neurogenic 
divisions is a process heavily controlled by cell cycle length (described in 
1.6.6.2.1) (Calegari and Huttner, 2003; Lange, Huttner and Calegari, 2009). 
Perturbing KIF22 gene dosage as a consequence of the 16p11.2 CNV may 
affect the timing of KIF22 protein reaching this threshold in neural progenitors 
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and therefore affect cell-cycle kinetics and perturb neurogenesis and 
neuronal output.   
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Figure 88: Hypothesis of altering KIF22 protein dosage in the 
16p11.2 CNV 
Here we show our hypothesis of how altering KIF22 protein dosage 
could alter mitosis. In the deletion (blue line), KIF22 protein levels 
are decreased so it takes longer for the required KIF22 protein levels 
required for mitotic entry to be reached, however these lower levels 
may also mean it is depleted quicker and the time for KIF22 levels to 
decrease sufficiently to allow mitotic exit is reduced. 
Conversely in the duplication (yellow line), KIF22 protein levels are 
higher so the time for protein levels to accumulate enough to enter 
mitosis is reduced, but the elevated levels also mean the time 
needed for KIF22 protein to be depleted to allow mitotic exit is 
increased. In both the duplication and deletion this is likely to have 
substantial effects on the overall timing of the cell cycle with the 
potential to disrupt the balance of proliferation and differentiation. 
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To consider another mechanism by which altering KIF22 levels could impact 
proliferation and subsequent brain size is its transcriptional role in cell cycle 
modulation by transcriptional repression of CDC25C. CDC25 is known to 
primarily facilitate mitotic progression by dephosphorylating and activating 
the CDK1/CyclinB complex. Therefore, by altering KIF22 levels in the 
16p11.2 CNV, this would alter CDC25C expression levels in a mirrored 
fashion (increased CDC25C expression in the deletion and decreased in the 
duplication), potentially impacting the time of mitotic entry and therefore cell 
cycle length. When KIF22 levels are depleted (as in the deletion), CDC25C 
expression would increase thus accelerating mitotic entry and shortening the 
cell cycle making NPCs more likely to undergo proliferative divisions. This 
matches with the phenotype of the 16p11.2 del mouse model in which 
increased progenitor proliferation is observed (Pucilowska et al., 2015). 
Conversely, when KIF22 levels are heightened (as in the duplication), 
CDC25C expression would be repressed further slowing mitotic entry, 
prolonging the cell cycle and making NPCs more likely to take neurogenic 
divisions. This hypothesis is summarised in Figure 89. However, it is 
important to consider that KIF22 is only one of the 29 genes whose dosage is 
altered in the CNV, therefore predicting effects of only altering KIF22 dosage 
does not take into account the likely interactions or compensatory 








Figure 89: Potential model for the effect of altered KIF22 levels 
on the cell cycle 
This schematic shows how altering KIF22 protein dosage could 
impact cell cycle length. In box one, reduced KIF22 dosage reduces 
the transcriptional repression of CDC25C increasing its levels which 
speeds up mitotic entry shortening the cell cycle length. In the 
second scenario the opposite is seen, more KIF22 represses 
CDC25C slowing mitotic exit and increasing cell cycle length. 
 245 
 
4.4.3 Experimental limitations 
When examining our results in the context of the literature, it also critically 
important to consider the limitations of our experiments.  
In this chapter, we only predominantly focus on the germinative zones, the 
VZ and SVZ for our analysis. However, our IHC analysis (4.3.1) showed a 
small number of cells in the subplate/cortical plate region to be expressing 
KIF22 protein. While we did not study them in this work, this could warrant 
further study to identify what these might be; one hypothesis could be they 
are migratory interneurons. 
 
Our result that KIF22 peaks in the M-phase of the cell cycle is dependent on 
correlations between KIF22 and KI67. We make the assumption here that 
KI67 protein levels change accurately throughout the cell cycle, however 
there is a solid body of literature confirming that it does (Scholzen and 
Gerdes, 2000; Miller et al., 2018) and assume that the KI67 protein levels 
vary with the cell cycle in our system in the same way as the systems from 
the literature. We can be relatively confident of that by our result that we see 
many of the highest KI67 expression cells are found at the VE, the location at 
which aRGCs undergo mitosis. 
 Our result is dependent on correlations, and ideally, we would have liked to 
confirm by co-immunostaining for KIF22 and pH3, an M-phase marker. We 
did make several attempts at this, however the conditions required for each 
antibody which are shown in Table 41 were not compatible. 
 
Table 41: Optimisation of KIF22 and pH3 antibodies 
Fixation 
method 
Processing KIF22 antibody pH3 antibody 
Methacarne paraffin Worked Failed 
4% PFA cryo Failed Worked 
4% PFA Paraffin Failed Failed 
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In addition, the cell counting could be improved with automation, to eliminate 
any chance of human bias. Automated cell counting would allow many more 
cells to be counted in a short space of time without the need for a human, 
however the very high nuclear density of the ventricular zone meant no 
automated cell counting programs could accurately identify individual cells.  
 
 
4.4.4 Future directions 
What we have presented here is a clear, descriptive study using high level 
histology of KIF22 protein expression in the human fetal cerebral cortex. For 
studying the normal expression pattern of genes in human corticogenesis, 
we were fortunate to be able to access human fetal tissue which is ideal for a 
descriptive study such as this. However, to take this study further there are 
several lines of experimental investigation that were beyond the scope of this 
thesis. One fundamental limitation of human fetal tissue is its lack of 
manipulability; however, this can be overcome to an extent by 
complementary experiments involving the use of human cerebral organoids. 
Before anything significant can be concluded from these artificial cortical 
structures, it is important to first confirm that the gene of interest is expressed 
in the same pattern in organoids as in the human fetal brain, which is part of 
why our descriptive study in human tissue is so powerful as a foundation 
study. It would be of great value to take this study further to manipulate 
KIF22 levels in cerebral organoids and study the effects of their proliferative 
growth as well as growing cerebral organoids from cells obtained from 
16p11.2 CNV patients.  
 
Narrowing the picture from the context of the 16p11.2 CNV to just the KIF22 
gene, it would be interesting to understand a little more about how the many 
functions of the KIF22 protein contribute to normal brain development. In 
Figure 72 we show the many domains of KIF22 protein and their associated 
functions. Therefore, it could be interesting to disrupt specific KIF22 protein 
domains in organoids to understand more about how the individual protein 
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domains contribute to normal cortical proliferation. This has been previously 
performed in cell culture (Tokai-Nishizumi et al., 2005). 
 
Our stains (Figure 76 is a clear example), also show high KIF22 protein 
expression in the ganglion eminence (GE) of the brain. The GE is the 
birthplace of inhibitory interneurons which migrate up to the cortex as 
described in Figure 5, therefore studying the role of KIF22 in ventral 
organoids could provide interesting insight into its role in interneuron 
development and migration.  
 
Overall there are many other interesting avenues for future study of KIF22, 
both as an independent gene and as part of the more complex system of the 
16p11.2 CNV, to fully understand its role in neural development and how 




5 ALDOA protein levels do not differ 
between proliferating and post-mitotic 





In chapter three we identified two candidate genes from the 16p11.2 locus 
whose transcripts were enriched in progenitors and significantly 
downregulated in post-mitotic cells. We are particularly interested in the 
genes whose transcripts are progenitor-enriched and then downregulated as 
cells become post-mitotic as they are likely to function specifically in 
neurogenesis. In chapter four we describe more about KIF22 and in this 
chapter we will further study the second of these genes: ALDOA. 
 
A summary of the analysis of the scRNA-seq dataset which identified ALDOA 
as a gene of interest is shown in Figure 90. In this violin plot we see the 
numbers of cells expressing different levels of ALDOA mRNA in the different 
cardinal cell classes. This shows that while the greater proportion of cells 
expressing the highest levels of ALDOA mRNA are progenitors (blue plot), 
there are also a substantial number of principal cells (red plot) expressing 
similarly high levels of ALDOA transcripts although very few interneurons 




Figure 90: ALDOA mRNA expression 
Violin plot showing the distribution of ALDOA in different 
cell types. Cortical progenitors = blue, post-mitotic neurons 
= red and interneurons = green. 
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We wanted to study the ALDOA protein expression during human cerebral 
cortex development to understand more about its role in neurogenesis. In 
this introduction we will briefly summarise what is known about ALDOA 
protein from the literature and outline the aims of this chapter.  
 
 
5.1.1 The glycolytic pathway 
 
The process of brain development requires a vast and consistent supply of 
energy. Glucose is the predominant energy substrate for the fetal brain 
(Gustafsson, 2009), therefore efficient and controlled glycolysis is essential 
for normal brain development. Glycolysis is the 10-step process by which 
glucose is broken down into two molecules of pyruvate and a net gain of two 
ATP molecules and two NADH molecules, both of which are high energy 
molecules. The process is shown in Figure 91 and comprise two main 
phases: The preparatory (green) phase, where energy is consumed, and the 
payoff phase (pink) which has the end net gain of high-energy molecules, 
ATP and NADH. This glycolysis process produces pyruvate as its final step 
which then feeds into the citric acid cycle facilitating further reactions within 
the cell. Interestingly elevated pyruvate levels have been identified in ASD 
children as well as alterations to the mitochondrial citric acid cycle (Giulivi et 
al., 2010) suggesting that any variation to these pathways may contribute to 
the ASD phenotype. 
 
Disruption of glycolysis is seen commonly in cancer cells, which undergo 
rapid and uncontrolled proliferation and perform glycolysis at ten times the 
rate of non-cancerous cells of the same type (Alfarouk et al., 2014). 
Maintenance of glycolysis is essential for normal function of most, if not all, of 
the body’s functions and disruption to any part of the pathway is likely to 






Figure 91: The glycolytic pathway 
This figure summarises the glycolytic pathway. This pathway 
comprises ten steps which can be split into two main phases: The 
preparatory, or investment, phase in green, and the payoff phase in 
pink. 
Step 1) An ATP molecule is consumed from which a phosphate 
molecule is transferred to the Glucose producing Glucose 6-
phosphate. 
Step 2) Glucose 6-phosphate is rearranged into its isomer Fructose 
6-phosphate. 
Step 3) Another ATP molecule is consumed to turn the Fructose 6-
phosphate into Fructose 1,6-bisphosphate. 
Step 4) Aldolase catalyses the reversible reaction Fructose 1,6-
bisphosphate to Dihydroxyacetone phosphate and Glutaraldehyde 3-
phosphate. 
Step 5) Dihydroxyacetone is converted into Glutaraldehyde 3-
phosphate. 
Step 6) Simultaneous oxidisation of Glutaraldehyde 3-phosphate and 
transformation of NAD+ into NADH and H+ providing energy to 
phosphorylate the oxidised molecule creating 1,3-
bisphosphoglycerate. 
Step 7) The first molecule of ATP is produced by 1,3-
bisphosphoglycerate donating a phosphate group to ADP and 
transforming into 3-phosphoglycerate. 
Step 8) 3-phosphoglycerate is converted to its isomer 2-
phosphoglycerate. 
Step 9) 2-phosphoglycerate loses a water molecule, creating the 
highly unstable phosphoenolpyruvate molecule. 
Step 10) In the final step, the second ATP molecule is generated by 
the unstable phosphoenolpyruvate donating a phosphate group to 







The fourth step of glycolysis, the reversable conversion of fructose 1,6-
bisphosphate to dihydroxyacetone phosphate and glutaraldehyde 3-
phosphate, is catalysed by the Aldolase family members (highlighted in 
yellow in Figure 91). There are three isoforms of Aldolase, each encoded by 
a different gene and differentially expressed during development. They are 
shown in Table 42 (Alfarouk et al., 2014). 
 
Table 42: Aldolase isoforms 
Isoform Gene Location Expression Pattern of Protein 
ALDOA 16p11.2 High in the developing embryo and 
in adult muscle tissue  
ALDOB 9q31.1 Expressed in the adult liver 
ALDOC 17q11.2 Expressed in the brain  
 
In this chapter we are focussed on the Aldolase A (from now on this will be 
consistently referred to as ALDOA). ALDOA transcripts were identified as 
being significantly down-regulated as cells moved from the progenitor to 
post-mitotic state in our scRNA-seq analysis 3.3.1.2. 
 
 
5.1.3 ALDOA  
5.1.3.1 Cytoplasmic ALDOA 
 
ALDOA is a multifunctional protein, however it was originally known for its 
essential cytoplasmic role in glycolysis (Horecker et al., 1981). As shown in 
Figure 91 it catalyses the reversible reaction Fructose 1,6-bisphosphate to 
Dihydroxyacetone phosphate and Glutaraldehyde 3-phosphate by cleaving 
the C3-C4 bond. Interestingly ALDOA protein is highly expressed in many 
cancers, likely enhancing glycolysis allowing for the unconstrained growth 
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associated with cancer cells and indeed, its upregulation can correlate with 
overall reduced patient survival rates in several cancer types (Chang et al., 
2018). 
 
However, ALDOA is a protein of many roles, and it also has other non-
glycolytic “moonlighting” roles within the cytoplasm. These include regulating 
cytoskeleton stability and mitochondrial function by interacting with 
macromolecules not associated with glycolysis such as F-actin, α-tubulin and 
dynein light chain 8 (Pagliaro and Taylor, 1992; Kao et al., 1999; Jewett and 
Sibley, 2003; Buscaglia et al., 2006; Merkulova et al., 2011). These roles of 
ALDOA protein, both metabolic and other moonlighting functions, are all 
cytoplasmic and indeed, ALDOA does typically localise to the cytoplasm. 
However, there is evidence for ALDOA protein to localise to the nucleus.  
 
5.1.3.2 Nuclear ALDOA protein 
 
Despite its stereotypical cytoplasmic localisation, ALDOA protein has been 
identified in the nucleus of certain cell types. It was first observed in the 
nucleus of pig cardiomyocytes in 2004 (Mamczur and Dzugaj, 2004) and 
then in porcine smooth muscle cells in 2008 (Mamczur and Dzugaj, 2008). 
Perhaps of most interest to this thesis was a study in 2013 that showed 
ALDOA to localise to the nucleus of proliferating cells (Mamczur et al., 2013), 
and a complementary study the previous year showed silencing of ALDOA 
inhibited cell proliferation (Ritterson Lew and Tolan, 2012) suggesting that 
ALDOA acts to affect cellular proliferation through a mechanism unrelated to 
its glycolytic functions. However, this effect on proliferation could also be 
related to ALDOA’s metabolic role as cells will require energy to divide.  
 
 One proposed nuclear mechanism is that ALDOA influences the cell cycle 
by positively regulating cyclin D1 expression to mediate G1/S phase 
progression (Fu et al., 2018). Therefore, it appears that the nuclear 
localisation of ALDOA can allow it to exert an effect directly on cellular 
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proliferation independent of glycolysis, an interesting consideration for our 
result that showed the ALDOA transcript to be highest in the proliferating 
progenitors. An interesting and unanswered question is the mechanism by 
which ALDOA protein is transported to the nucleus, as the protein lacks a 




5.1.4 ALDOA in the human fetal cortex 
 
The literature suggests a variety of roles for ALDOA protein, including both 
cytoplasmic glycolytic function and mediating cellular proliferation through 
nuclear localisation, making it a very interesting candidate for study. We 
know from our scRNA-seq analysis in 3.3.1.2 that ALDOA transcripts are 
highly expressed in progenitors and down-regulated as cells become post-
mitotic, and our in situ hybridisation in 3.3.5.4 results show its mRNA to be 
very strongly expressed in the germinative zones. While there are several 
published studies, as described above, on the many functions of ALDOA 
protein, nothing is known about its expression or potential roles during 
human fetal cortex development. Indeed, the majority of ALDOA protein 
studies have used highly abnormal cancer tissue, or artificial cell culture 
systems in which glycolytic enzymes have been shown to be increased. 
scRNA-seq analysis showed increased ALDOA  mRNA in human cerebral 
organoids compared to human fetal brain samples suggesting that cell 
culture systems may not fully reflect the physiological roles of ALDOA protein 
(Ritterson Lew and Tolan, 2012; Mamczur et al., 2013; Fu et al., 2018; Pollen 
et al., 2019). Therefore, a key question is to ask how these observations of 




5.1.5 Chapter aims 
 
This chapter has the following aims: 
 
1) To characterize the anatomical expression pattern of the ALDOA 
protein during human fetal cortical development using high-level 
immunohistochemistry.  
2) To identify if, in this system, ALDOA protein levels are higher in 
proliferating cells and if the levels vary with the cell cycle. 
3) To determine if ALDOA protein nuclear localisation is higher in 






5.2.1 Fetal tissue used  
The fetal tissue used for this chapter was paraffin embedded tissue from the 
HDBR. Details of tissue preparation is provided in 2.1.1 and the ages used 
are shown in Table 43.  
 
Table 43: Fetal ages used in this chapter 





5.2.2 Immunofluorescence of ALDOA and KI67 
For our immunofluorescence study of ALDOA, the IF protocol was performed 
as described in 2.3.1. The antibodies used for this chapter are detailed in 
Table 44. 
 
Table 44: Antibodies used for ALDOA IF 
















5.2.2.1 Cell Counting for immunofluorescence  
 
For the IF study of ALDOA at the single-cell level we performed high-
magnification confocal imaging of tissue from the germinative zones: the VZ 
and SVZ. Using FIJI, a grid of counting boxes (20x145μm) was overlaid and 
cells were randomly selected on the DAPI channel ensuring their selection 
was blind to their ALDOA and KI67 staining. As shown in Figure 92 a, we 
ensured that once a cell was included for analysis, all nuclei adjacent to it 
were excluded from analysis to ensure their cytoplasm’s would not overlap. 
For each cell nucleus we then moved the Z-plane to focus through the middle 
of the cell (the widest part) and we drew a region of interest (ROI) around the 
nucleus, as shown in Figure 92 b, which was identified by the DAPI stain. We 
then took measurements of this nuclear ROI on the green KI67 and red 
ALDOA channels and recorded that as the nuclear mean fluorescence value 
for KI67 and ALDOA.  
 
Next we wanted to obtain the ALDOA cytoplasmic intensity, our method for 
this is shown in Figure 92 b. To do this we traced around the nuclear outline 
as shown by the DAPI stain with a four-pixel thick tool to create a “donut” 
which is indicated by the cytoplasm label in Figure 92 b.  Switching then to 
the red ALDOA channel, this allowed us to obtain a reading of the mean 
fluorescence of ALDOA protein in just the cytoplasmic area. To produce the 
final cell body ALDOA value we added together the mean fluorescence 
values of the nucleus and the cytoplasm of each cell. This analysis was 
performed for ten cells in each box and the counts from individual boxes 







Figure 92: Method of cell selection and delineating nucleus 
and cytoplasm 
a) Our method of selecting cells for analysis. Cell nuceli were 
selected blind on the DAPI channel and cells with an adjacent 
nucleus to an already included cell were excluded to ensure their 
cytoplasm’s would no overlap. Ten cells were counted per box and 
examples of cells included are indicated by green arrows. 
b) Our method of delineating the nucleus and cytoplasm. This 
shows the DAPI channel which stains the cell nucleus. We drew 
around the nucleus and took the mean fluorescence value of KI67 
and ALDOA, and then drew an additional four-pixel ring around this 
to allow an approximation of the cytoplasm and recorded the mean 




5.2.2.2 Data analysis and statistics for immunofluorescence 
 
We examined ALDOA and KI67 levels by recording fluorescent intensity as 
described above. Cells were considered KI67- if their expression level fell 
below that of a background reading taken from recording mean fluorescence 
of several clearly KI67- cells and averaging those values.  
 
We wanted to determine if cell body ALDOA levels differed between KI67+ 
and KI67- so for each cell we combined the mean fluorescent value for the 
nucleus and cytoplasm to give the cell body value. Prior to statistical testing 
we log transformed the data to produce normal distribution where possible. 
However, as some values = 0 it was necessary to do a +1(log) 
transformation where we added a value of one to every data point prior to the 
log transformation. We then created boxplots from the individual cell values 
in each sample, determined the distribution of the data and performed the 
appropriate test based on the distribution for each data. To determine 
distribution, data distribution was displayed as a histogram and distribution 
determined by eye: bimodal distribution required a Mann-Whitney test and 
normal distribution required an unpaired t-test with Welch’s correction. Our 
analysis is accompanied by the clear caveat that any result is derived from 
pseudo-replication as it a dataset from within a single sample, however it 
allowed us to gauge if there was significant difference in any of the samples. 
As we saw no difference at any age, we then combined the data by 
averaging the ALDOA values for each age in KI67+ and KI67- cells. We 
considered each age a separate n value, +1(log) transformed the data and 




For determining if nuclear ALDOA levels were higher in KI67+ cells compared 
to KI67- cells we used only nuclear values from the cells measured. We 
handled and transformed the data in the same way as above.  
 
All analysis was performed, and graphs generated, in GraphPad Prism 
version 6.0 with the exception of the correlation graphs which were created in 




5.3 Results  
 
5.3.1 ALDOA protein is highest in the germinal zones of the 
cortex 
 
In chapter three our bioinformatics analysis in 3.3.1.2, and our in situ 
hybridisation in 3.3.5.4, show that ALDOA mRNA levels are highest in 
progenitor cells and decrease as cells move towards a neuronal fate. First, 
we wanted to characterize ALDOA protein expression across the 
telencephalic wall, for which we used immunofluorescence to visualise 
ALDOA protein at three developmental timepoints: 12, 14 and 16pcw. Our 
results are shown in Figure 93 (a-c) and are consistent across the ages; 
ALDOA immunofluorescence appears most intense in the proliferative VZ 
and SVZ before decreasing in the intermediate zone and cortical plate in a 
pattern that matches the mRNA in 3.3.5.4. Looking at higher magnification in 
Figure 93 d, with double immunofluorescence for KI67 and ALDOA and all 
cell nuclei stained with DAPI, we can see that the ALDOA protein (red) is 
predominantly localized outside the blue DAPI+ nucleus in the cytoplasm and 
ALDOA is expressed by both KI67+ proliferating cells (green) and non-






Figure 93: ALDOA expression in the cortex 
ALDOA protein fluorescence intensity across the telencephalic wall 
at a) 12, b) 14 and c) 16pcw. Scale bars = 100μm. d) High 
magnification immunofluorescence of KI67 and ALDOA proteins. 
Scale bar = 10μm. Blue = DAPI, green = KI67, red = ALDOA 
On b) blue arrows indicate non-specific antibody binding to blood 
vessels. On d) grey arrows indicate KI67- cells and ALDOA 
expression in KI67- cells. Orange arrows indicate KI67+ cells and 
ALDOA expression in KI67+ cells. 
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5.3.2 Cell body ALDOA protein levels are not higher in 
proliferating cells 
 
Our scRNA-seq analysis in Figure 90 indicated that ALDOA mRNA was 
enriched in progenitor cells. To see if this was also the case for the protein, 
we used our analysis of immunofluorescence to compare cell body ALDOA 
protein levels in proliferating KI67+ and non-proliferating KI67- cells. Our 
results are shown in Figure 94 and we saw no significant difference at 12pcw 
(Figure 94 a), 14pcw (Figure 94 b) nor 16pcw (Figure 94 c). Combining all 
ages as described in 5.2.2.2, also revealed no significant difference in the 
cellular levels of ALDOA between proliferating and non-proliferating cells 










Figure 94: Cell body ALDOA quantification 
 Cell body ALDOA protein fluorescence intensity in KI67+ and KI67- 
cells. 
a) 12pcw, raw data transformation = +1(log), bimodal 
distribution, Mann-Whitney test, p = 0.3702. 
b) 14pcw, raw data transformation = +1(log), normal distribution, 
unpaired t-test with Welch’s correction, p = 0.2032. 
c) 16pcw, raw data transformation = +1(log), normal distribution, 
unpaired t-test with Welch’s correction, p = 0.3523. 
d) 12, 14 and 16pcw individual datasets averaged, raw data 
transformation = +1(log), paired t-test, p = 0.0836. 
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Next, we wanted to see if there was any fluctuation in ALDOA protein levels 
with the cell cycle, so we quantified immunofluorescence for KI67 and cell 
body ALDOA (nucleus and adjacent cytoplasm) using the same analysis as 
for KIF22 as described in (4.2.3). Our analysis presented in Figure 95 
showed no correlation or pattern at 12pcw (Figure 95 a) (R2=0.018), 14pcw 
(Figure 95 b) (R2=2e-4), 16pcw (Figure 95 c) (R2=0.00992) or when we 
combined all the data points from the three ages onto one graph (Figure 95 
d) (R2=0.0049). These data show that in human cerebral cortex 
development, cellular ALDOA protein levels do not correlate with proliferation 










Figure 95: Quantification of cell body ALDOA and nuclear KI67 
 Correlation of cell body ALDOA and nuclear KI67 fluorescence 
intensity levels at a) 12pcw, b) 14pcw, c) 16pcw and d) data from all 
the ages combined onto one graph. Colour coding indicates 
distance of each cell from the apical surface (key at bottom). 
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5.3.3 Nuclear ALDOA protein levels are not higher in 
proliferating cells 
 
As described in the introductory part of this chapter (5.1.3.2), previous work 
in different systems has shown ALDOA protein to localise to the nucleus of 
proliferating cells (Mamczur et al., 2013). We wanted to see if this was the 
case in the developing human cortex, so we quantified both nuclear ALDOA 
and KI67 to compare ALDOA protein levels in the nucleus of proliferating 
KI67+ cells and non-proliferating KI67- cells at three developmental ages as 
shown in Figure 96. We saw no significance difference in nuclear ALDOA 
fluorescence intensity between KI67+ and KI67- cells at 12pcw (Figure 96 a), 
14pcw (Figure 96 b), 16pcw (Figure 96 c), nor when we combined the 





Figure 96: Nuclear ALDOA quantification 
Nuclear ALDOA fluorescence intensity in KI67+ and KI67- cells 
a) 12pcw, raw data transformation = +1(log), normal 
distribution, unpaired t-test with Welch’s correction, p = 
0.7543. 
b) 14pcw, raw data transformation = +1(log), normal 
distribution, unpaired t-test with Welch’s correction, p 
=0.0694. 
c) 16pcw, raw data transformation = +1(log), normal 
distribution, unpaired t-test with Welch’s correction, p = 
0.0772 
d) 12, 14 and 16pcw individual datasets averaged, raw data 
transformation = +1(log), paired t-test, p = 0.1330. 
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Next, we wanted to see if the nuclear localisation of ALDOA correlated in any 
way with the cell cycle by analysing nuclear ALDOA and KI67 fluorescence 
intensity with the results in Figure 97.  Our analysis established no 
correlation or pattern at 12pcw (Figure 97 a) (R2 = 5e-05), 14pcw (Figure 97 
b) (R2 = 0.0365), 16pcw (Figure 97 c) (R2 = 0.0723) nor when we combined 














Figure 97: Quantification of nuclear ALDOA and KI67 
fluorescence intensity 
Correlation of nuclear ALDOA and nuclear KI67 fluorescence 
intensity levels at a) 12pcw, b) 14pcw, c) 16pcw and d) data from all 
the ages combined onto one graph. Colour coding indicates distance 
of each cell from the apical surface (key at bottom). 
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5.3.4 Summary of results 
Our results have shown ALDOA protein to be present across the 
telencephalic wall, with stronger staining in the germinative zone. At the sub-
cellular level, we have shown ALDOA protein to be predominantly localised 
to the cytoplasm of the cell, with a small amount in the nucleus; an 
expression pattern that does not differ between proliferating and non-






Figure 98: Schematic of ALDOA protein localisation 
Summary schematic showing our findings that ALDOA protein is 
predominantly located in the cytoplasm and less in the nucleus 
in both KI67+ proliferating cells and KI67- post-mitotic cells. 
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We have also shown that, unlike the KIF22 protein, ALDOA protein levels do 
not change in relation to the cell cycle as shown in summary Figure 99. 
 
   
  
Figure 99: ALDOA cell cycle summary 
Model showing that ALDOA protein levels 
do not change with the cell cycle. 
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5.4 Discussion  
 
In beginning to understand the many ways by which the polygenic 16p11.2 
CNV affects prenatal brain development, we must understand the roles of its 
individual genes in neural development. As altered brain size at birth is one 
of the most common patient phenotypes, this suggests some of the genes in 
the CNV may impact neural proliferation and ultimately brain size. Hence, we 
aimed to identify genes from this locus whose transcripts were enriched in 
progenitors and downregulated as cells became post-mitotic. Our scRNA-seq 
analysis in chapter three presented ALDOA as a candidate for further study. 
We have shown its protein to be expressed across the telencephalic wall, 
highest in the germinative zones and the protein to be predominantly 
localised to the cytoplasm in both proliferating and non-proliferating cells of 
the germinative zones. In this discussion section of chapter five we will 
discuss our results, the limitations of our study and avenues of future 
exploration.  
 
5.4.1 ALDOA protein expression in the developing cerebral 
cortex 
 
At the tissue level, our results show ALDOA protein to be expressed across 
the width of the cortex, highest in the germinative regions, the VZ and SVZ. 
This result matches that of the in situ hybridisation demonstrating that 
ALDOA mRNA and protein are expressed in a similar pattern. However, 
some of this result, may arise from the fact that the germinative zones, and in 
particular the VZ, have such a high cell density. With the fibres from 
germinative zone cells extending all the way to the pial surface it is also 
impossible to know whether cytoplasmic ALDOA observed in the upper 
regions belongs to the cells in those regions, is localised to the fibres of VZ 
and SVZ progenitor cells, or both possibilities. As the scRNA-seq analysis 
focusses on the VZ and SVZ, these are the regions we focused on for our 
single-cell protein analysis. 
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5.4.2 ALDOA subcellular localisation 
 
Our results show that at all ages ALDOA predominantly localises to the 
cytoplasm, and its level in cells does not vary between proliferating and non-
proliferating cells. From our study of the literature, we found that nuclear 
ALDOA localisation has been previously linked to proliferation (Mamczur et 
al., 2013; Fu et al., 2018) and hypothesised that may also be the case in the 
human fetal cortex. However, while we were able to detect ALDOA in the 
nucleus, it was predominantly localised to the cytoplasm and we found no 
clear relationship between ALDOA protein levels and cellular proliferation 
state.  
 
This finding differs to our result from the scRNA-seq analysis which showed 
ALDOA mRNA levels to be higher in proliferating than non-proliferating cells. 
Our quantitative analysis of ALDOA protein did not identify any increase in 
ALDOA levels in the cell body of proliferating KI67+ cells. One possibility is 
that this could be a technical problem with our analysis, however this is 
unlikely as we used an identical analysis to determine KIF22 protein levels 
are increased in KI67+ cells in 4.3.2.1. However, given that neuronal cells 
have an elongated shape, with processes extending from the nucleus, rather 
than the more stereotypical “fried egg” shape and that ALDOA protein (unlike 
KIF22) fills the whole cell, and our analysis cannot identify protein localised 
to the radial fibres of neural progenitors, nor that localised to the neurites of 
post-mitotic cells. However, given how densely packed with cells the 
developing brain is, it would be impossible to use a stain like N-cadherin to 
identify individual cell bodies and their fibres as we would not be able to 
determine which process belonged to which cell. 
 
We wanted to consider possible explanations for why ALDOA mRNA does 
not correlate well with the protein levels. One possibility is that ALDOA 
mRNA expression is higher in progenitors and subsequently downregulated 
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as cells become post-mitotic, but the ALDOA protein is very stable, so it 
persists in post-mitotic cells after ALDOA mRNA levels decline. A second 
possibility is that the total ALDOA protein levels are higher in progenitors but 
the subcellular distribution of the protein changes as cells become post-
mitotic, e.g. ALDOA protein in the radial processes of progenitors 
redistributes towards the nucleus as cells become postmitotic, such that the 
levels of protein in and around the nucleus remain constant. These two 







Figure 100: Possibilities for ALDOA protein levels 
Schematic showing two possible explanations for why ALDOA mRNA 
does not correlate well with the protein levels. 
a) In possibility one, the mRNA expression (purple) is higher in 
the progenitors and decreasing when the cell becomes post-
mitotic but the protein (red) is stable and persists in the post-
mitotic cells. 
b) In the second possibility, there is a redistribution of the protein 
as cells become post-mitotic and while the progenitors have 
higher overall protein level it is widely distributed and when 
cells become post-mitotic the protein redistributes towards the 
nucleus and the area we considered to be the cytoplasm in our 
analysis which is indicated in yellow. Therefore, we saw no 
difference within our area of analysis which may not be 
representative of the entire cell. 
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With the post-mortem tissue available for this study we cannot distinguish 
between these two possibilities. One solution to this could be to test in 
dissociated cell culture where the whole cell is visible, but this was not 
possible in this work and in any case such an experiment would not be 
physiological which is a particular concern as ALDOA mRNA is known to be 
elevated in some culture contexts (Pollen et al., 2019). Overall our results 
show that ALDOA protein is abundant in progenitor cells of the developing 
human cerebral cortex and therefore, may well play a role in neurogenesis 
phenotypes. However, the fact that we see persistent expression of ALDOA 
protein as cells become post-mitotic suggests potential roles for ALDOA in 
differentiated neurons. Some of these will likely be glycolytic as neurons are 
metabolically active, however given its known interactions with the 
cytoskeleton (Pagliaro and Taylor, 1992), it’s possible ALDOA may have 
additional roles in neuronal migration or axon branching.  
 
 
5.4.3 Altering ALDOA dosage 
 
When ALDOA dosage is altered in the developing brain, as in the CNV, it is 
likely to substantially impact energy metabolism by altering the flow of 
metabolites through the glycolytic pathway and impacting subsequent 
pathways that feed on the outputs of glycolysis. There is some evidence for 
this in the literature: disruption to energy metabolism during development has 
previously been linked to ASD and ADHD (Rash et al., 2018). Additionally 
the offspring of hyperglycaemic mice presented microcephaly, a phenocopy 
of the microcephaly observed in 16p11.2 microduplication patients (Rash et 
al., 2018). Disruptions to energy metabolism, including increased glycolysis, 
may contribute to the microcephaly seen in the offspring of Zika infected 
mothers which is also a phenocopy (albeit Zika microcephaly is much more 
severe) of the 16p11.2 microduplication patients (Gilbert-Jaramillo et al., 
2019). So, although the interactions between these pathways are highly 
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complex, there is some evidence suggesting increased glucose of glycolysis 
contribute to microcephaly. Therefore, this suggests that disrupting glycolysis 
by altering ALDOA dosage will have significant effects on brain growth and 
potentially cellular composition. 
 
Looking at medical literature revealed no homozygous null ALDOA patients, 
suggesting that ALDOA is essential for life and its functions cannot be 
compensated for by the ALDOB or ALDOC isoforms. However, there were 
some case studies in which patients with changes to ALDOA levels were 
identified. One patient presented with microcephaly, and was found to have 
reduced ALDOA activity (Kreuder et al., 1996), and another presented 
reduced ALDOA activity and intellectual disability (Beutler et al., 1973). 
Interestingly, one case study identified upregulated cortical ALDOA levels in 
post-mortem brains of schizophrenia patients (Beasley et al., 2006) which is 
particularly noteworthy as the 16p11.2 microduplication is strongly 
associated with risk of schizophrenia.  This, coupled with our results that 
ALDOA is expressed in all cell types of the developing human cerebral 
cortex, makes it clear that any changes to ALDOA dose will affect energy 




5.4.4 Future directions 
 
Here we have presented a clear, descriptive study to show the expression 
pattern and sub-cellular localisation of ALDOA protein in the developing 
human cerebral cortex. In order to take this study further, there are a few 
interesting lines of investigation that were outwith the scope of this PhD 
project. A limitation of our study was our inability to clearly visualise the entire 
cell due to the density of the post-mortem brain tissue. One option for 
building on this could be to dissociate cells and image the whole cell, 
however this would need to be considered carefully for a protein like ALDOA, 
whose mRNA transcript levels in artificial cell culture have been shown to be 
elevated compared to post-mortem tissue samples (Pollen et al., 2019). A 
follow-on question from this could be to again utilise cell culture, using hIPSC 
derived NPCs where ALDOA levels have been reduced and asses any 
impact on cellular proliferation. 
 
Considering ALDOA protein within the context of the 16p11.2 CNV, it would 
be interesting to again use cell culture where NPCs with the 16p11.2 CNV 
are used to determine if ALDOA protein sub-cellular localisation differs 
between 16p11.2 CNV and control lines, and in response to addition of 
different metabolic substrates.   
 
Overall, there are many interesting future studies for ALDOA both as an 
independent gene and as part of the 16p11.2 patient phenotype and there 




Summary and concluding remarks 
In this thesis we have presented a descriptive study utilising bioinformatics 
analysis, in situ hybridisation of mRNA and high-level histology of protein 
expression in the developing human cerebral cortex. We began examining 
the expression level of the transcripts of each gene in the ASD-implicated 
16p11.2 CNV locus to identify which genes had transcripts enriched in 
progenitor cells and down-regulated as cells become post-mitotic with the 
reasoning that these genes would be important for regulating neurogenesis. 
Following the scRNA-seq analysis and complementary in situ hybridisation 
we identified two significantly progenitor enriched candidate genes for further 
study: ALDOA and KIF22. We then proceeded to characterize their protein 
expression in sections of the developing human fetal cortex during the late 
first and early second trimester. We showed KIF22 protein to be restricted to 
proliferating cells and its levels to vary with the cell cycle, while ALDOA was 
expressed throughout the cortex although highest in the germinative zones 
and predominantly localised to the cytoplasm in both proliferating and non-
proliferating cells. This work is publicly available in a manuscript published on 
preprint server BioRXiv (Morson et al., 2019) (see appendix).  
 
This is a powerful descriptive study using human fetal material, and it has 
indicated that further investigation into the normal function of ALDOA and 
KIF22 and the consequences of altering their dosage on neurogenesis is 
likely to further our understanding of how the 16p11.2 CNV impacts brain 
development. We have set the foundations for describing these genes in the 
developing brain and proposed hypotheses about their function for future 
testing in more genetically manipulatable systems such as cerebral 
organoids.  
 
It is important to also consider that the 16p11.2 CNV is a polygenic mutation 
and there are likely to a multitude of interactions between the CNV genes 
which contribute to the phenotype. Therefore, it is important to study these 
genes both independently and as part of the CNV to fully understand their 
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role in neural development, and the impact of altering their dosage. Only by 
considering both these approaches will we fully begin to understand the 
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The 593 kbp 16p11.2 copy number variation (CNV) affects the gene dosage of 29 
protein coding genes, with heterozygous 16p11.2 microduplication or microdeletion 
implicated in about 1% of autism spectrum disorder (ASD) cases. The 16p11.2 CNV 
is frequently associated with macrocephaly or microcephaly indicating early defects 
of neurogenesis may contribute to subsequent ASD symptoms, but it is unknown 
which 16p11.2 transcripts are expressed in progenitors and whose levels are likely, 
therefore, to influence neurogenesis. Analysis of human fetal gene expression data 
revealed that of all the 16p11.2 transcripts only two, ALDOA and KIF22, are 
significantly enriched in progenitors. To investigate the role of ALDOA and KIF22 in 
human cerebral cortex development we used immunohistochemical staining to 
 310 
describe their expression in late first and early second trimester human cerebral cortex. 
KIF22 protein is restricted to proliferating cells with its levels increasing during the 
cell cycle and peaking at mitosis. ALDOA protein is expressed in all cell types and 
does not vary with cell-cycle phase. Our expression analysis suggests the hypothesis 
that the simultaneous changes in KIF22 and ALDOA dosage in cortical progenitors 
causes defects in neurogenesis that may contribute to ASD in 16p11.2 CNV patients. 
 
Keywords: 




Large, recurrent Copy Number Variations (CNVs) are implicated in many 
neuropsychiatric disorders including autism spectrum disorders (ASD), epilepsy, 
intellectual disability (ID) and schizophrenia (McCarthy et al. 2009; Girirajan and 
Eichler 2010; Levy et al. 2011; Sanders et al. 2011; Malhotra and Sebat 2012). The 
16p11.2 CNV (OMIM 611913) encompasses a 593 kb DNA sequence in the p11.2 
region of human chromosome 16 (BP4-BP5). This region harbors  29 protein coding 
genes and is strongly linked to neurodevelopmental disorders (NDDs) including ASD 
(Kumar et al. 2008; Bijlsma et al. 2009; Rosenfeld et al. 2010; Shinawi et al. 2010; 
Zufferey et al. 2012). This 16p11.2 region is flanked by two homologous 147kbp 
sequences that arose after the evolutionary divergence of humans from other primates, 
generating a hot-spot for mis-aligned recombination that explains the high frequency 
of the 16p11.2 CNV in the human population and also the high frequency of de novo 
16p11.2 CNV (Nuttle et al. 2016). In humans, the 16p11.2 microdeletion is associated 
with transient infant brain overgrowth and focal thickening of the cerebral cortex, 
while the 16p11.2 microduplication is associated with reduced brain size 
(microcephaly) (Qureshi et al. 2014; Blackmon et al. 2018). The early manifestation 
of anatomical phenotype in newborns, along with the onset of ASD symptoms in 
infancy, suggests crucial roles for 16p11.2 genes during neural development. 16p11.2 
is the most prevalent CNV associated with ASD, ~1% incidence, making this CNV 
particularly intriguing and providing motivation for investigating the role played by 
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16p11.2 genes in brain development and function (Weiss et al. 2008). Available lines 
of evidence from 16p11.2 rodent models, 16p11.2 patient derived lymphoblastoid cell 
lines, and human induced pluripotent stem cells genetically engineered to harbor the 
16p11.2 CNV indicate that all 16p11.2 mRNAs’ levels reflect the altered gene dosage 
of 16p11.2 genes (50% in microdeletion and 150% in microduplication heterozygotes) 
(Horev et al. 2011; Blumenthal et al. 2014; Pucilowska et al. 2015; Tai et al. 2016). 
This indicates that multiple 16p11.2 transcript levels are affected by the 16p11.2 CNV 
and that the pathology of the 16p11.2 CNV could stem from altered dosage of one or 
more them.  
 
While none of the individual 16p11.2 genes have been identified as sole causative 
genes for the 16p11.2 phenotype, the use of different models has implicated individual 
CNV genes in various phenotypes. MAPK3, QPRT, KCTD13, ALDOA, and KIF22 
have been individually associated with a variety of neural phenotypes including cell 
proliferation, neuronal morphology, axonal projection and spine morphogenesis, 
altered head size, and behavioral phenotypes. A study in which 16p11.2 genes were 
systematically knocked down in zebrafish embryos reported neuroanatomical 
phenotypes for the vast majority of 16p11.2 genes tested, suggesting that the 16p11.2 
phenotype is likely to be polygenic (Blaker-Lee et al. 2012; de Anda et al. 2012; Golzio 
et al. 2012; Pucilowska et al. 2015, 2018). 
 
The cellular mechanisms by which the CNV causes the patient phenotype are poorly 
understood. One plausible hypothesis is that disrupted neurogenesis causes changes in 
neuronal output that produces a brain with abnormal cell number or composition and 
that this contributes to the 16p11.2 pathology. Consistent with this hypothesis, the 
16p11.2 deletion mouse model exhibits proliferation defects in cortical progenitors 
during pre-natal brain development and subsequently develops ASD-like symptoms 
(Horev et al. 2011; Pucilowska et al. 2015). However, it is unknown which of the 
proteins produced by 16p11.2 CNV genes are expressed by progenitor cells in the 




We focused on the potential for the 16p11.2 CNV to affect neurogenesis in developing 
human cerebral cortex by identifying 16p11.2 genes that are highly expressed in 
cerebral cortex progenitors and down-regulated as cells become post-mitotic. We 
analysed previously published human fetal cortex single cell RNA sequencing 
(scRNA-seq) data (Pollen et al. 2015) to identify candidate genes and characterize their 
expression in sections of developing human fetal cerebral cortex from the late first and 




Material and Methods 
Human Tissue 
Human embryos ranging in age from 12-16 post-conceptual weeks were obtained 
from the MRC/Wellcome-Trust funded Human Developmental Biology Resource at 
Newcastle Univeristy (HDBR, http://www.hdbr.org/) with appropriate maternal 
written consent and approval from the Newcastle and North Tyneside NHS Health 
Authority Joint Ethics Committee. HDBR is regulated by the UK Human Tissue 
Authority (HTA; www.hta.gov.uk) and operates in accordance with the relevant 
HTA Codes of Practice. 
For cryosections 12 PCW week brains were fixed in 4%PFA/PBS for 1 week then 
cryoprotected with 30% sucrose/PBS and then embedded in 50:50 30%sucrose:OCT, 
flash frozen and sectioned at 12μm using a Leica Cryostat. 




The publicly available scRNA-seq data set (Pollen et al. 2015) was used to identify 
candidate genes. Prior to dataset publication the reads were aligned, we normalized 
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the RPKMs as log(x+1). Analysis was performed using R studio. To determine genes 
with significant changes a Wilcox test by FindAllMarkers in Seurat package was 
used. Monocle2 R package was used to order cells in pseudotime. To identify cell-




Immunohistochemistry was carried out on paraffin sections obtained from HDBR. 
Antigen retrieval consisting of boiling sections in 10mM sodium citrate pH6 for 10 
mins was used for all stains. Primary antibodies were diluted in 20% blocking serum 
in pH7.6 Tris buffered saline (TBS) and sections incubated overnight at 4°C.  
Primary antibodies used: KID 1/5000 DAB, 1/2000 fluorescent (Invitrogen PA5-
29490), KI67 1/800 (Novus Biologicals NBP2-22112), ALDOA 1/100 (Sigma 
HPA004177). 
 For colourmetric stains, sections were incubated 1hr at room temperature with 
biotinylated secondary antibody (1/200) followed by incubation for 1 hour with ABC 
(Vector Labs) and developed with diaminobenzidine solution (Vector Labs), washed, 
counterstained with nuclear fast red, dehydrated and then mounted using DPX. 
For immunofluorescence sections were incubated with secondary antibodies 1/200 1 
hour room temperature, counterstained with 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI;ThermoFisher) and mounted with Vectashield H1400 
Hardset Mounting Medium (Vector Labs). Extensive TBS washes were carried out 
between each step.  
 
In Situ Hybridisation 
Cryosections of 12 PCW brain were used for ALDOA and KIF22 in situ 
hybridisation. 
PCR primers used to clone in situ probes from human cDNA into pGEMTeasy for 
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preparation of DIG labelled RNA were as follows: ALDOA Forward: CTG TCA 
CTG GGA TCA CCT T, ALDOA Reverse: GTG ATG GAC TTA GCA TTC AC. 
KIF22 Forward: CGA GAG CGG ATG GTG CTA AT, KIF22 Reverse: GAG ACC 
CAG GAT GTT TGC CT. In situ hybridisation was performed as described 
previously (Radonjić et al. 2014). Briefly, 12μm cryosections were dried at 37°C for 
3 hours then incubated overnight at 70°C in hybridization mix containing 1x salts 
(200mM NaCl, 10mM Tris HCl (pH 7.5), 1mM Tris Base, 5mM NaH2PO42H2O, 
5mM Na2HPO4, 0.5M EDTA: Sigma-Aldrich), 50% deionized formamide, 10% 
dextran sulfate, 1mg/ml rRNA, 1x Denhardt’s, and DIG-labelled RNA probe. Next 
day sections were washed 3 times at 70°C in wash buffer comprising 1x SSC, 50% 
formamide, 0.1% Tween-20 and then 3 times at RT in 1x MABT (20mM Maleic 
acid, 30mM NaCl, 0.5% Tween-20 and pH adjusted to 7.5 with 10mM NaOH). 
Sections were incubated 1hr RT in 1x MABT blocking solution (20% sheep serum, 
2% blocking reagent) and then incubated overnight with anti-DIG antibody 1:1500 in 
blocking solution at 4°C followed by colour reaction overnight at RT. 
 Microscopy and Imaging 
DAB and in situ hybridisation images were taken using a Leica DMNB microscope 
with an attached Leica DFC480 Camera. Fluorescence images were obtained with a 
Leica DM5500B epifluorescence microscope with a DFC360FX camera. Confocal 
images were obtained using Nikon A1R FILM microscope and analysed in ImageJ. 
 Image Analysis and Quantification 
For DAB stains and in situ hybridisation the images were stitched in ImageJ using 
the stitching plugin (Preibisch et al. 2009). 
For KIF22 analysis of DAB stains rectangular counting boxes (34x88µm) were 
overlaid across the section. Using ImageJ cell counting plugin cells in each box were 
counted and denoted KIF22+ (brown) or KIF22- (red). The distinction between the 
regions (VZ, SVZ, IZ/CP) was determined anatomically by cell density. The count 
for each box was averaged with other boxes in the region to provide the final value. 
For analysis of KIF22/KI67 double staining counting boxes (20x145µm) were 
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overlaid over the VZ and SVZ (determined based on cell density). For determining 
intensity cells were randomly selected on the DAPI channel, the nucleus outlined and 
intensity of KIF22 and KI67 recorded. 20 cells were selected per box and the counts 
from individual boxes combined to give final values. 
For subcellular ALDOA analysis counting boxes (20x145µm) were overlaid over the 
VZ and SVZ. Cells were randomly selected on the DAPI channel, far enough apart to 
ensure their cytoplasm would not overlap, the Z plane through the center of the cell 
was used and the nucleus outlined. The KI67 and ALDOA intensity was measured 
constituting the nuclear value. To obtain ALDOA cytoplasmic intensity the nuclear 
outline was duplicated and extended 4 pixels allowing a reading of just the 
cytoplasmic area to be obtained (see Fig.5e). This was performed for 10 cells in each 
box and the counts from individual boxes combined to give final values. 
Data Analysis and Statistics 
Where error bars are shown they are expressed as mean ± SEM. Boxplots show median 
and upper and lower quartiles. Statistical comparison between two groups was 
performed with a t test. Statistical comparison between more than two groups was 
performed with ANOVA followed by post hoc test. P<0.05 was considered 
statistically significant. Analysis was performed using GraphPad Prism. 
 
Results 
Analysis of scRNA-seq data identifies KIF22 and ALDOA as progenitor-enriched 
16p11.2 transcripts in the developing human fetal cerebral cortex.  
The 16p11.2 CNV involves microduplication or microdeletion of a 593 kb locus on 
human chromosome 16 containing 29 protein coding genes (Fig.1a). The aim of the 
current study is to identify 16p11.2 genes that are potential candidates for being 
involved in neurogenesis in the developing human cerebral cortex (Fig.1b) and whose 
altered dosage in 16p11.2 microdeletion or microduplication patients may disrupt 
neurogenesis and contribute to the CNV phenotype. We reasoned that 16p11.2 genes 
important for neurogenesis would be highly expressed in proliferating progenitor cells 
and down-regulated as cells became post-mitotic. 
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We took advantage of a published single cell RNA-sequencing (scRNA-seq) data-set 
acquired from 393 cells of the ventricular zone (VZ) and subventricular zone (SVZ) 
of gestational week (GW) 16-18 human fetal cerebral cortex (equivalent to post 
conception week (PCW) 14-16) to perform an unbiased screen to identify 16p11.2 
transcripts that matched this expression profile (Pollen et al. 2015). Dimensional 
reduction of the scRNA-seq data separated the cells into three clusters based on 
transcriptome similarity (Fig.1c – each dot on the tSNE plot represents an individual 
cell) that were subsequently identified as the three cardinal cell classes of progenitors 
(blue), post-mitotic neurons/ principal cells (red) and interneurons (green), by 
expression of cell-type specific transcripts. We next used the monocle2 R package to 
order the cells in pseudotime using the normalized expression levels of selected 
differentially expressed genes (DEGs) as input to order the cells (Trapnell et al. 2014; 
Qiu et al. 2017) (Fig.1d) moving from the progenitor state (left) to post mitotic state 
(right) along the X-axis. We plotted the average expression of each 16p11.2 transcript 
at each pseudotime-point on the Y-axis. We found that two genes, KIF22 (blue line) 
and ALDOA (brown line), were notable for having high expression in progenitors that 
declined as cells became post-mitotic. A Wilcox test identified ALDOA and KIF22 as 
the only 16p11.2 transcripts that were significantly higher in progenitor than neuronal 
populations (p<<0.05). Although not significantly enriched in progenitors HIRIP3 
(orange line), MAZ (red line), PAGR1 (green line), and SPN (turquoise line) transcripts 
were expressed in progenitors at higher levels than the remaining 16p11.2 transcripts 
(shown as grey lines), many of which were barely expressed at all. 
 
We focused on ALDOA and KIF22 transcripts and used a combination of in situ 
hybridisation on 12 PCW human cerebral cortex and analysis of the scRNA-seq data 
to investigate their expression in more detail. In situ hybridisation shows that KIF22 
mRNA expression is most prominent in the VZ and SVZ with a few expressing cells 
in the IZ and SP/CP (Fig.1e). Violin plots of the numbers of cells expressing different 
levels of KIF22 mRNA in the different cardinal cell classes show that KIF22 is 
expressed predominantly in progenitors (Fig.1f) and mapping the expression level of 
KIF22 onto the tSNE plot (Fig.1g) revealed that KIF22 expression is highest in a 
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subset of the progenitor cluster (arrow in Fig.1g) with a substantial proportion of 
progenitor cells expressing relatively low levels of KIF22. Very few post-mitotic 
neurons, both interneurons and principal cells, express appreciable levels of KIF22 
(Fig.1f,g). The expression of KIF22 in a subset of progenitors prompted us to ask 
whether its expression was related to the cell-cycle phase. We used the expression of 
cell-cycle phase specific transcripts using function CellCycleScoring from Seurat R 
package to divide the cells into three classes (Macosko et al. 2015; Tirosh et al. 2016), 
G1/S, G2/M, and post-mitotic neurons, and compared KIF22 transcript levels between 
these three groups using a violin plot (Fig.1h). We found that the majority of cells in 
G2/M phase expressed higher levels of KIF22 (red plot), cells in G1/S expressed lower 
levels (blue plot) while the vast majority of post-mitotic cells expressed low levels of 
KIF22 (green plot). 
 
We performed the same analysis for ALDOA transcripts. In situ hybridisation showed 
that while ALDOA mRNA expression is most prominent in the proliferative VZ and 
SVZ there are substantial numbers of ALDOA expressing cells in the SP/CP (Fig.1i). 
Violin plots (Fig.1j) show that while a greater proportion of cells expressing the 
highest levels of ALDOA are progenitors (blue plot) there are also a substantial number 
of principal cells (red plot) expressing similarly high levels of ALDOA transcripts 
although very few interneurons (green plot). Mapping ALDOA expression level onto 
the tSNE plot (Fig.1k) shows cells expressing high levels of ALDOA are evenly 
distributed throughout the progenitor cluster with appreciable numbers of principal 
cells expressing high levels of ALDOA and a much lower proportion of interneurons. 
In contrast to KIF22, there is no clear difference in the partitioning of ALDOA 
expression level between different phases of the cell-cycle (Fig.1l).  
 
To conclude, of all the 29 16p11.2 transcripts, only two, KIF22 and ALDOA, are 
significantly enriched in progenitors compared to post-mitotic cells making them 
candidates for having specific roles in neurogenesis in the developing human fetal 
cerebral cortex. Although both are enriched in progenitors, KIF22 and ALDOA 
transcript expression shows notable differences: KIF22 transcripts are more restricted 
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to progenitors and their levels vary as the cell-cycle progresses. We next describe the 









KIF22 protein is expressed in germinal zones of 12, 14 and 16 PCW cortex 
 
Here we characterize KIF22 protein expression during human corticogenesis. Coronal 
cortex sections spaced along the rostral-caudal axis were immunostained for KIF22 
protein and counterstained with Nuclear Fast Red (NFR) to show cytoarchitecture. 
KIF22+ (brown) and KIF22- (red) cells were counted for each region in the 
telencephalic wall (VE, VZ, SVZ, IZ and CP) (see methods for details of sampling) 
and lamination was identified by cell density (Bayer and Altman 2002, 2005). These 
data are shown for three developmental stages, 12 PCW (Fig 2 a-d), 14 PCW (Fig 2 
a’-d’), and 16 PCW (Fig 2 a*-d*). At all stages and rostro-caudal positions KIF22 
expressing cells appear most abundant in the VE followed by the VZ and SVZ with 
the IZ and CP presenting a very low to complete absence of KIF22 (Fig.2 c, c’, and c* 
with higher magnification of boxed regions from each zone shown in d, d’, and d* 
respectively, green arrows indicate examples of individual KIF22+ cells).  
 
We next pooled  KIF22+ cell count data in two ways to compare between all ages (Fig 
2e) and anatomical regions (Fig 2f) and found that the percentage of KIF22+ cells in 
the VE (40-50%) was consistently higher than other regions, followed by the VZ (20-
Fig 1: a) 16p11.2 region and genes. b) schematic of human cortical structure 
during development.  c) tSNE clustering of cell types. d) changing mRNA 
expression levels of 16p11.2 genes as cells move from progenitors to 
neurons with KIF22 and ALDOA identified as changing significantly. e) 
in situ hybridisation images of KIF22 at 12 PCW. f) Violin plots showing 
distribution of KIF22 in different cell types. g) KIF22 gradient plot. h) 
Violin plots showing distribution of KIF22 at different cell cycle stages i) 
in situ hybridisation images of ALDOA at 12 PCW. j) Violin plots 
showing distribution of ALDOA mRNA levels in different cell types. k) 
ALDOA gradient plot. l) Violin plots showing distribution of ALDOA 
mRNA at different cell cycle stages. Scale bars = 100µm.  
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30%) and SVZ (10%), with even fewer cells (<10%) in the IZ, and CP (Fig.2e,f). This 
result describes KIF22 protein as predominantly restricted to a subset of cells in the 









Fig 2. KIF22 protein expression levels in the cerebral cortex at 12, 14 and 
16 PCW: a, a’, a*) schematic showing brain regions sectioned. b, b’, b*) 
images of whole brain section, scale bars =2mm. c, c’, c*) sections 
spanning the rostral-caudal axis showing KIF22 expression in the 
telencephalic wall, scale bars = 100μm. d, d’, d*) high magnification 
images of different cortical zones rostral-caudal. KIF22+ cells in brown 
and examples indicated by green arrows, KIF22- cells in pink, scale bars 
=25 μm. e) Quantification of KIF22 expressing cells with all three ages 
combined. f) Quantification of KIF22 expressing cells with rostral, 
middle, caudal values combined. 
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KIF22 protein expression is restricted to proliferating cells 
 
KIF22 protein expression is almost exclusively restricted to a subset of cells in the 
proliferative regions. From the scRNA-seq data, we expect these to be progenitor cells 
(Fig.1). To identify these KIF22 positive cells we performed double 
immunofluorescence for KIF22 and KI67 (a protein expressed in all proliferating cells 
(Scholzen and Gerdes 2000; Miller et al. 2018)). KIF22+ cells were predominantly 
located in the VE, VZ and SVZ (Fig.2), therefore these regions were examined for 
analysis. Low magnification of KI67/KIF22 staining are shown in 12 PCW (Fig.3a) 
and 14 PCW (Fig.3b) with higher magnification showing individual cells in Fig.3c. 
Cell counts for KIF22+/KI67+ labelled cells show that the majority (80-90%) of KI67+ 
cells also express KIF22 both at 12 (Fig.3d) and 14 PCW (Fig.3e) or across the rostral-
caudal axis. Combining the data for anatomical locations and ages revealed 
significantly more KIF22+/KI67+ cells than KIF22+/KI67- and KIF22-/KI67+ cells 
(Fig.3f).  
 
Quantification of nuclear KIF22 fluorescence level at the single-cell level shows 
KIF22 protein is variable, but also significantly higher in KI67+ (proliferating) cells 
than in KI67-, across the rostral caudal axis at 12 (Fig.4a-c) and 14 PCW (Fig.4g-i). 
Combining data from the two ages and locations showed significantly higher KIF22 
fluorescence in KI67+ cells (Fig.4m). Thus, we confirm KIF22+ cells are proliferating 






KIF22 levels vary with cell-cycle phase 
From the scRNA-seq analysis, and the variable KIF22 protein levels in KI67+ cells, 
we hypothesised that KIF22 protein levels change throughout the cell cycle. To test 
this, we quantified nuclear immunofluorescence intensity of KIF22 and KI67 in two 
12 PCW brains (see methods for details of sampling procedure). KI67 protein levels 
vary during the cell cycle: lowest in G1 phase, increasing through S and G2 to peak in 
mitosis (Fig.4o) (Scholzen and Gerdes 2000; Miller et al. 2018). We found a strong 
correlation between KIF22 and KI67 intensity (Brain 1 rostral R2=0.8095, middle 
R2=0.8139, caudal R2= 0.6691. Brain 2 rostral R2 = 0.7489, middle R2=0.7447, caudal 
R2=0.7763) (Fig.4d-f). To ensure the correlation observed was not a result of nucleus 
size changing with cell cycle, we confirmed that KIF22 protein levels did not correlate 
with nuclear size by DAPI staining (Brain 1 rostral KIF22 R2=0.104, middle KIF22 
R2=0.0874, caudal KIF22 R2=0.2969. Brain 2 rostral KIF22 R2=0.1183, middle KIF22 
R2=0.0512, caudal KIF22 R2=0.2287). A strong positive correlation was also observed 
at 14 PCW (Brain 1 rostral R2=0.7465, middle R2=0.6668, caudal R2= 0.634, Fig.4j-
l). Again, we confirmed that KIF22 protein levels did not correlate with nuclear size 
(rostral KIF22 R2=0.1239, middle KIF22 R2=0.0599, caudal KIF22 R2=0.0229). This 
demonstrates that the correlation between KI67 and KIF22 is consistent between ages 
and rostral-caudal location. Combining all values of KI67/KIF22 nuclear intensity 
values showed that KIF22 was expressed at significantly higher levels in KI67+ cells 
(Fig.4m) with a strong correlation (R2=0.7236) between KIF22 and KI67 levels 
Fig 3. Immunofluorescence of KIF22 and KI67 in the cortex: a) KIF22 
and KI67 at 12 PCW, low magnification scale bars = 4mm, high 
magnification scale bars = 100 μm. b) KIF22 and KI67 at 14 PCW, low 
magnification scale bars = 4mm, high magnification scale bars = 100 
μm. c) high magnification of KI67/KIF22 expressing cells. Scale bars = 
10 μm. d) Percentage of cells expressing KIF22, KI67 or both at 12 
PCW. e) Percentage of cells expressing KIF22, KI67 or both at 14 




(Fig.4n). Although KIF22 expressing cells were scattered throughout the VE, VZ and 
SVZ there was a general trend for the cells expressing the highest levels of KIF22 to 
be closest to the apical surface (yellow coloured dots on scatterplots Fig.4d-g, g-i,n) 
with lower expressing cells tending to be further from the apical surface (blue coloured 
dots on scatterplots Fig.4 d-g, g-I,). During interkinetic nuclear movement radial glial 
cell nuclei move to the apical surface to perform mitosis so this spatial distribution 
suggests KIF22 is expressed at high levels by radial glial cells undergoing mitosis at 
the apical surface of the VZ. 
 
From these data we show that KIF22 protein levels change throughout the cell cycle 
in positive correlation with KI67: KIF22 is present in G1 and increases through S and 








ALDOA protein is highest in the germinal zones of the cortex 
 
Bioinformatics analysis and in situ hybridisation show ALDOA mRNA levels decrease 
as progenitor cells move towards a neuronal fate (Fig.1). Here we used 
immunofluorescence to characterize ALDOA protein expression across the 
telencephalic wall at 3 developmental time points; at 12, 14 and 16 PCW, ALDOA 
immunofluorescence is most intense in the VZ and SVZ before decreasing in the 
cortical plate (Fig.5 a-c). Double immunofluorescence for KI67 and ALDOA viewed 
at high magnification shows that ALDOA protein is primarily localized outside DAPI+ 
nuclei in the cytoplasm and that ALDOA is expressed by KI67+ progenitor cells and 
also by cells that do not express KI67 (Fig.5d). The schematic (Fig.5e) illustrates the 
Fig 4. Quantification of KIF22 Levels: a,b,c) 12 PCW quantification of 
KIF22 fluorescence intensity in KI67+/KI67- cells (raw data 
transformation =+1(log), unpaired t-test with Welch’s correction, 
p=<0.001). d,e,f) intensity correlations of KIF22 and KI67 nuclear 
fluorescence intensity at 12 PCW. g, h, i) 14 PCW quantification of 
KIF22 fluorescence intensity in KI67+/KI67- cells (raw data 
transformation =+1(log), unpaired t-test with Welch’s correction, 
p=<0.001). j, k, l) intensity correlations of KIF22 and KI67 nuclear 
fluorescence intensity at 14 PCW. m) quantification of KIF22 
fluorescence intensity in KI67+/KI67- cells 12 and 14 weeks combined 
(raw data transformation =(log), paired t-test, p=0.0122). n) intensity 
correlations of KIF22 and KI67 nuclear fluorescence intensity for rostral-
caudal points at 12 and 14 PCW with distance from apical surface 
indicated by dot colour. o) diagram of KI67 protein levels throughout the 
cell cycle. p) model based on our results of KIF22 protein levels 
throughout the cell cycle. 
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areas used for quantification of nuclear and whole cell ALDOA fluorescence presented 
in Fig.6. 
  
Fig 5. ALDOA Expression in the Cortex: ALDOA protein fluorescence 
intensity across the telencephalic wall at a) 12, b) 14 and c) 16 PCW. 
Scale bars = 100 μm. d) High magnification immunofluorescence of 




ALDOA protein levels do not correlate with proliferation 
 
Although examination of ALDOA mRNA expression indicated it was enriched in 
progenitors we were unable to find a significant difference in ALDOA protein levels 
between KI67+ and KI67- cells at 12 (Fig.6a), 14 (Fig.6b) and 16 PCW (Fig.6c) in the 
human cortex. To look for any fluctuation in ALDOA levels with the cell cycle we 
quantified immunofluorescence for KI67 and cell body ALDOA  (nucleus and 
adjacent cell body) using the same analysis as that described above for KIF22, and 
found no correlation or discernible pattern at 12 (Fig.6e) (R2= 0.018), 14 (Fig.6f) (R2= 
2e-4) or 16 PCW (Fig.6g) (R2= 0.00992). These data show that in human cortex 
development, cellular ALDOA protein levels do not correlate with proliferation or 
fluctuate with cell cycle. 
 
Previous work in different models demonstrated nuclear ALDOA level is greater in 
proliferating cells (Mamczur et al. 2010, 2013). To see if this was the case in human 
cortex development, we quantified nuclear ALDOA and KI67 (Fig.5e) but found no 
significant difference in nuclear ALDOA fluorescence between KI67+ and KI67- cells 
at 12 (Fig.6i), 14 (Fig.6j) or 16 PCW (Fig.6k). We next tested if nuclear ALDOA levels 
in proliferating cells varied with cell cycle. Analysis of ALDOA and KI67 nuclear 
intensity established no correlation or pattern at 12 (Fig.6m) (R2= 5e-05), 14 (Fig.6n) 
(R2= 0.0365) or 16 PCW (Fig.6o) (R2= 0.0723). This shows nuclear ALDOA levels 
do not increase with proliferation, nor fluctuate with cell cycle. We combined results 
across the 12, 14 and 16 PCW. There was no significant difference between KI67+ and 
KI67- cells when examining ALDOA protein intensity in the whole cell (Fig.6d) or the 
nucleus (Fig.6l). Using the pooled data, there was no correlation or discernible pattern 
when nuclear ALDOA intensity was graphed against nuclear KI67 level for the whole 






Fig 6. ALDOA Quantification: a-d) Cell body ALDOA protein fluorescent 
intensity in KI67+   and KI67- cells at a) 12 PCW (raw data transformation 
=+1(log), bimodal distribution, Mann-Whitney test, p = 0.3702), b) 14 
PCW (raw data transformation =+1(log), normal distribution, unpaired t-
test with Welch’s correction, p = 0.2032), c) 16 PCW (raw data 
transformation =+1(log), normal distribution, unpaired t-test with Welch’s 
correction, p = 0.3523). d) ALDOA cell body protein fluorescent intensity 
in KI67+ and KI67- cells, 12, 14 and 16 PCW individual datasets averaged, 
(raw data transformation =+1(log)), paired t-test, p = 0.0836. e-h) ALDOA 
cellular protein intensity levels ls correlated to nuclear KI67 protein 
intensity at e)12, f)14 and g)16 PCW with distance from ventricular edge 
indicated. h) ALDOA whole cell protein intensity levels correlated to 
nuclear KI67 protein intensity pooled 12, 14, 16 PCW. i-l) Nuclear 
ALDOA protein fluorescent intensity in KI67+ and KI67- cells at i) 12 PCW 
(raw data transformation =+1(log), normal distribution, unpaired t-test with 
Welch’s correction, p = 0.7543), j) 14 PCW (raw data transformation 
=+1(log), normal distribution, unpaired t-test with Welch’s correction, p = 
0.0694), k) 16 PCW (raw data transformation =+1(log), normal 
distribution, unpaired t-test with Welch’s correction, p = 0.0772). l) 
ALDOA nuclear protein fluorescent intensity in KI67+ and KI67- cells, 12, 
14 and 16 PCW individual datasets averaged, (raw data transformation 
=+1(log)), paired t-test, p = 0.1330. m-p) ALDOA nuclear protein intensity 
levels is correlated to nuclear KI67 protein intensity at m)12, n)14 and o)16 
PCW with distance from ventricular edge indicated. p) ALDOA nuclear 
protein intensity levels correlated to nuclear KI67 protein intensity pooled 
12, 14, 16 PCW. q) schematic demonstrating ALDOA protein is 
predominantly in the cytoplasm and lower in the nucleus in both KI67+ 
proliferating cells and KI67- post mitotic cells. r) model showing ALDOA 






16p11.2 transcript expression during human neurogenesis. 
The 16p11.2 CNV is a polygenic mutation that causes NDDs and the current study 
identified a number of the 29 16p11.2 transcripts expressed in progenitor cells of the 
cerebral cortex. In addition to ALDOA and KIF22 that are significantly enriched in 
progenitors, several other transcripts (e.g. HIRIP3, PAGR1, MAZ, and SPN) are also 
expressed in progenitors albeit at lower levels and are not significantly down-regulated 
as cells become post-mitotic. The simultaneous expression of multiple 16p11.2 genes 
in cells undergoing neurogenesis suggests that these cells may be particularly 
vulnerable to simultaneous alteration in their dosage as a consequence of the 16p11.2 
microdeletion or microduplication. This lends support to the hypothesis that 
neurogenesis is disrupted in 16p11.2 CNV patients and that this contributes to 








KIF22 is a multifunctional protein that can regulate cell proliferation through at least 
two distinct mechanisms. First, KIF22 is a kinesin-like microtubule-based motor that 
binds microtubules and chromosomes during mitosis and regulates mitotic spindle 
microtubule stability and symmetric/asymmetric cell division (Tokai et al. 1996; 
Tokai-Nishizumi et al. 2005; Sun and Hevner 2014). Second, KIF22 regulates the 
expression of the cell-cycle regulator CDC25C. During cell division, CDC25C 
dephosphorylates CDK1, thus activating the CDK1-cyclinB complex while the 
CDK1-cyclin B complex phosphorylates CDC25C, causing an amplification loop to 
drive cells to mitosis (Nilsson and Hoffmann 2000). KIF22 directly transcriptionally 
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represses CDC25C and inhibits mitosis; this transcriptional repression of CDC25C is 
dependent on KIF22 being phosphorylated on Thr463 (Ohsugi et al. 2003; Yu et al. 
2014). KIF22 depletion in a tumor cell line accelerates the G2/M transition and slows 
M/G1 transition (Yu et al. 2014).  
 
Overall it therefore appears that KIF22 can act at several different points in the cell 
cycle making it difficult to predict how increased or decreased dosage of KIF22 in the 
16p11.2 microduplication or microdeletion respectively would impact cell cycle in the 
specific context of cerebral cortex neural progenitors. Our observation that KIF22 
mRNA and KIF22 protein levels both increase during the cell cycle to achieve highest 
levels in G2/M phase that drop as cells enter G1 phase implies that KIF22 protein does 
not persist for long after it is translated and is degraded at the end of M-phase 
suggesting that both transcriptional and post-transcriptional mechanisms regulate its 
levels. A clear outcome of our study is that KIF22 levels positively correlate with KI67 
in neural progenitors and steadily rise as the cell progresses through G1>S>G2>M 
phases culminating in the maximum level during M-phase. One possibility is that 
KIF22 is required to reach a threshold for mitosis to occur, after which its levels must 
decrease sufficiently to allow mitotic exit. Whether cells undertake proliferative or 
neurogenic divisions is a process heavily controlled by cell cycle length (Borrell and 
Calegari 2014). Perturbing KIF22 gene dosage as a consequence of the 16p11.2 CNV 
might affect the timing of KIF22 protein reaching this threshold in neural progenitors 
and therefore affect cell-cycle kinetics and perturb neurogenesis and neuronal output.  
Our results suggest the hypothesis that KIF22 regulates neurogenesis in the human 




The process of brain development requires a vast and consistent supply of energy. 
Glucose is the predominant energy substrate for the fetal brain (Gustafsson 2009), 
therefore efficient and controlled glycolysis is essential for normal brain development. 
ALDOA is required for the fourth step of glycolysis, conversion of fructose 1,6-
biphospate to dihyroxyacetone phosphate and gluteraldehyde 3-phosphate. The 
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metabolic role of cytoplasmic ALDOA is well established, and ALDOA also has other 
non-glycolytic “moonlighting” roles such as regulating mitochondrial function and 
cyctoskeleton stability (Orosz et al. 1988; Pagliaro and Taylor 1992; Kao et al. 1999; 
Jewett and Sibley 2003; Buscaglia et al. 2006). In addition to its cytoplasmic roles, 
ALDOA has been observed in the nucleus (Mamczur and Dzugaj 2008; Mamczur et 
al. 2010, 2013) where it has been suggested to impact cell cycle by positively 
regulating cyclin D1 expression to mediate G1/S progression (Ritterson Lew and 
Tolan 2012; Fu et al. 2018). Cell-culture studies show ALDOA sub-cellular 
localisation depends on the availability of energetic substrates, with addition of 
glucose driving ALDOA protein to the cytoplasm (Mamczur et al. 2013). Therefore, 
it is likely the primary role for ALDOA is metabolic when cells require, and have 
available to them, large amounts of energy. The majority of ALDOA studies have used 
highly abnormal cancer tissue, or artificial cell culture systems in which glycolytic 
enzymes have been shown to be increased (Ritterson Lew and Tolan 2012; Mamczur 
et al. 2013; Fu et al. 2018; Pollen et al. 2019). How these observations of ALDOA in 
a variety of systems relate to its role in human cerebral cortex development is unclear. 
 
Altering ALDOA dosage in the developing brain will likely impact energy metabolism 
by altering the flow of metabolites through the glycolytic pathway and impacting 
subsequent pathways which feed on outputs of glycolysis. Disruption to energy 
metabolism during development has previously been linked to ASD and ADHD (Rash 
et al. 2018). The offspring of hyperglycaemic mice presented microcephaly, a 
phenocopy of the microcephaly observed in 16p11.2 microduplication patients (Rash 
et al. 2018) and disruptions to energy metabolism may contribute to the microcephaly 
seen in the offspring of Zika infected mothers (Gilbert-Jaramillo et al. 2019). No 
homozygous null ALDOA patients have been identified suggesting it is essential for 
life, but patients with changes to ALDOA levels have been identified; one patient with 
reduced ALDOA activity presented microcephaly (Kreuder et al. 1996) and another 
presented intellectual disability (Beutler et al. 1973). Of particular interest is the 
finding of schizophrenia patients with upregulated cortical ALDOA levels (Beasley et 
al. 2006) and 16p11.2 microduplication is strongly associated with risk of 
schizophrenia. This information, coupled with our results that ALDOA is expressed in 
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all cell types, make it clear that any changes to ALDOA dose will perturb energy 
metabolism at many stages in the brain, impacting its development.  
 
ALDOA is much more abundant in the cytoplasm and we also found no clear 
relationship between cell body ALDOA levels and cell proliferation status. Nuclear 
ALDOA has been linked to cell proliferation (Mamczur et al. 2010, 2013; Fu et al. 
2018). While we were able to detect nuclear ALDOA we found no clear relationship 
between ALDOA protein levels and cell proliferation status. While ALDOA mRNA 
levels are higher in proliferating cells compared to non-proliferating cells, quantitative 
analysis of ALDOA protein failed to identify increased levels in proliferating KI67+ 
cells. This seems unlikely to reflect a technical problem with our quantification method 
because an identical analysis of KIF22 protein found increased levels of KIF22 protein 
in KI67+ cells (see above). However, our quantification method was restricted to 
measuring signal in the nucleus and adjacent cytoplasm so may be more appropriate 
for a nuclear protein (like KIF22) than a protein that fills the whole cell (like ALDOA) 
and will specifically fail to identify protein localized to the radial fibers of neural 
progenitors or neurites of post-mitotic cells.  Our finding that ALDOA mRNA levels 
do not appear to correlate well with protein levels could therefore have several 
explanations. One possibility is that ALDOA mRNA expression is higher in 
progenitors and subsequently down-regulated in cells that become post-mitotic but 
ALDOA protein translated when the cells are progenitors is very stable so persists in 
post-mitotic cells after ALDOA mRNA levels decline. Another possibility is that total 
ALDOA protein levels are higher in progenitors but the subcellular distribution 
changes as cells become post-mitotic, for example ALDOA protein in the radial 
processes of progenitors redistributes towards the nucleus as cells become post mitotic, 
such that the levels of protein in and around the nucleus remain constant. We cannot 
distinguish between these possibilities using the fixed post-mortem material available 
for this study, but it would be possible to test in dissociated cell culture where the 
whole cell is visible. In any case, it is clear that while ALDOA protein is abundant in 
progenitor cells of the developing human cerebral cortex and so may play a role in 
neurogenesis phenotypes, the persistent expression of ALDOA protein as cells become 
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Our study of gene expression in developing human fetal cerebral cortex indicates that 
further investigation into the normal function of ALDOA and KIF22 and the 
consequences of altering their dosage on neurogenesis is likely to be a fruitful line of 
enquiry for understanding the 16p11.2 phenotypes. Further studies are required to 
unpick the mechanisms involved, but given the nature of the tissue, the scope for 
studying this in vivo is currently limited. However, growth of new model systems in 
which 16p11.2 gene expression can be manipulated such as human cerebral organoids 
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